KR20180130060A - Genetic diagnostic method using 30 genes associated with Alzheimer's disease - Google Patents

Genetic diagnostic method using 30 genes associated with Alzheimer's disease Download PDF

Info

Publication number
KR20180130060A
KR20180130060A KR1020170065179A KR20170065179A KR20180130060A KR 20180130060 A KR20180130060 A KR 20180130060A KR 1020170065179 A KR1020170065179 A KR 1020170065179A KR 20170065179 A KR20170065179 A KR 20170065179A KR 20180130060 A KR20180130060 A KR 20180130060A
Authority
KR
South Korea
Prior art keywords
protein
gene
receptor
disease
binding
Prior art date
Application number
KR1020170065179A
Other languages
Korean (ko)
Other versions
KR102040364B1 (en
Inventor
안성수
김상윤
보반야우
에바바진스키
심규환
Original Assignee
가천대학교 산학협력단
서울대학교병원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가천대학교 산학협력단, 서울대학교병원 filed Critical 가천대학교 산학협력단
Priority to KR1020170065179A priority Critical patent/KR102040364B1/en
Publication of KR20180130060A publication Critical patent/KR20180130060A/en
Application granted granted Critical
Publication of KR102040364B1 publication Critical patent/KR102040364B1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to a method for providing information for diagnosing Alzheimer′s disease and a diagnostic kit using the same. According to the result of gene mutation analysis using the method of the present invention, individualized diagnosis and treatment on Alzheimer′s disease patients will be possible. Using the method of the present invention, 30 genes associated with Alzheimer′s disease may be screened to identify genetic problems that a patient has, and individualized treatment can be applied.

Description

알츠하이머병 관련 ３０개 유전자를 이용한 유전적 진단방법{Genetic diagnostic method using 30 genes associated with Alzheimer's disease} [0001] The present invention relates to a method for diagnosing Alzheimer's disease using 30 genes associated with Alzheimer's disease,

본 발명은 알츠하이머병의 유전적 진단방법 관한 것이다. 보다 상세하게는, 본 발명은 알츠하이머 환자에서 나타나는 30개 유전자의 돌연변이를 검사하여 치매를 진단할 수 있는 유전자 분석 진단방법에 관한 것이다. The present invention relates to a method for genetic diagnosis of Alzheimer's disease. More particularly, the present invention relates to a gene analysis diagnostic method capable of diagnosing dementia by examining mutations of 30 genes in Alzheimer's patients.

알츠하이머병 (AD), 전두측두엽성 치매 (FTD), 근위축성측삭경화증 (ALS), 프리온 질환 (CJD) 및 파킨슨병 (PD)을 비롯한 많은 신경 퇴행성 질환 (neurodegenerative diseases, ND)은 여러 임상적, 병리적 및 분자적 특징이 공통적으로 나타나는 것으로 보고되었다(Bertram L, et al. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115(6):1449-1457). 신경 퇴행성 질환은 신경 세포의 선택적 손실 및 임상 증상으로 기능적 장애를 갖는 질환으로 정의된다. 의료기술이 발달하면서 평균 수명이 길어짐에 따라 질환은 세계에서 주요 건강 문제가 되고 있다. 이러한 문제를 해결하기 위해 전 임상 단계에서 성공적인 치료를 위한 새로운 진단 방법이 필요하다.Many neurodegenerative diseases (ND), including Alzheimer's disease (AD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), prion disease (CJD) and Parkinson's disease (PD) (Bertram L, et al., Genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115 (6): 1449-1457). Neurodegenerative disease is defined as a disease that has functional impairment due to selective loss of nerve cells and clinical symptoms. Diseases are becoming a major health problem in the world as the average life expectancy increases as medical technology develops. To solve these problems, new diagnostic methods for successful treatment at the preclinical stage are needed.

Next generation sequencing (NGS)은 인 비트로(in vitro) 및 인 비보(in vivo) 상에서 쉽게 유전적 서열을 확인할 수 있는 기술로서, 최근 몇 년 동안 유전학 연구는 sequencing 기술의 출현으로 인해 상당한 진보를 보였다. NGS 기술을 통하여 점점 더 많은 수의 유전자를 조사할 수 있게 되었고, 이러한 기술의 발달로 질병 진단과 치료를 위해 유전적 돌연변이 발견이 용이해졌다. 최근 확인된 치매와 연관된 대다수의 유전자는 Aβ42 생성 및 제거에 영향을 주거나 ND 병인에 있어서 중요한 경로에 영향을 주는 것으로 알려졌다(Karch CM, et al. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biological psychiatry. 2015;77(1):43-51; Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707-720). 하지만 어떠한 돌연변이 유전자가 어떤 질병과 연관성이 있는지 규명되지 않은 부분이 상당히 많다. 특히 다양한 퇴행성 뇌질환의 경우 복잡한 상호연관성을 가지고 있기 때문에(Bertram L, et al. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115(6):1449-1457) 한 가지 유전자로 해당 질병을 진단하거나 치료에 적용하기에 문제점이 있다. Next generation sequencing (NGS) is a technology that can easily identify genetic sequences in vitro and in vivo . In recent years, genetic research has made considerable progress due to the emergence of sequencing technology. NGS technology enables more and more genes to be investigated, and the development of these technologies has made it easier to detect genetic mutations for disease diagnosis and treatment. Most recently identified genes associated with dementia have been shown to affect the production and elimination of A? 42 or affect important pathways in ND pathogenesis (Karch CM, et al. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biological psychiatry. Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease, 2013; Zhang B, et al. networks in late-onset Alzheimer ' s disease. Cell. 2013; 153: 707-720). However, there are a number of areas where no mutation gene is associated with any disease. In particular, a variety of degenerative brain diseases have complex interrelationships (Bertram L, et al., Genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115 (6): 1449-1457) Or to apply it to treatment.

본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

본 발명자들은 치매 중 가장 높은 비중을 차지하고 하고 있는 알츠하이머를 진단할 수 있는 방법을 찾고자 예의 연구 노력하였다. 그 결과 본 발명자들은 알츠하이머 환자에게서 발견된 알츠하이머 관련 돌연변이 유전자30개를 선별하여 이에 대한 NGS 분석용 프라이머를 디자인 하였고, 이 프라이머를 이용하여 뇌질환 의심 환자들의 대한 돌연변이를 분석함으로써 알츠하이머를 진단할 수 있음을 확인하였다.The present inventors have sought to find a method for diagnosing Alzheimer's disease, which occupies the highest proportion of dementia. As a result, the present inventors selected 30 mutant genes for Alzheimer's disease found in Alzheimer's patients and designed a NGS analysis primer for them. By using this primer, mutations of patients with suspected brain diseases can be analyzed to diagnose Alzheimer's disease Respectively.

따라서, 본 발명의 목적은 알츠하이머 진단을 위한 정보제공방법을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a method for providing information for diagnosing Alzheimer's disease.

본 발명의 다른 목적은 알츠하이머 진단 또는 예후 분석용 키트를 제공하는데 있다.Another object of the present invention is to provide a kit for the diagnosis or prognosis of Alzheimer's disease.

본 발명의 또 목적은 퇴행성 뇌질환 진단을 위한 정보제공방법을 제공하는데 있다.It is another object of the present invention to provide a method for providing information for diagnosing degenerative brain disease.

본 발명의 또 목적은 퇴행성 뇌질환 진단 또는 예후 분석용 키트를 제공하는데 있다.It is another object of the present invention to provide a kit for diagnosing or prognosing a degenerative brain disease.

본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

본 발명의 일 양태에 따르면, 본 발명은 진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 알츠하이머 진단을 위한 정보제공방법을 제공한다. According to one aspect of the present invention, the present invention comprises a method for analyzing a genetic mutation of a biological sample separated from an individual to be diagnosed, wherein the gene mutation is selected from the group consisting of APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), Cadherin-associated protein alpha 3, DNMBP (Dynamin binding protein) (Low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), SORL1 (sortilin-related receptor 1), BACE1 (beta-secretase 1), PICALM (phosphatidylinositol binding clathrin assembly protein) , ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS -Sarcoma), GRN (PGRN) (progranulin), MAP TEN (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1) , Exon of a gene selected from the group consisting of LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP exon) site mutation, which provides information for diagnosing Alzheimer's disease.

본 발명자들은 치매 중 가장 높은 비중을 차지하고 하고 있는 알츠하이머를 진단할 수 있는 방법을 찾고자 예의 연구 노력한 결과, 알츠하이머 환자에게서 발견된 알츠하이머 관련 돌연변이 유전자 30개를 선별하여 이에 대한 NGS 분석용 프라이머를 디자인 하였고, 이 프라이머를 이용하여 여러 뇌질환 의심 환자들의 대한 돌연변이를 분석함으로써 알츠하이머를 진단할 수 있음을 확인하였다. The inventors of the present invention searched for a method for diagnosing Alzheimer's disease that occupies the highest proportion of dementia. As a result, 30 mutant genes of Alzheimer's disease found in Alzheimer's patients were selected and a primer for NGS analysis was designed. Using this primer, we could confirm the diagnosis of Alzheimer 's by analyzing the mutation of suspected patients with various brain diseases.

본 발명에서는 EOAD 환자에서 APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3 및 PRNP 유전자의 돌연변이를 발견하였으며, 특히, PSEN1, CLU, CTNNA3, SORL1, LRP6, ABCA7, PINK1, ATP13A2 (PARK9), LRRK2, FUS, GRN (PGRN), ALS2, CSF1R, NOTCH3 및 PRNP 유전자에서 신규한(novel) 돌연변이가 발견되었다.In the present invention, APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, (PGRN), ALS2, LRRK2, FISH, GRN (PGRN), PARK9, SNCA, LRRK2, CSF1R, NOTCH3 and PRNP genes. Novel mutations were found in the CSF1R, NOTCH3 and PRNP genes.

또한, LOAD 환자에서도 APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3 및 PRNP 유전자의 돌연변이를 발견하였고, 특히 APP, CLU, ADAM10, ATP13A2 (PARK9), LRRK 및 NOTCH3 유전자의 신규한 돌연변이를 발견하였다.In addition, in LOAD patients, APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3 and PRNP Found mutations, particularly novel mutations in APP, CLU, ADAM10, ATP13A2 (PARK9), LRRK and NOTCH3 genes.

본 발명의 일 구현예에 따르면, 상기 유전자는 APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3 및 PRNP 및 이의 조합으로 구성된 군에서 선택될 수 있다. 본 발명의 다른 구현예에 따르면, 상기 유전자는 APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3 및 PRNP 및 이의 조합으로 구성된 군에서 선택될 수 있다.According to an embodiment of the present invention, These genes include APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, , LRRK2, CSF1R, NOTCH3 and PRNP, and combinations thereof. According to another embodiment of the present invention, the gene is selected from the group consisting of APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3, and PRNP, and combinations thereof.

본 발명의 특정 구현예에 따르면, 알츠하이머의 진단에 있어서 상기 30개의 유전자의 돌연변이를 분석하되, 각 유전자에서 1 이상의 돌연변이를 검출할 수 있고, 각 유전자의 돌연변이 검출에 있어서는 1개 이상의 프라이머 세트를 사용할 수 있다. 상기 돌연변이는 하기 실시예의 표 2 및 표 3에 기재되어 있다.According to a specific embodiment of the present invention, in the diagnosis of Alzheimer's disease, the mutation of the above 30 genes is analyzed, at least one mutation can be detected in each gene, and at least one primer set can be used for mutation detection of each gene . These mutations are shown in Tables 2 and 3 of the following examples.

본 발명에서 상기 생물학적 시료는 혈액, 정액, 질 세포, 모발, 타액, 소변, 구강세포, 태반세포 또는 태아세포를 포함하는 양수 및 이의 혼합물로 구성된 군에서 선택되는 시료로부터 분리된 DNA 시료이다. 본 발명의 일 구현예에 따르면, 상기 생물학적 시료는 혈액으로부터 분리된 DNA 시료이다.In the present invention, the biological sample is a DNA sample separated from a sample selected from the group consisting of blood, semen, vaginal cells, hair, saliva, urine, oral cells, placental cells or amniotic fluid including fetal cells, and mixtures thereof. According to one embodiment of the present invention, the biological sample is a DNA sample separated from blood.

상기 DNA 시료는 당업계에 공지된 통상적인 방법을 통해 수득할 수 있다. 예컨대, 상기 조직에 DNA 용해 완충액(예컨대, tris-HCl, EDTA, EGTA, SDS, 디옥시콜레이트(deoxycholate), 및 트리톤X (tritonX) 및/또는 NP-40을 포함)을 처리하여 DNA를 분리한다.The DNA sample can be obtained through a conventional method known in the art. For example, DNA is isolated by treating the tissue with a DNA lysis buffer (e.g., tris-HCl, EDTA, EGTA, SDS, deoxycholate, and Triton X and / or NP-40) .

본 발명의 일 구현예에 따르면, DNA 시료는 DNA를 포함하는 생물학적 시료(biological sample)이다. According to one embodiment of the present invention, the DNA sample is a biological sample containing DNA.

본 명세서에 기술된 용어 “증폭”은 핵산 분자를 증폭하는 반응을 의미한다. 다양한 증폭 반응들이 당업계에 보고 되어 있으며, 이는 중합효소 연쇄반응(이하 PCR이라 한다)(미국 특허 제4,683,195, 4,683,202, 및 4,800,159호), 역전사-중합효소 연쇄반응(이하 RT-PCR로 표기한다)(Sambrook 등, Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press(2001)), Miller, H. I.(WO 89/06700) 및 Davey, C. 등(EP 329,822)의 방법, 리가아제 연쇄 반응(ligase chain reaction; LCR)(17, 18), Gap-LCR(WO 90/01069), 복구 연쇄 반응(repair chain reaction; EP 439,182), 전사-중재 증폭(transcription-mediated amplification; TMA)(19) (WO 88/10315), 자가 유지 염기서열 복제(self sustained sequence replication)(20)(WO 90/06995), 타깃 폴리뉴클레오티드 염기서열의 선택적 증폭(selective amplification of target polynucleotide sequences)(미국 특허 제6,410,276호), 컨센서스 서열 프라이밍 중합효소 연쇄 반응(consensus sequence primed polymerase chain reaction; CP-PCR)(미국 특허 제4,437,975호), 임의적 프라이밍 중합효소 연쇄 반응(arbitrarily primed polymerase chain reaction; AP-PCR)(미국 특허 제5,413,909호 및 제5,861,245호), 핵산 염기서열 기반 증폭(nucleic acid sequence based amplification; NASBA)(미국 특허 제5,130,238호, 제5,409,818호, 제5,554,517호, 및 제6,063,603호), 가닥 치환 증폭(strand displacement amplification) 및 고리-중재 항온성 증폭(loop-mediated isothermal amplification; LAMP)을 포함하나, 이에 한정되지는 않는다. 사용 가능한 다른 증폭 방법들은 미국특허 제5,242,794, 5,494,810, 4,988,617호 및 미국 특허 제09/854,317호에 기술되어 있다.The term " amplification " as described herein refers to a reaction that amplifies a nucleic acid molecule. A variety of amplification reactions have been reported in the art, including polymerase chain reaction (PCR) (US Pat. Nos. 4,683,195, 4,683,202, and 4,800,159), reverse transcription-polymerase chain reaction (RT- , The method of Miller, HI (WO 89/06700) and Davey, C. et al (EP 329,822), the method of ligase chain reaction (Sambrook et al., Molecular Cloning, A Laboratory Manual, 3rd ed. Cold Spring Harbor Press ligase chain reaction (LCR) (17, 18), Gap-LCR (WO 90/01069), repair chain reaction (EP 439,182), transcription-mediated amplification (TMA) WO 88/10315), self sustained sequence replication (20) (WO 90/06995), selective amplification of target polynucleotide sequences (US Patent No. 6,410,276) , Consensus sequence primed polymerase chain reaction (C P-PCR (US Patent No. 4,437,975), arbitrarily primed polymerase chain reaction (AP-PCR) (U.S. Patent Nos. 5,413,909 and 5,861,245), nucleic acid sequence based amplification (NASBA) (US Pat. Nos. 5,130,238, 5,409,818, 5,554,517 and 6,063,603), strand displacement amplification and loop-mediated isothermal amplification. LAMP), but is not limited thereto. Other amplification methods that may be used are described in U.S. Patent Nos. 5,242,794, 5,494,810, 4,988,617 and U.S. Patent No. 09 / 854,317.

PCR은 가장 잘 알려진 핵산 증폭 방법으로, 그의 많은 변형과 응용들이 개발되어 있다. 예를 들어, PCR의 특이성 또는 민감성을 증진시키기 위해 전통적인 PCR 절차를 변형시켜 터치다운(touchdown) PCR, 핫 스타트(hot start) PCR, 네스티드(nested) PCR 및 부스터(booster) PCR이 개발되었다. 또한, Emulsion PCR, Polony PCR, 멀티플렉스(multiplex) PCR, 실시간(real-time) PCR, 분별 디스플레이 PCR(differential display PCR, D-PCR), cDNA 말단의 신속 증폭(rapid amplification of cDNA ends, RACE), 인버스 PCR (inverse polymerase chain reaction: IPCR), 벡토레트(vectorette) PCR, 및 TAIL-PCR(thermal asymmetric interlaced PCR)이 특정한 응용을 위해 개발되었다. PCR에 대한 자세한 내용은 McPherson, M.J., 및 Moller, S.G. PCR. BIOS Scientific Publishers, Springer-Verlag New York Berlin Heidelberg, N.Y. (2000)에 기재되어 있으며, 그의 교시사항은 본 명세서에 참조로 삽입된다.PCR is the most well-known nucleic acid amplification method, and many variations and applications thereof have been developed. For example, touchdown PCR, hot start PCR, nested PCR and booster PCR have been developed by modifying traditional PCR procedures to enhance the specificity or sensitivity of PCR. In addition, PCR amplification using Polymerase Chain Reaction (PCR), Polony PCR, multiplex PCR, real-time PCR, differential display PCR (D-PCR), rapid amplification of cDNA ends Inverse polymerase chain reaction (IPCR), vectorette PCR, and TAIL-PCR (thermal asymmetric interlaced PCR) have been developed for specific applications. For more information on PCR see McPherson, M.J., and Moller, S.G. PCR. BIOS Scientific Publishers, Springer-Verlag New York Berlin Heidelberg, N.Y. (2000), the teachings of which are incorporated herein by reference.

본 발명에서 상기 돌연변이 분석은 상기 유전자에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자를 증폭하고, 상기 증폭산물의 시퀀싱(sequencing) 데이터를 이용하여 유전자 돌연변이를 분석함으로써 실시할 수 있다. 또는 상기 돌연변이 분석은 RFLP (Restriction frangment length polymorphism) 또는 Allele specific PCR 의 방법을 이용하여 분석할 수도 있다. In the present invention, the mutation analysis can be performed by amplifying a gene using each primer complementarily binding to the gene, and analyzing gene mutation using sequencing data of the amplification product. Alternatively, the mutation analysis may be performed using restriction fragment length polymorphism (RFLP) or Allele specific PCR.

본 발명의 일 구현예에 따르면, 상기 시퀀싱은 NGS (next generation sequencing) 방법을 이용하여 실시할 수 있다. 본 발명에서 NGS 데이터세트는 Torrent Suite Software v.4.4.3 (Life Technologies)으로 분석하였으며, 돌연변이 분석은 Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/)로 진행하였다.According to an embodiment of the present invention, the sequencing may be performed using a next generation sequencing (NGS) method. In the present invention, the NGS data set was analyzed with Torrent Suite Software v.4.4.3 (Life Technologies), and the mutation analysis was conducted with the Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/).

본 발명에서는 각 유전자에 대한 프라이머를 이용하여 돌연변이 분석을 실시할 수 있으며, 각 유전자별로 한 쌍(pair) 이상의 프라이머 세트를 이용할 수 있다. 본 발명에서 이용한 프라이머는 표 4 내지 표 33에 개시되어 있다. In the present invention, mutation analysis can be performed using primers for each gene, and more than one pair of primers can be used for each gene. The primers used in the present invention are shown in Tables 4 to 33.

본 발명의 특정 구현예에 따르면, 본 발명의 방법에서 APP 유전자의 엑손(exon)에 상보적으로 결합하는 프라이머 세트를 1세트 내지 18세트 사용할 수 있고; 상기 PSEN1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 12세트 사용할 수 있고; 상기 PSEN2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 13세트 사용할 수 있고; 상기 CR1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 52세트 사용할 수 있고; 상기 BIN1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 16세트 사용할 수 있고; 상기 TREM2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 4세트 사용할 수 있고; 상기 CLU 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 10세트 사용할 수 있고; 상기 CTNNA3 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 19세트 사용할 수 있고; 상기 DNMBP 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 23세트 사용할 수 있고; 상기 SORL1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 48세트 사용할 수 있고; 상기 BACE1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 9세트 사용할 수 있고, 상기 PICALM 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 19세트 사용할 수 있고; 상기 LPR6 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 25세트 사용할 수 있고; 상기 ADAM10 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 16세트 사용할 수 있고; 상기 ABCA7 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 47세트 사용할 수 있고; 상기 CD33 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 8세트 사용할 수 있고; 상기 TDP43 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 11세트 사용할 수 있고; 상기 SIGMAR1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 6세트 사용할 수 있고; 상기 FUS 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 15세트 사용할 수 있고; 상기 GRN 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 13세트 사용할 수 있고; 상기 MAPT 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 15세트 사용할 수 있고; 상기 ALS2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 39세트 사용할 수 있고; 상기 PINK1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 9세트 사용할 수 있고; 상기 PARK7 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 7세트 사용할 수 있고; 상기 PARK9 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 28세트 사용할 수 있고; 상기 SNCA 유전자에 상보적으로 프라이머 세트를 1세트 내지 6세트 사용할 수 있고; 상기 LRRK2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 54세트 사용할 수 있고; 상기 CSF1R 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 22세트 사용할 수 있고; 상기 NOTCH3 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 35세트 사용할 수 있고; 상기 PRNP 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 4세트 사용할 수 있다. According to a specific embodiment of the present invention, one to eight sets of primer sets complementary to the exon of the APP gene can be used in the method of the present invention; One to twelve sets of primer sets complementarily binding to the PSEN1 gene can be used; One to thirteen sets of primer sets complementarily binding to the PSEN2 gene can be used; One set to 52 sets of primer sets complementary to the CR1 gene can be used; One to 16 sets of primer sets complementary to the BIN1 gene can be used; One to four primer sets complementary to the TREM2 gene may be used; One to ten sets of primer sets complementary to the CLU gene may be used; One to 19 sets of primer sets complementary to the CTNNA3 gene can be used; One to 23 sets of primer sets complementary to the DNMBP gene can be used; One to 48 sets of primer sets complementary to the SORL1 gene can be used; One to nine primer sets complementary to the BACE1 gene may be used, and one to 19 sets of primer pairs complementary to the PICALM gene may be used; One to 25 sets of primer sets complementary to the LPR6 gene can be used; One to 16 sets of primer sets complementary to the ADAM10 gene can be used; One set to 47 sets of primer sets complementary to the ABCA7 gene can be used; One to eight sets of primer sets complementary to the CD33 gene can be used; One to eleven sets of primer sets complementary to the TDP43 gene can be used; One to six sets of primer sets complementary to the SIGMAR1 gene can be used; One to 15 sets of primer sets complementary to the FUS gene can be used; One to thirteen sets of primer sets complementary to the GRN gene can be used; One to 15 sets of primer sets complementary to the MAPT gene can be used; One to 39 sets of primer sets complementary to the ALS2 gene can be used; One to nine sets of primer sets complementary to the PINK1 gene can be used; One set to seven sets of primer sets complementary to the PARK7 gene can be used; One to 28 sets of primer sets complementary to the PARK9 gene can be used; One to six primer sets complementary to the SNCA gene can be used; One to 54 sets of primer sets complementary to the LRRK2 gene can be used; One set to 22 sets of primer sets complementary to the CSF1R gene can be used; One to 35 sets of primer sets complementary to the NOTCH3 gene can be used; One set to four sets of primers that complementarily bind to the PRNP gene can be used.

본 발명에서는 유전자 당 1 세트 이상의 프라이머를 사용하여 돌연변이를 검출하는데 사용할 수 있다.In the present invention, one or more primers per gene may be used to detect mutations.

본 발명의 일 구현예에 따르면, 상기 프라이머를 이용한 유전자 증폭을 위하여, 멀티플렉스 PCR(Polymerase Chain Reaction) 증폭방법을 사용할 수 있다. 본 발명의 다른 구현예에 따르면, 상기 멀티플렉스 증폭은 에멀젼(emulsion) 멀티플렉스 PCR 증폭이다.According to an embodiment of the present invention, a multiplex PCR (Polymerase Chain Reaction) amplification method can be used for gene amplification using the primer. According to another embodiment of the present invention, the epitaxial amplification is an emulsion multiplex PCR amplification.

본 발명의 또 다른 구현예에 따르면, 상기 프라이머를 이용한 유전자 증폭을 위하여, Emulsion PCR, Polony PCR 또는 Bridge PCR 방법을 사용할 수 있다. According to another embodiment of the present invention, Emulsion PCR, Polony PCR or Bridge PCR method can be used for gene amplification using the primer.

본 발명의 다른 양태에 따르면, 본 발명은 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 알츠하이머 진단 또는 예후 분석 키트를 제공한다.According to another aspect of the present invention, the present invention provides a method for the treatment of amyloid precursor protein (APP), presenilin, PSEN2, complement receptor 1 (CR1), bridging integrator 1 (BIN1), triggering receptor expressed on myeloid cells 2), CLU (clusterin), Cadherin-associated protein alpha 3, DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein ), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig- (TAR-DNA binding protein-43), sigma non-opioid intracellular receptor 1, FUS (fused-in-Sarcoma), GRN (PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 sclerosis, PTEN-induced putative kinase 1, PARK7 (Colony Stimulating Factor 1 Receptor), P ARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP protein gene, and a combination thereof. The present invention provides an Alzheimer's disease diagnosis or prognosis assay kit for analyzing a gene mutation using each primer complementarily binding to an exon region of a gene selected from the group consisting of:

본 발명의 알츠하이머 진단 또는 예후 분석 키트는 상술한 “알츠하이머 진단을 위한 정보제공방법”을 이용하기 때문에, 공통된 사항은 본 명세서의 과도한 중복성을 피하기 위해 그 기재를 생략한다.Since the Alzheimer's disease diagnosis or prognosis assay kit of the present invention uses the above-described " information providing method for Alzheimer's disease diagnosis ", the description thereof is omitted in order to avoid excessive redundancy of the present specification.

본 발명의 또 다른 양태에 따르면, 본 발명은 진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 신경 퇴행성 질환(neurodegenerative disease) 진단을 위한 정보제공방법을 제공한다.According to another aspect of the present invention, there is provided a method for detecting a mutation in a biological sample, the method comprising analyzing a genetic mutation of a biological sample isolated from an individual to be diagnosed, wherein the gene mutation is selected from the group consisting of amyloid precursor protein (APP), PSEN1 Presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein) , SORL1 (sortilin-related receptor 1), BACE1 (beta-secretase 1), PICALM (phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain- ), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1) in-Sarcoma), GRN (PGRN) (progranuli ), MAPK (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1) A gene selected from the group consisting of Alpha synuclein, LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) The present invention provides a method for providing information for diagnosing a neurodegenerative disease, which is a mutation in an exon region of a neurodegenerative disease.

본 발명의 또 다른 양태에 따르면, 본 발명은 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 신경 퇴행성 질환(neurodegenerative disease) 진단 또는 예후 분석 키트를 제공한다.According to yet another aspect of the present invention, the present invention provides a pharmaceutical composition comprising amyloid precursor protein (APP), presenilin (PSEN1), presenilin 2 (PSEN2), complement receptor 1 (CR1), bridging integrator 1 myeloid cells 2), CLU (clusterin), cadherin-associated protein alpha 3, DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig- TGR43, SIGMAR1, Sigma non-opioid intracellular receptor 1, FUS, GRN (PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis, PTEN-induced putative kinase 1, PARK7 (Colony Stimulating Factor 1 Receptor ), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3) a neurodegenerative disease diagnosis or prognosis analysis kit for analyzing gene mutations using respective primers complementarily binding to an exon region of a gene selected from the group consisting of a prion protein gene and a combination thereof, Lt; / RTI >

본 발명에서 신경 퇴행성 질환은 알츠하이머병(Alzheimer's disease), 루게릭병(Amyotrophic Lateral Sclerosis), 전두측두엽성 치매(Frontotemporal dementia), 루이소체 치매(Dementia with Lewy Bodies), 크루츠펠트 야콥병 (Creutzfeldt Jakob Disease), 파킨슨병(Parkinson’s disease), 뇌졸중(stroke), 근위축성측색경화증(amyotrophic lateral sclerosis), 빈스완거병(Binswanger’s disease), 헌팅톤 무도병(Huntington’s chorea), 다발성 경화증(multiple sclerosis), 중증 근무력증(myasthenia gravis) 및 피크병(Pick’s disease)을 포함하며 이에 한정되는 것은 아니다.In the present invention, neurodegenerative diseases include Alzheimer ' s disease, Amyotrophic Lateral Sclerosis, Frontotemporal dementia, Dementia with Lewy Bodies, Creutzfeldt Jakob Disease, Parkinson ' s disease, stroke, amyotrophic lateral sclerosis, Binswanger's disease, Huntington's chorea, multiple sclerosis, myasthenia gravis, and Pick's disease.

상기 신경 퇴행성 질환과 관련된 유전자는 하기 실시예 표 1에 개시되어 있다.The genes associated with the neurodegenerative diseases are shown in Table 1 below.

본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:

(a) 본 발명은 알츠하이머 진단을 위한 정보제공방법 및 이를 이용한 진단키트에 관한 것이다.(a) The present invention relates to a method for providing information for Alzheimer's diagnosis and a diagnostic kit using the same.

(b) 본 발명의 방법을 이용한 유전자 돌연변이 분석결과에 따라 알츠하이머병 환자에게 개인적 맞춤 진단 및 치료가 가능할 것으로 기대된다.(b) According to the result of gene mutation analysis using the method of the present invention, it is expected that personalized diagnosis and treatment of Alzheimer's disease patients will be possible.

(c) 본 발명의 방법을 이용하여 알츠하이머와 연관된 30개의 유전자를 스크리닝하여 환자가 가지고 있는 유전적 문제점을 확인 후 개별 맞춤 치료를 적용할 수 있다. 국내에서 알츠하이머 환자에게 다양한 유전자 검사를 적용하여 치료에 활용하는 경우는 없으므로 본 발병은 알츠하이머 진단에 있어 충분한 경쟁력이 있을 것으로 예상된다.(c) Screening the 30 genes associated with Alzheimer's using the method of the present invention, and then identifying the genetic problems that the patient has and then applying individualized treatment. In Korea, there is no case where a variety of genetic tests are applied to patients with Alzheimer's disease. Therefore, it is expected that this disease will be competitively enough to diagnose Alzheimer's disease.

도 1은 염색체 상의 30개 후보 유전자 위치를 나타낸다.
도 2는 PCR 매개 유전자 스플라이싱 전략을 나타내는 모식도이다.Figure 1 shows the location of 30 candidate genes on chromosomes.
2 is a schematic diagram showing a PCR mediator gene splicing strategy.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

실시예Example

실험 방법Experimental Method

1. 프라이머 디자인1. Primer design

Primer3Plus (www.primer3plus.com) 소프트웨어를 활용하여 해당 유전자에 가장 적합한 프라이머를 디자인하였다(하기 표 4 내지 표 33 참조). 유전자의 full-length를 전부 PCR로 증폭하여 샘플을 준비하는 과정이 어렵기 때문에 각 엑손(exon)마다 프라이머를 만들어 진행하였다. 그리고 겹치는 부분이 있기 때문에 최종적으로 full-length DNA를 만들 수 있다(도 2 참조). 도 3은 실험의 전반적인 흐름을 도식화하여 나타낸 것이다.Primer3Plus (www.primer3plus.com) software was used to design primers suitable for the gene (see Tables 4 to 33 below). Since it is difficult to prepare the sample by amplifying the full-length of the entire PCR by PCR, a primer was prepared for each exon. Finally, full-length DNA can be made because there is overlap (see FIG. 2). Figure 3 is a schematic representation of the overall flow of the experiment.

2. 차세대 염기서열분석 (next generation sequencing, NGS)2. Next generation sequencing (NGS)

Ion Torrent PGM system을 이용하여 NGS를 실행하였다. 20 ng DNA를 이용하여 멀티플렉스 PCR 을 수행하였다(Ion AmpliSeq Customized Panel, Life Technologies, Grand Island, NY, USA). 단편 라이브러리는 DNA 단편화, 바코드 및 어댑터 결합 및 Ion DNA Barcoding 키트 (Life Technologies, Grand Island, NY, USA)를 이용한 라이브러리 증폭에 의해 구축되었다. DNA 단편의 크기 분포를 High Sensitivity Kit (Agilent, Santa Clara, CA, USA)를 사용하여 Agilent Bioanalyzer로 분석하였다. 주형 제작, 에멀젼(emulsion) PCR 및 이온 구형 입자 (ISP) 농축은 제조사의 지침에 따라 Ion Xpress Template kit (Life Technologies, Grand Island, NY, USA)를 사용하여 수행하였다. ISP를 P1 칩에 로딩하고 이온 P1 시퀀싱 200 키트 (Life Technologies, Grand Island, NY, USA)를 사용하여 시퀀싱하였다. NGS에서 나온 결과는 Torrent Suite Software v.4.4.3 (Life Technologies)으로 분석하였으며, 돌연변이 분석은 Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/)로 진행하였다.NGS was implemented using the Ion Torrent PGM system. Multiplex PCR was performed using 20 ng of DNA (Ion AmpliSeq Customized Panel, Life Technologies, Grand Island, NY, USA). The fragment library was constructed by DNA fragmentation, barcode and adapter binding and library amplification using an Ion DNA Barcoding kit (Life Technologies, Grand Island, NY, USA). The size distribution of the DNA fragments was analyzed with an Agilent Bioanalyzer using the High Sensitivity Kit (Agilent, Santa Clara, Calif., USA). Template making, emulsion PCR and ion globule particle (ISP) enrichment were performed using the Ion Xpress Template kit (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. The ISP was loaded onto the P1 chip and sequenced using the ion P1 sequencing 200 kit (Life Technologies, Grand Island, NY, USA). Results from NGS were analyzed with Torrent Suite Software v.4.4.3 (Life Technologies), and mutation analysis was conducted with Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/).

선행 연구결과나 다른 논문에서 보고된 결과, 또는 Alzforum에 있는 정보를 토대로 30개 유전자를 선정하였다(하기 표 1 참조). 선정된 30개의 유전자에 대해 디자인된 프라이머를 사용하여 NGS 데이터를 얻었다. 선정된 30개의 유전자는 퇴행성 뇌질환을 분석 및 치료 목적으로 활용하였다. 표 2 및 표 3은 디자인된 프라이머로 66명의 EOAD (Early Onset Alzheimer's Disease) 환자와 26명의 LOAD (Late Onset Alzheimer's Disease) 포함 치매환자에게서 30개 유전자에 대한 돌연변이를 분석한 결과이다. 이와 같이 본 발명의 프라이머를 이용하여 여러 뇌질환 의심 환자들의 대한 돌연변이를 분석할 수 있다. 본 발명의 방법에 의한 돌연변이 분석 결과를 다른 진단 기술과 접목하여 진단의 정확도를 높일 수 있으며, 해당 돌연변이에 의한 생물학적 문제가 생길 것으로 예측하여, 이와 관련된 치료에 접근할 수 있다.Thirty genes were selected based on the results of previous studies or reported in other papers, or on information in Alzforum (see Table 1, below). NGS data were obtained using primers designed for selected 30 genes. The selected 30 genes used degenerative brain disease for analysis and treatment. Table 2 and Table 3 show the results of analysis of mutations of 30 genes in designed primers in 66 patients with EOAD (Early Onset Alzheimer's Disease) and 26 patients with dementia including LOAD (Late Onset Alzheimer's Disease). As described above, mutations of suspect patients with various brain diseases can be analyzed using the primers of the present invention. The results of the mutation analysis by the method of the present invention can be combined with other diagnostic techniques to increase the accuracy of diagnosis and anticipate biological problems caused by the mutation and to approach therapies related therewith.

실험결과Experiment result

디자인된 프라이머를 사용하여 초기 발병 알츠하이머 환자 (EOAD, Early onset Alzheimer’s disease)와 후발성 알츠하이머 환자 (LOAD, late onset Alzheimer’s disease)의 혈액에서 DNA를 추출하여 돌연변이를 분석하였다. 66명의 EOAD 환자와 26명의 LOAD포함 치매환자에게서 30개 유전자에 대한 돌연변이를 분석한 결과를 정리하여 표 2에 나타내었다. 도 1은 선별된 유전자들이 위치한 염색체를 보여주며, 선별된 유전자와 유전자들이 연관된 질병을 표 1에 나타내었다. 표 1에 기대된 30개의 유전자는 기존 선행연구와 다른 선행문헌을 통해 선별된 유전자이다.Using the designed primers, DNA was extracted from early onset Alzheimer's disease (EOAD) and late onset Alzheimer's disease (LOAD) patients and mutations were analyzed. Table 2 summarizes the mutation analysis of 30 genes in 66 EOAD patients and 26 LOAD-containing demented patients. Figure 1 shows the chromosomes where the selected genes are located, and Table 1 shows the diseases associated with the selected genes and genes. The 30 genes expected in Table 1 are genes selected through previous studies and other prior literature.

30 개 후보유전자 및 관련 질병30 candidate genes and related diseases 관련 질병Related diseases 유전자수Number of genes 후보 유전자 선정Candidate gene selection Alzheimer's disease (AD) Alzheimer's disease (AD) 1616 APP, APP, PSEN1PSEN1 , , PSEN2PSEN2 , CR1, , CR1, BIN1BIN1 , , TREM2TREM2 , , CLUCLU , CTNNA3, , CTNNA3, DNMBPDNMBP , , SORL1SORL1 , , BACE1BACE1 , , PICALMPICALM , , LPR6LPR6 , ADAM10, , ADAM 10, ABCA7ABCA7 , CD33., CD33. ALS (Amyotrophic Lateral Sclerosis)
& FTD (Frontotemporal dementia)ALS (Amyotrophic Lateral Sclerosis)
& FTD (Frontotemporal dementia) 66 TDP43TDP43 , , SIGMAR1SIGMAR1 , , FUSFUS , , GRNGRN , , MAPTMAPT , , ALS2ALS2 PD (Dementia with Lewy Bodies)PD (Dementia with Lewy Bodies) 55 PINK1PINK1 , , PARK7PARK7 , , PARK9PARK9 , , SNCASNCA , , LRRK2LRRK2 기타 퇴행성 질환Other degenerative diseases 33 CSF1RCSF1R , , NOTCH3NOTCH3 , , PRNPPRNP

Ion AmpliSeq™ NGS Panel 을 이용하여 66 명 EOAD 환자를 분석한 결과 (T means tolerated, D means damaging)We analyzed 66 patients with EOAD using Ion AmpliSeq ™ NGS Panel (T means tolerated, D means damaging) GenesGenes DNA changeDNA change Protein changeProtein change Mutation frequencyMutation frequency rsrs ID ID PolyPhen2PolyPhen2
HumDivHumDiv Sift scoreSift score Clinical featuresClinical features


PSEN1PSEN1 c.356C>T
(Exon 5)c.356C> T
(Exon 5) p.T119Ip.T119I 1/661/66 NovelNovel 0.9
(D)0.9
(D) 0.06
(T)0.06
(T) Novel mutationNovel mutation c.626G>C
(Exon 7)c.626G> C
(Exon 7) p.G209Ap.G209A 1/661/66 NovelNovel 1
(D)One
(D) 0
(D)0
(D) Novel mutationNovel mutation c.695T>C
(Exon 7)c.695T> C
(Exon 7) p.L232Pp.L232P 1/661/66 NovelNovel 1
(D)One
(D) 0
(D)0
(D) Novel mutationNovel mutation c.1250G>C
(Exon 12)c.1250G> C
(Exon 12) p.G417Ap.G417A 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0
(D)0
(D) Novel mutationNovel mutation PSEN2PSEN2 c.505C>A
(Exon 6)c.505C> A
(Exon 6) p.H169Np.H169N 1/661/66 0.00016480.0001648 0.925
(D)0.925
(D) 0.04
(D)0.04
(D) Known mutation, pathogenic nature unclear Known mutation, pathogenic nature unclear TREM2TREM2 No mutationNo mutation





CR1CR1 c.394A>Cc.394A> C p.T132Pp.T132P 1/661/66 rs55906048rs55906048 0.07
(B)0.07
(B) 0.345
(T)0.345
(T) Probable benign variantProbable benign variant c.4973A>Gc.4973A> G p.H1658Rp.H1658R 16/6616/66 rs2274567rs2274567 0.98
(D)0.98
(D) 0.89
(T)0.89
(T) Possible risk factor for ADPossible risk factor for AD c.5573C>Tc.5573C> T p.T1858Mp.T1858M 32/10032/100 rs3737002rs3737002 0.995
(D)0.995
(D) 0.019
(D)0.019
(D) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.6178A>Tc.6178A> T p.T2060Sp.T2060S 66/6666/66 rs4844609rs4844609 0.95
(D)0.95
(D) 0.019
(D)0.019
(D) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.6193A>Gc.6193A> G p.I2065Vp.I2065V 18/6618/66 rs6691117rs6691117 0.005
(B)0.005
(B) 1
(T)One
(T) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.6653T>Cc.6653T> C p.V2218Ap.V2218A 1/661/66 rs191751915rs191751915 0.85
(D)0.85
(D) 0.19
(T)0.19
(T) Possible AD risk factorPossible AD risk factor c.6830C>Gc.6830C> G p.P2277Rp.P2277R 18/6618/66 rs3811381rs3811381 0.032
(B)0.032
(B) 0.44
(T)0.44
(T) Probable benign variantProbable benign variant c.7255A>Gc.7255A> G p.T2419Ap.T2419A 29/6629/66 rs2296160rs2296160 0.001
(B)0.001
(B) 0.98
(T)0.98
(T) Common variantCommon variant BIN1BIN1 c.1292C>Tc.1292C> T p.P431Lp.P431L 4/664/66 rs141119288rs141119288 0.99
(D)0.99
(D) 0.07
(T)0.07
(T) Probably AD risk factorProbably AD risk factor CLUCLU c.380G>Ac.380G> A p.R127Hp.R127H 1/661/66 NovelNovel 0.56
(D)0.56
(D) 0.003
(D)0.003
(D) Probably AD risk factorProbably AD risk factor

CTNNA3CTNNA3 c.1787G>Ac.1787G> A p.S596Np.S596N 14/6614/66 rs4548513rs4548513 0.001
(B)0.001
(B) 1
(T)One
(T) Possible risk factor for LOAD and autismPossible risk factor for LOAD and autism c.1850T>Cc.1850T> C p.I617Tp.I617T 2/662/66 NovelNovel 0.928
(D)0.928
(D) 0.001
(D)0.001
(D) Unknown significanceUnknown significance c.2404G>Tc.2404G> T p.D802Yp.D802Y 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0.001
(D)0.001
(D) Unknown significanceUnknown significance

DNMBPDNMBP c.2633C>Tc.2633C> T p.A878Vp.A878V 1/661/66 rs116707029rs116707029 0.67
(D)0.67
(D) 0.035
(D)0.035
(D) Unknown significanceUnknown significance c.3154C>Tc.3154C> T p.R1052Wp.R1052W 1/661/66 rs115117818rs115117818 1
(D)One
(D) 0.001
(D)0.001
(D) Unknown significanceUnknown significance c.3410G>Ac.3410G> A p.R1137Qp.R1137Q 1/661/66 rs116296676rs116296676 0.99
(D)0.99
(D) 0.006
(T)0.006
(T) Unknown significanceUnknown significance c.4239T>Gc.4239T> G p.C1413Wp.C1413W 28/6628/66 rs11190305rs11190305 0.094
(B)0.094
(B) 0.18
(T)0.18
(T) Common variantCommon variant







SORL1SORL1 c.829G>Cc.829G> C p.V277Lp.V277L 1/661/66 NovelNovel 0.173
(B)0.173
(B) 0.01
(D)0.01
(D) Unknown significanceUnknown significance c.1528G>Cc.1528G> C p.G511Rp.G511R 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0
(D)0
(D) Unknown significanceUnknown significance c.1582G>Ac.1582G> A p.A528Tp.A528T 22/6622/66 rs2298813rs2298813 0.59
(D)0.59
(D) 0.3
(T)0.3
(T) AD risk factorAD risk factor c.2586T>Gc.2586T> G p.D862Ep.D862E 1/661/66 NovelNovel 0.178
(B)0.178
(B) 0.05
(D)0.05
(D) UnknownUnknown :c.3220C>G: c.3220C> G p.E1074Qp.E1074Q 66/6666/66 rs1699107rs1699107 0
(B)0
(B) 0.16
(T)0.16
(T) Common variantCommon variant c.3476G>Ac.3476G> A p.R1159Qp.R1159Q 1/661/66 rs527617199rs527617199 0.62
(D)0.62
(D) 0.45
(T)0.45
(T) UnknownUnknown :c.4447A>G: c.4447A> G p.T1483Ap.T1483A 1/661/66 rs143286467rs143286467 0.002
(D)0.002
(D) 0.3
(T)0.3
(T) UnknownUnknown c.4570G>Ac.4570G> A p.G1524Rp.G1524R 2/662/66 rs201415809rs201415809 0.99
(D)0.99
(D) 0.005
(D)0.005
(D) UnknownUnknown c.5899A>Gc.5899A> G p.V1967Ip.V1967I 66/6666/66 rs1792120 rs1792120 0.003
(B)0.003
(B) 1
(T)One
(T) Common, unknownCommon, unknown c.6289G>Ac.6289G> A p.V2097Ip.V2097I 1/661/66 rs74642146rs74642146 0.9
(D)0.9
(D) 0.16
(T)0.16
(T) UnknownUnknown BACE1BACE1 c.1141C>Tc.1141C> T p.C481Rp.C481R 66/6666/66 rs539765rs539765 0
(B)0
(B) 0.4
(T)0.4
(T) Common mutationCommon mutation

LRP6LRP6 c.379T>Ac.379T> A p.S127Tp.S127T 2/662/66 rs17848270rs17848270 0.001
(B)0.001
(B) 0.8
(T)0.8
(T) UnknownUnknown c.427A>Gc.427A> G p.I143Vp.I143V 1/661/66 NovelNovel 0.93
(D)0.93
(D) 0.13
(T)0.13
(T) UnknownUnknown c.2902C>Tc.2902C> T p.R968Wp.R968W 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0.001
(D)0.001
(D) UnknownUnknown c.3184G>Ac.3184G> A p.V1062Ip.V1062I 59/6659/66 rs2302685rs2302685 0
(B)0
(B) 1
(T)One
(T) Common mutation, possible AD risk factorCommon mutation, possible AD risk factor ADAM10ADAM10 c.763A>Gc.763A> G p.T255Ap.T255A 2/662/66 rs147572059rs147572059 0.004
(B0.004
(B 0.88
(T)0.88
(T) UnknownUnknown















ABCA7ABCA7 c.563A>Gc.563A> G p.E188Gp.E188G 9/669/66 rs3764645rs3764645 0.06
(B)0.06
(B) 0.67
(T)0.67
(T) UnknownUnknown c.955A>Gc.955A> G p.T319Ap.T319A 11/6611/66 rs3752232rs3752232 0.142
(B)0.142
(B) 0.446
(T)0.446
(T) Possible AD risk factorPossible AD risk factor c.1184A>Gc.1184A> G p.H395Rp.H395R 11/6611/66 rs3764647rs3764647 0.02
(B0.02
(B 1
(T)One
(T) Possible AD risk factorPossible AD risk factor c.1384G>Cc.1384G> C p.V462Lp.V462L 1/661/66 NovelNovel 0.08
(B)0.08
(B) 0.086
(T)0.086
(T) UnknownUnknown c.1388G>Ac.1388G> A p.R463Hp.R463H 3/663/66 rs3752233rs3752233 0.8
(D)0.8
(D) 0.25
(T)0.25
(T) UnknownUnknown c.2153A>Cc.2153A> C p.N718Tp.N718T 3/663/66 rs3752239rs3752239 0.58
(D)0.58
(D) 0.24
(T)0.24
(T) UnknownUnknown c.1620delCc.1620delC p.D540fsp.D540fs 1/661/66 NovelNovel -- -- UnknownUnknown c.1832T>Gc.1832T> G p.V611Gp.V611G 1/661/66 NovelNovel 0.97
(D)0.97
(D) 0.004
(D)0.004
(D) UnknownUnknown c.2892C>Gc.2892C> G p.D964Ep.D964E 2/662/66 rs117390715rs117390715 1
(D)One
(D) 0
(D)0
(D) UnknownUnknown c.2923C>Tc.2923C> T p.R975Cp.R975C 1/661/66 NovelNovel 1 (D)1 (D) 0 (D)0 (D) UnknownUnknown c.3629G>Ac.3629G> A p.R1210Qp.R1210Q 1/661/66 NovelNovel 0.006
(B)0.006
(B) 1
(T)One
(T) UnknownUnknown c.3641G>Ac.3641G> A p.W1214*p.W1214 * 1/661/66 KnownKnown -- -- AD risk factor, stop codonAD risk factor, stop codon c.4046G>Ac.4046G> A p.R1349Qp.R1349Q 6/666/66 rs3745842rs3745842 0.004
(B)0.004
(B) 0.54
(T)0.54
(T) Common variant, unknown Common variant, unknown c.4211A>Gc.4211A> G p.K1404Rp.K1404R 1/661/66 NovelNovel 0.03
(B)0.03
(B) 0.002
(D)0.002
(D) UnknownUnknown c.4580G>Cc.4580G> C p.G1527Ap.G1527A 29/6629/66 rs3752246rs3752246 0
(B)0
(B) 0.87
(T)0.87
(T) Common variant, unknownCommon variant, unknown c.5057A>Gc.5057A> G p.Q1686Rp.Q1686R 3/663/66 rs4147918rs4147918 0.004
(B)0.004
(B) 0.23
(T)0.23
(T) Common variant, unknownCommon variant, unknown c.5069T>Cc.5069T> C p.I1690Tp.1690T 2/662/66 rs184218896rs184218896 0.911
(D)0.911
(D) 0.001
(T)0.001
(T) UnknownUnknown c.5666C>Tc.5666C> T p.P1898Sp.P1898S 1/661/66 NovelNovel 0.9
(D)0.9
(D) 0.08
(T)0.08
(T) UnknownUnknown c.5789A>Gc.5789A> G p.N1930Sp.N1930S 1/661/66 NovelNovel 0.98
(D)0.98
(D) 0.002
(D)0.002
(D) UnknownUnknown c.5963G>Tc.5963G> T p.C1988Fp.C1988F 1/661/66 rs142573667rs142573667 1
(D)One
(D) 0
(D)0
(D) UnknownUnknown c.6133G>Tc.6133G> T p.A2045Sp.A2045S 11/6611/66 rs4147934rs4147934 0.051
(B)0.051
(B) 0.96
(T)0.96
(T) Common mutation, unknownCommon mutation, unknown c.6633G>Tc.6633G> T p.F2071Cp.F2071C 2/662/66 NovelNovel 0.5
(B)0.5
(B) 0.46
(T)0.46
(T) Common mutation, unknownCommon mutation, unknown
CD33CD33 c.41C>Tc.41C> T p.A14Vp.A14V 1/661/66 rs12459419rs12459419 0.023
(B)0.023
(B) 0.08
(T)0.08
(T) AD risk factorAD risk factor c.205A>Gc.205A> G p.R69Gp.R69G 3/663/66 rs2455069rs2455069 0.009
(B)0.009
(B) 0.33
(T)0.33
(T) UnknownUnknown c.594A>Gc.594A> G p.I198Mp.I198M 1/661/66 rs200827254rs200827254 0.105
(B)0.105
(B) 0.006
(T)0.006
(T) UnknownUnknown c.880G>Tc.880G> T p.V294Lp.V294L 1/661/66 rs2271652rs2271652 0.001
(B)0.001
(B) 0.16
(T)0.16
(T) UnknownUnknown


PINK1PINK1 c.755A>Tc.755A> T p.E252Vp.E252V 1/661/66 NovelNovel 0.605
(D)0.605
(D) 0.05
(D)0.05
(D) unknownunknown c.1018G>Ac.1018G> A p.A340Tp.A340T 35/6635/66 rs3738136rs3738136 0.001
(B)0.001
(B) 1
(T)One
(T) UnknownUnknown c.1562A>Cc.1562A> C p.N521Tp.N521T 33/6633/66 rs1043424rs1043424 0.005
(B)0.005
(B) 0.24
(T)0.24
(T) UnknownUnknown PARK7PARK7 c.535G>Ac.535G> A p.A179Tp.A179T 1/661/66 rs71653622rs71653622 0. 001
(B)0. 001
(B) 0.56
(T)0.56
(T) UnknownUnknown

ATP13A2ATP13A2 (PARK9) (PARK9) c.317A>Gc.317A> G p.Q106Rp.Q106R 1/661/66 NovelNovel 0.008
(B)0.008
(B) 0.47
(T) 0.47
(T) UnknownUnknown c.1817C>Gc.1817C> G p.P606Rp.P606R 1/661/66 NovelNovel 0.93
(D)0.93
(D) 0.025
(D)0.025
(D) UnknownUnknown c.3175C>Tc.3175C> T p.L1059Fp.L1059F 1/661/66 NovelNovel 0.74
(D)0.74
(D) 0.005
(D)0.005
(D) UnknownUnknown SNCASNCA c.381G>Ac.381G> A p.M127Ip.M127I 1/661/66 rs191055637rs191055637 0.77
(D)0.77
(D) 0.16
(T)0.16
(T) UnknownUnknown PARK2PARK2 c.500G>Ac.500G> A p.S167Np.S167N 16/6616/66 rs1801474rs1801474 0.03
(B)0.03
(B) 0.31
(T)0.31
(T) Benign variantBenign variant c.799T>Cc.799T> C p.Y267Hp.Y267H 1/661/66 rs114696251rs114696251 0.99
(D)0.99
(D) 0
(D)0
(D) UnknownUnknown c.1138G>Cc.1138G> C p.V380Lp.V380L 4/664/66 rs1801582rs1801582 0
(B)0
(B) 0.37
(T)0.37
(T) Benign variantBenign variant LRRK2LRRK2 c.149A>Gc.149A> G p.R50Hp.R50H 66/6666/66 rs2256408rs2256408 0
(B)0
(B) 1
(T)One
(T) Common variant, PD risk factorCommon variant, PD risk factor c.691T>Cc.691T> C p.S231Pp.S231P 1/661/66 rs201332859rs201332859 0.004
(B)0.004
(B) 0.3
(T)0.3
(T) UnknownUnknown c.1256C>Tc.1256C> T p.A419Vp.A419V 2/662/66 rs34594498rs34594498 0.49
(D)0.49
(D) 0.03
(D)0.03
(D) PD risk factorPD risk factor c.1598T>Cc.1598T> C p.V533Ap.V533A 1/661/66 NovelNovel 0.5
(T)0.5
(T) 0.004
(D)0.004
(D) UnknownUnknown c.1653C>Gc.1653C> G p.N551Kp.N551K 16/6616/66 rs7308720rs7308720 0.005
(D)0.005
(D) 0.972
(D)0.972
(D) Possible PD risk factorPossible PD risk factor c.2167A>Gc.2167A> G p.I723Vp.I723V 2/662/66 rs10878307rs10878307 0.001
(B)0.001
(B) 0.68
(T)0.68
(T) Possible PD risk factorPossible PD risk factor c.4193G>Ac.4193G> A p.R1398Hp.R1398H 13/6613/66 rs7133914rs7133914 0.58
(D)0.58
(D) 0.1
(T)0.1
(T) Possible PD risk factorPossible PD risk factor c.4337C>Tc.4337C> T p.P1446Lp.P1446L 1/661/66 rs74681492rs74681492 1
(D)One
(D) 0.008
(T)0.008
(T) Possible risk factorPossible risk factor c.4939T>A,c.4939T > A, p.S1647Tp.S1647T 30/6630/66 rs11564148rs11564148 0
(B)0
(B) 0.95
(T)0.95
(T) Possible risk factorPossible risk factor c.7153G>Ac.7153G> A p.G2385Rp.G2385R 5/665/66 rs34778348rs34778348 0.013(B)0.013 (B) 0.4 (T)0.4 (T) Possible PD risk factorPossible PD risk factor c.7190T>Cc.7190T> C p.M2397Tp.M2397T 43/6643/66 rs3761863rs3761863 0
(B)0
(B) 0.466
(T)0.466
(T) Possible PD risk factorPossible PD risk factor SIGMAR1SIGMAR1 c.5A>Cc.5A> C p.Q2Pp.Q2P 11/6611/66 rs1800866rs1800866 0
(B)0
(B) 0.343
(T)0.343
(T) Possible risk factorPossible risk factor c.622C>Tc.622C> T p.R208Wp.R208W 6/666/66 rs11559048rs11559048 0.94
(D)0.94
(D) 0.01
(D)0.01
(D) UnknownUnknown c.632G>Ac.632G> A p.R211Qp.R211Q 1/661/66 rs192644838rs192644838 0.57
(D)0.57
(D) 0.29
(T)0.29
(T) UnknownUnknown FUSFUS c.451C>Tc.451C> T p.P151Sp.P151S 1/661/66 NovelNovel 0.007
(B)0.007
(B) 0.03
(D)0.03
(D) UnknownUnknown GRNGRN (PGRN) (PGRN) c.119G>Ac.119G> A p.S40Np.S40N 1/661/66 NovelNovel 0.75
(D)0.75
(D) 0.015
(D)0.015
(D) Probable novel mutationProbable novel mutation c.1690C>Tc.1690C> T p.R564Cp.R564C 1/661/66 NovelNovel 0.87
(D)0.87
(D) 0.04
(D)0.04
(D) AD risk factor mutationAD risk factor mutation MAPTMAPT c.418C>Tc.418C> T p.P140Sp.P140S 3/663/66 rs151115928rs151115928 0.846
(D)0.846
(D) 0.04
(D)0.04
(D) UnknownUnknown c.1321T>Cc.1321T> C p.Y441Hp.Y441H 59/6659/66 rs112757188rs112757188 0
(B)0
(B) 0.97
(T)0.97
(T) Common mutation, unknownCommon mutation, unknown TDP43TDP43 No mutation-No mutation-

ALS2ALS2 c.475G>Ac.475G> A p.E159Kp.E159K 2/662/66 NovelNovel 0.156
(B)0.156
(B) 0.15
(T)0.15
(T) UnknownUnknown c.1102G>Ac.1102G> A p.V368Mp.V368M 66/6666/66 NovelNovel 0.009
(B)0.009
(B) 0.191
(T)0.191
(T) Common mutation, unknownCommon mutation, unknown c.2278C>Gc.2278C> G p.L760Vp.L760V 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0.14
(T)0.14
(T) UnknownUnknown c.2953C>Tc.2953C> T p.L985Fp.L985F 1/661/66 rs41308836rs41308836 0.0953
(D)0.0953
(D) 0.005
(D)0.005
(D) UnknownUnknown c.3517G>Ac.3517G> A p.E1173Kp.E1173K 3/663/66 rs41309046rs41309046 0.8
(D)0.8
(D) 0.003
(D)0.003
(D) UnknownUnknown c.4892A>Gc.4892A> G p.Y1631Cp.Y1631C 1/661/66 NovelNovel 0.003
(D)0.003
(D) 0.18
(T)0.18
(T) UnknownUnknown
CSF1RCSF1R c.544G>Tc.544G> T p.G182Cp.G182C 1/661/66 NovelNovel 0.782
(D)0.782
(D) 0.01
(D)0.01
(D) UnknownUnknown c.635T>Ac.635T> A p.L212Qp.L212Q 1/661/66 NovelNovel 0.2
(D)0.2
(D) 0.14
(T)0.14
(T) Possible novel variantPossible novel variant c.637G>Ac.637G> A p.V213Mp.V213M 1/661/66 NovelNovel 0.93
(D)0.93
(D) 0.001
(D)0.001
(D) UnknownUnknown c.835G>Ac.835G> A p.V279Mp.V279M 3/663/66 rs3829986rs3829986 0.19
(B)0.19
(B) 0.11
(T)0.11
(T) UnknownUnknown c.1085A>Gc.1085A> G p.H362Rp.H362R 40/6640/66 rs10079250rs10079250 0.15
(B)0.15
(B) 0.06
(T)0.06
(T) Common mutation, possible cancer risk factorCommon mutation, possible cancer risk factor c.2806G>Ac.2806G> A p.G936Sp.G936S 1/661/66 NovelNovel 0.78
(D)0.78
(D) 0.01
(D)0.01
(D) Possible novel variantPossible novel variant NOTCH3NOTCH3 c.709G>Ac.709G> A p.V237Mp.V237M 1/661/66 rs2285981rs2285981 0.25
(B)0.25
(B) 0.001
(D)0.001
(D) UnknownUnknown c.2320C>Gc.2320C> G p.P774Ap.P774A 1/661/66 NovelNovel 0.99
(D)0.99
(D) 0.004
(T)0.004
(T) UnknownUnknown c.2519G>Ac.2519G> A p.G840Ep.G840E 1/661/66 NovelNovel 1
(D)One
(D) 0.001
(D)0.001
(D) UnknownUnknown c.3523C>Tc.3523C> T p.R1175Wp.R1175W 1/661/66 rs200504060rs200504060 0.91
(D)0.91
(D) 0.004
(D)0.004
(D) UnknownUnknown c.3620A>Gc.3620A> G p.N1207Sp.N1207S 2/662/66 rs141418355rs141418355 0.99
(D)0.99
(D) 0.002
(D)0.002
(D) UnknownUnknown c.4348G>Ac.4348G> A p.A1450Tp.A1450T 3/663/66 NovelNovel 0.61
(D)0.61
(D) 0.11
(T)0.11
(T) UnknownUnknown c.6668C>Tc.6668C> T p.A2223Vp.A2223V 18/6618/66 rs1044009rs1044009 0.003
(B)0.003
(B) 0.14
(T)0.14
(T) Common mutationCommon mutation


PRNPPRNP c.385A>Gc.385A> G p.M129Vp.M129V 1/661/66 rs1799990rs1799990 0.012
(B)0.012
(B) 0.024
(D)0.024
(D) Pathogenic nature complicatedPathogenic nature complicated c.655G>Ac.655G> A p.E219Kp.E219K 7/667/66 rs1800014rs1800014 0.003
(B)0.003
(B) 0.035
(D)0.035
(D) Pathogenic nature complicatedPathogenic nature complicated c.674A>Gc.674A> G p.Y225Cp.Y225C 1/661/66 NovelNovel 0.98
(D)0.98
(D) 0.001
(D)0.001
(D) May be involved in CJD, novelMay be involved in CJD, novel c.695T>Gc.695T> G p.M232Rp.M232R 1/661/66 rs74315409rs74315409 0.707
(D)0.707
(D) 0.001
(D)0.001
(D) CJD or AD involvementCJD or AD involvement

Ion AmpliSeq™ NGS Panel을 이용하여 26 명 환자 (LOAD + Unknown + dementia)에서 30개 유전자를 분석한 결과 (T means tolerated, D means damaging)We analyzed 30 genes in 26 patients (LOAD + Unknown + dementia) using Ion AmpliSeq ™ NGS Panel (T means tolerated, D means damaging) GenesGenes DNA changeDNA change Protein changeProtein change Mutation frequencyMutation frequency ExACExAC frequency frequency PolyPhen2PolyPhen2
HumDivHumDiv Sift scoreSift score Clinical featuresClinical features APPAPP c.674T>Cc.674T> C p.V225Ap.V225A 1/261/26 NovelNovel 0.577 (D)0.577 (D) 0.496 (T)0.496 (T) Unknown significanceUnknown significance PSEN1PSEN1 No mutationNo mutation PSEN2PSEN2 No mutationNo mutation TREM2TREM2 No mutationNo mutation



CR1CR1 c.5573C>Tc.5573C> T p.1858Mp.1858M 17/2617/26 0.27500.2750 0.995(D)0.995 (D) 0.019 (D)0.019 (D) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.6193A>Gc.6193A> G p.I2065Vp.I2065V 5/265/26 0.33410.3341 0.005(B)0.005 (B) 1 (T)1 (T) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.6178A>Tc.6178A> T p.T2060Sp.T2060S 26/2626/26 0.98530.9853 0.95(D)0.95 (D) 0.019(D)0.019 (D) Common variant, possible AD risk factorCommon variant, possible AD risk factor c.7255A>Gc.7255A> G p.T2419Ap.T2419A 24/2624/26 0.81590.8159 0.001(B)0.001 (B) 0.98(T)0.98 (T) Common variantCommon variant c.6830C>Gc.6830C> G p.P2277Rp.P2277R 4/264/26 0.24030.2403 0.032(B)0.032 (B) 0.44(T)0.44 (T) Probable benign variantProbable benign variant BIN1BIN1 c.1292C>Tc.1292C> T p.P431Lp.P431L 1/261/26 0.0034130.003413 0.99(D)0.99 (D) 0.07(T)0.07 (T) Probably AD risk factorProbably AD risk factor CLUCLU c.545G>Ac.545G> A p.R182Hp.R182H 1/261/26 NovelNovel 0.87(D)0.87 (D) 0.1(T)0.1 (T) Probably AD risk factorProbably AD risk factor c.1283C>Gc.1283C> G p.P428Rp.P428R 1/261/26 NovelNovel 1(D)1 (D) 0.001(D)0.001 (D) Probably AD risk factorProbably AD risk factor CTNNA3CTNNA3 c.1787G>Ac.1787G> A p.S596Np.S596N 17/2617/26 0.41200.4120 0.001 (B)0.001 (B) 1.0 (T)1.0 (T) Common variantCommon variant

DNMBPDNMBP c.1119C>Gc.1119C> G p.N373Kp.N373K 1/261/26 0.045180.04518 0.016 (B)0.016 (B) 0.195 (T)0.195 (T) Unknown significanceUnknown significance c.4138G>Ac.4138G> A p.G1380Sp.G1380S 1/261/26 0.00065990.0006599 0.002 (B)0.002 (B) 0.94 (T)0.94 (T) Unknown significanceUnknown significance c.4239T>Gc.4239T> G p.C1413Wp.C1413W 4/264/26 0.34420.3442 0.094 (B)0.094 (B) 0.18 (T)0.18 (T) Common variantCommon variant

SORL1SORL1 c.1582G>Ac.1582G> A p.A528Tp.A528T 10/2610/26 0.072190.07219 0.59 (D)0.59 (D) 0.3 (T)0.3 (T) AD risk factorAD risk factor c.3220C>Gc.3220C> G p.E1074Qp.E1074Q 26/2626/26 0.99490.9949 0 (B)0 (B) 0.16 (T)0.16 (T) Common variantCommon variant c.4570G>Ac.4570G> A p.G1524Rp.G1524R 1/261/26 0.00018130.0001813 0.99(D)0.99 (D) 0.005(D)0.005 (D) UnknownUnknown c.5899A>Gc.5899A> G p.V1967Ip.V1967I 26/2626/26 0.99530.9953 0.003(B)0.003 (B) 1(T)1 (T) Common, unknownCommon, unknown BACE1BACE1 c.1141C>Tc.1141C> T p.C481Rp.C481R 26/2626/26 0.99970.9997 0(B)0 (B) 0.4 (T)0.4 (T) Common mutationCommon mutation
LRP6LRP6 c.379T>Ac.379T> A p.S127Tp.S127T 1/261/26 0.0019800.001980 0.001(B)0.001 (B) 0.8(T)0.8 (T) UnknownUnknown c.3184G>Ac.3184G> A p.V1062Ip.V1062I 26/2626/26 0.84740.8474 0(B)0 (B) 1(T)1 (T) Common mutation, possible AD risk factorCommon mutation, possible AD risk factor ADAM10ADAM10 c.1661A>Gc.1661A> G p.D554Gp.D554G 1/261/26 NovelNovel 0.02 (B)0.02 (B) 0.377 (T)0.377 (T) UnknownUnknown









ABCA7ABCA7 c.563A>Gc.563A> G p.E188Gp.E188G 21/2621/26 0.48380.4838 0.06 (B)0.06 (B) 0.67 (T)0.67 (T) UnknownUnknown c.955A>Gc.955A> G p.T319Ap.T319A 4/264/26 0.060390.06039 0.142 (B)0.142 (B) 0.446 (T)0.446 (T) Possible AD risk factorPossible AD risk factor c.1184A>Gc.1184A> G p.H395Rp.H395R 4/264/26 0.062980.06298 0.02 (B0.02 (B 1 (T)1 (T) Possible AD risk factorPossible AD risk factor c.1388G>Ac.1388G> A p.R463Hp.R463H 8/268/26 0.047750.04775 0.8 (D)0.8 (D) 0.25 (T)0.25 (T) UnknownUnknown c.1570C>Tc.1570C> T p.R524Wp.R524W 2/262/26 0.00022590.0002259 0.75 (D)0.75 (D) 0.01 (D)0.01 (D) UnknownUnknown c.2153A>Cc.2153A> C p.N718Tp.N718T 9/269/26 0.070280.07028 0.58 (D)0.58 (D) 0.24 (T)0.24 (T) UnknownUnknown c.4046G>Ac.4046G> A p.R1349Qp.R1349Q 17/2617/26 0.44330.4433 0.004 (B)0.004 (B) 0.54 (T)0.54 (T) Common variant, unknown Common variant, unknown c.4580G>Cc.4580G> C p.G1527Ap.G1527A 24/2624/26 0.84050.8405 0 (B)0 (B) 0.87(T)0.87 (T) Common variant, unknownCommon variant, unknown c.5057A>Gc.5057A> G p.Q1686Rp.Q1686R 8/268/26 0.047850.04785 0.004(B)0.004 (B) 0.23 (T)0.23 (T) Common variant, unknownCommon variant, unknown c.5609G>Tc.5609G> T p.G1870Vp.G1870V 1/261/26 0.0000083950.000008395 0.99 (D)0.99 (D) 0 (D)0 (D) UnknownUnknown c.6133G>Tc.6133G> T p.A2045Sp.A2045S 24/2624/26 0.73170.7317 0.051 (B)0.051 (B) 0.96 (T)0.96 (T) Common mutation, unknownCommon mutation, unknown
CD33CD33 c.41C>Tc.41C> T p.A14Vp.A14V 11/2611/26 0.29390.2939 0.023 (B)0.023 (B) 0.08 (T)0.08 (T) AD risk factorAD risk factor c.205A>Gc.205A> G p.R69Gp.R69G 3/263/26 0.35770.3577 0.009 (B)0.009 (B) 0.33 (T)0.33 (T) UnknownUnknown PINK1PINK1 c.1018G>Ac.1018G> A p.A340Tp.A340T 10/2610/26 0.092110.09211 0.001(B)0.001 (B) 1 (T)1 (T) UnknownUnknown c.1562A>Cc.1562A> C p.N521Tp.N521T 14/2614/26 0.092110.09211 0.005 (B)0.005 (B) 0.24 (T)0.24 (T) UnknownUnknown PARK7PARK7 No mutationNo mutation ATP13A2ATP13A2 (PARK9) (PARK9) c.1499G>Tc.1499G> T p.R500Lp.R500L 1/261/26 NovelNovel 1 (D)1 (D) 0 (D)0 (D) UnknownUnknown c.745G>Ac.745G> A p.A249Tp.A249T 1/261/26 0.00011730.0001173 0.006(B)0.006 (B) 0.25 (T)0.25 (T) UnknownUnknown SNCASNCA No mutationNo mutation PARK2PARK2 c.500G>Ac.500G> A p.S167Np.S167N 20/2620/26 0.067580.06758 0.03(B)0.03 (B) 0.310.31 Benign variantBenign variant c.1138G>Cc.1138G> C p.V380Lp.V380L 4/264/26 0.16460.1646 0 (B)0 (B) 0.37 (T)0.37 (T) Benign variantBenign variant LRRK2LRRK2 c.149A>Gc.149A> G p.R50Hp.R50H 26/2626/26 0.99110.9911 0 (B)0 (B) 1 (T)1 (T) Common variant, PD risk factorCommon variant, PD risk factor c.1653C>Gc.1653C> G p.N551Kp.N551K 7/267/26 0.086070.08607 0.005(D)0.005 (D) 0.972 (D)0.972 (D) Possible PD risk factorPossible PD risk factor c.2264C>Tc.2264C> T p.P755Lp.P755L 1/661/66 NovelNovel 0.2
(B)0.2
(B) 0.3
(T)0.3
(T) PD risk factorPD risk factor c.4193G>Ac.4193G> A p.R1398Hp.R1398H 7/267/26 0.084120.08412 0.58 (D)0.58 (D) 0.1(T)0.1 (T) Possible PD risk factorPossible PD risk factor c.4337C>Tc.4337C> T p.P1446Lp.P1446L 1/261/26 0.00024730.0002473 1 (D)1 (D) 0.008 (T)0.008 (T) Possible risk factorPossible risk factor c.4939T>Ac.4939T> A p.S1647Tp.S1647T 14/2614/26 0.29830.2983 0 (B)0 (B) 0.95 (T)0.95 (T) Possible risk factorPossible risk factor c.7153G>Ac.7153G> A p.G2385Rp.G2385R 3/263/26 0.11290.1129 0.013(B)0.013 (B) 0.4 (T)0.4 (T) Possible PD risk factorPossible PD risk factor c.7190T>Cc.7190T> C p.M2397Tp.M2397T 19/2619/26 0.62400.6240 0 (B)0 (B) 0.466(T)0.466 (T) Possible PD risk factorPossible PD risk factor SIGMAR1SIGMAR1 c.5A>Cc.5A> C p.Q2Pp.Q2P 16/2616/26 0.18400.1840 0 (B)0 (B) 0.343(T)0.343 (T) Possible risk factorPossible risk factor c.632G>Ac.632G> A p.R211Qp.R211Q 1/261/26 0.000099340.00009934 0.57 (D)0.57 (D) 0.29 (T)0.29 (T) UnknownUnknown c.622C>Tc.622C> T p.R208Wp.R208W 3/263/26 0.0077820.007782 0.94 (D)0.94 (D) 0.01(D)0.01 (D) UnknownUnknown FUSFUS No mutationNo mutation GRNGRN No mutationNo mutation MAPTMAPT c.530A>Tc.530A> T p.D177Vp.D177V 2/262/26 0.00072730.0007273 0.846 (D)0.846 (D) 0.04 (D)0.04 (D) Possible involvement with FTDPossible involvement with FTD c.1321T>Cc.1321T> C p.Y441Hp.Y441H 18/2618/26 0.00017990.0001799 0.92 (D)0.92 (D) 0 (D)0 (D) UnknownUnknown TDP43TDP43 No mutationNo mutation ALS2ALS2 c.1102G>Ac.1102G> A p.V368Mp.V368M 26/2626/26 0.91060.9106 0.009(B)0.009 (B) 0.191(T)0.191 (T) Common mutation, unknownCommon mutation, unknown c.3517G>Ac.3517G> A p.E1173Kp.E1173K 1/261/26 0.0022110.002211 0.8 (D)0.8 (D) 0.003(D)0.003 (D) UnknownUnknown
CSF1RCSF1R c.835G>Ac.835G> A p.V279Mp.V279M 3/263/26 0.0025370.002537 0.19(B)0.19 (B) 0.11(T)0.11 (T) UnknownUnknown c.1085A>Gc.1085A> G p.H362Rp.H362R 16/2616/26 0.000099840.00009984 0.15 (B)0.15 (B) 0.06 (T)0.06 (T) Common mutation, possible cancer risk factorCommon mutation, possible cancer risk factor c.733G>Tc.733G> T p.A245Tp.A245T 1/261/26 0.000050220.00005022 0.008(B)0.008 (B) 0.6(T)0.6 (T) UnknownUnknown NOTCH3NOTCH3 c.224G>Ac.224G> A p.R75Qp.R75Q 1/261/26 0.00046390.0004639 0.6(D)0.6 (D) 0.25(T)0.25 (T) UnknownUnknown c.709G>Ac.709G> A p.V237Mp.V237M 1/261/26 0.0000084490.000008449 0.25(B)0.25 (B) 0.001(D)0.001 (D) UnknownUnknown c.2208C>Ac.2208C> A p.D736Ep.D736E 1/261/26 NovelNovel 0.97(D)0.97 (D) 0.004(T)0.004 (T) UnknownUnknown c.2966T>Gc.2966T> G p.L989Rp.L989R 1/261/26 NovelNovel 0.001(B)0.001 (B) 0.06 (T)0.06 (T) UnknownUnknown c.6668C>Tc.6668C> T p.A2223Vp.A2223V 23/2623/26 0.75910.7591 0.003(B)0.003 (B) 0.14(T)0.14 (T) Common mutationCommon mutation PRNPPRNP c.385A>Gc.385A> G p.M129Vp.M129V 1/261/26 0.30780.3078 0.012 (B)0.012 (B) 0.024 (D)0.024 (D) Pathogenic nature complicatedPathogenic nature complicated c.655G>Ac.655G> A p.E219Kp.E219K 2/262/26 0.0087280.008728 0.003 (B)0.003 (B) 0.035 (D)0.035 (D) Pathogenic nature complicatedPathogenic nature complicated

본 발명에서 디자인된 프라이머 (PSEN2)The primer designed in the present invention ( PSEN2 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) XM_005273198.1_ex1F XM_005273198.1_ex1F cccagtggacgagggaaccccagtggacgagggaac 6161 6666 122122 XM_005273198.1_ex1R XM_005273198.1_ex1R gctccagcggagtttacggctccagcggagtttacg 5959 6161 122122 XM_005273198.1_ex2F XM_005273198.1_ex2F tctgttagcagcggtgtttgtctgttagcagcggtgtttg 6060 5050 265265 XM_005273198.1_ex2R XM_005273198.1_ex2R taaacaggggtgaggtctgctaaacaggggtgaggtctgc 6060 5555 265265 XM_005273198.1_ex3F XM_005273198.1_ex3F cagggggaggaaggtgagcaggggggaggaaggtgag 6161 6767 366366 XM_005273198.1_ex3R XM_005273198.1_ex3R aaaatgccacagcaaactccaaaatgccacagcaaactcc 6060 4545 366366 XM_005273198.1_ex4F XM_005273198.1_ex4F tgtgtccaagtctccaggtctgtgtccaagtctccaggtc 5959 5555 350350 XM_005273198.1_ex4R XM_005273198.1_ex4R atcagggaatgaatgtctggatcagggaatgaatgtctgg 6060 4848 350350 XM_005273198.1_ex5F XM_005273198.1_ex5F caaacttctcatttctggttcccaaacttctcatttctggttcc 5858 4141 395395 XM_005273198.1_ex5R XM_005273198.1_ex5R agtgaccaacacaggctgctagtgaccaacacaggctgct 6161 5555 395395 XM_005273198.1_ex6F XM_005273198.1_ex6F ccctagcaggtccagaatcaccctagcaggtccagaatca 6060 5555 316316 XM_005273198.1_ex6R XM_005273198.1_ex6R tctaaaggcggctgtttcactctaaaggcggctgtttcac 6060 5050 316316 XM_005273198.1_ex7F XM_005273198.1_ex7F gacaccttgtgatcgtgcaagacaccttgtgatcgtgcaa 6060 5050 213213 XM_005273198.1_ex7R XM_005273198.1_ex7R gaagactggagctcgatggtgaagactggagctcgatggt 5959 5555 213213 XM_005273198.1_ex8F XM_005273198.1_ex8F ttgggactgaatggtggtaattgggactgaatggtggtaa 5959 4545 398398 XM_005273198.1_ex8R XM_005273198.1_ex8R caagcccttcagcacctgcaagcccttcagcacctg 6161 6161 398398 XM_005273198.1_ex9F XM_005273198.1_ex9F cggggatagtttgacaaggacggggatagtttgacaagga 6060 5050 173173 XM_005273198.1_ex9R XM_005273198.1_ex9R accccgagtcaggcagagaccccgagtcaggcagag 6161 6666 173173 XM_005273198.1_ex10F XM_005273198.1_ex10F ttctgggacgcagactggttctgggacgcagactgg 6161 6161 272272 XM_005273198.1_ex10R XM_005273198.1_ex10R actcatgcctctcagggaagactcatgcctctcagggaag 5959 5555 272272 XM_005273198.1_ex11F XM_005273198.1_ex11F cactctgaccagctgttgtttccactctgaccagctgttgtttc 6060 5050 282282 XM_005273198.1_ex11R XM_005273198.1_ex11R cctcatgccctcctccaccctcatgccctcctccac 6262 6767 282282 XM_005273198.1_ex12F XM_005273198.1_ex12F attctgtgcacgcctcttcaattctgtgcacgcctcttca 6262 5050 203203 XM_005273198.1_ex12R XM_005273198.1_ex12R accacgaggcagctggacaccacgaggcagctggac 6262 6666 203203 XM_005273198.1_ex13F XM_005273198.1_ex13F ctcacagctcctgtccacacctcacagctcctgtccacac 5959 6060 236236 XM_005273198.1_ex13R XM_005273198.1_ex13R cctgtggcacaccatgtccctgtggcacaccatgtc 5959 6161 236236

본 발명에서 디자인된 프라이머 (CR1)The primer ( CR1 ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_000573.3_ex1F NM_000573.3_ex1F atgtgcttggggagaatgggatgtgcttggggagaatggg 6161 5555 212212 NM_000573.3_ex1R NM_000573.3_ex1R gctgcacgcgagttctctgctgcacgcgagttctct 6060 6161 212212 NM_000573.3_ex2F NM_000573.3_ex2F tggtcttgatctccaggtcatggtcttgatctccaggtca 6060 5050 221221 NM_000573.3_ex2R NM_000573.3_ex2R gggttcccactccagagttacgggttcccactccagagttac 6060 5757 221221 NM_000573.3_ex3F NM_000573.3_ex3F accatcagaactgcgtgtgtaccatcagaactgcgtgtgt 6060 5050 234234 NM_000573.3_ex3R NM_000573.3_ex3R tcaagagatgccaactcaccctcaagagatgccaactcaccc 6060 5252 234234 NM_000573.3_ex4F NM_000573.3_ex4F ggtagttgacctgtgtctggtagttgacctgtgtct 5959 5050 254254 NM_000573.3_ex4R NM_000573.3_ex4R tcttcagccgtgtgaaggactcttcagccgtgtgaaggac 6060 5555 254254 NM_000573.3_ex5_1F NM_000573.3_ex5_1F cctgctcttcctttttccaggcctgctcttcctttttccagg 5858 5252 260260 NM_000573.3_ex5_1R NM_000573.3_ex5_1R catttggaggcgtgcatttgcatttggaggcgtgcatttg 6161 5050 260260 NM_000573.3_ex5_2F NM_000573.3_ex5_2F ccgcccctcagtgcattataccgcccctcagtgcattata 6161 5555 262262 NM_000573.3_ex5_2R NM_000573.3_ex5_2R tgatccaacagcaacgcatgtgatccaacagcaacgcatg 6161 5050 260260 NM_000573.3_ex6F NM_000573.3_ex6F gctgtactttgtttctctctccccgctgtactttgtttctctctcccc 6060 5050 262262 NM_000573.3_ex6R NM_000573.3_ex6R ggcatgtggagaataaagacgcggcatgtggagaataaagacgc 5959 5050 262262 NM_000573.3_ex7F NM_000573.3_ex7F gcgtctttattctccacatgccgcgtctttattctccacatgcc 6060 5050 182182 NM_000573.3_ex7R NM_000573.3_ex7R gcaggtcaggcaagctcatagcaggtcaggcaagctcata 5959 5555 182182 NM_000573.3_ex8F NM_000573.3_ex8F gggttctcttggctgaaacaggggttctcttggctgaaacag 6060 5252 182182 NM_000573.3_ex8R NM_000573.3_ex8R atgaagggagagactggcctatgaagggagagactggcct 5959 5555 182182 NM_000573.3_ex9F NM_000573.3_ex9F acctctggtgaaactcctgaacctctggtgaaactcctga 6060 5050 330330 NM_000573.3_ex9R NM_000573.3_ex9R atggagggcctgggttagatatggagggcctgggtagat 6060 5555 330330 NM_000573.3_ex10F NM_000573.3_ex10F gaggaaacacactgggtatcgaggaaacacactgggtatc 5656 5050 277277 NM_000573.3_ex10R NM_000573.3_ex10R tgcagacatgggaaagatcctgcagacatgggaaagatcc 5959 5050 277277 NM_000573.3_ex11F NM_000573.3_ex11F ctctacctggctccaaaacactctacctggctccaaaaca 5757 5050 161161 NM_000573.3_ex11R NM_000573.3_ex11R accaagagatgttgctgccaaccaagagatgttgctgcca 6060 5050 161161 NM_000573.3_ex12F NM_000573.3_ex12F gctgtcaggaagttgatgaggtgctgtcaggaagttgatgaggt 6060 5050 185185 NM_000573.3_ex12R NM_000573.3_ex12R taaacggtggggtgaatgggtaaacggtggggtgaatggg 6060 5555 185185 NM_000573.3_ex13_1F NM_000573.3_ex13_1F gcaagactctgtcccaaggtgcaagactctgtcccaaggt 6060 5555 269269 NM_000573.3_ex13_1R NM_000573.3_ex13_1R tataatgcactgaggggccgtataatgcactgaggggccg 6060 5555 269269 NM_000573.3_ex13_2F NM_000573.3_ex13_2F cggcccctcagtgcattatacggcccctcagtgcattata 6060 5555 255255 NM_000573.3_ex13_2R NM_000573.3_ex13_2R acagcaacgcatgtcacttgacagcaacgcatcgtcacttg 6060 5050 255255 NM_000573.3_ex14F NM_000573.3_ex14F gctgtactttgtttctctctccccgctgtactttgtttctctctcccc 6060 5050 262262 NM_000573.3_ex14R NM_000573.3_ex14R ggcatgtggagaataaagacgcggcatgtggagaataaagacgc 6060 5050 262262 NM_000573.3_ex15F NM_000573.3_ex15F gcgtctttattctccacatgccgcgtctttattctccacatgcc 6060 5050 214214 NM_000573.3_ex15R NM_000573.3_ex15R agactgattcccaaccccaaagactgattcccaaccccaa 5959 5050 214214 NM_000573.3_ex16F NM_000573.3_ex16F gggttctcttggctgaaacaggggttctcttggctgaaacag 6060 5252 182182 NM_000573.3_ex16R NM_000573.3_ex16R atgaagggagagactggcctatgaagggagagactggcct 6060 5555 182182 NM_000573.3_ex17F NM_000573.3_ex17F acctctggtgaaactcctgaacctctggtgaaactcctga 6060 5050 330330 NM_000573.3_ex17R NM_000573.3_ex17R atggagggcctgggttagatatggagggcctgggtagat 6060 5555 330330 NM_000573.3_ex18F NM_000573.3_ex18F gaggaaacacactgggtatcgaggaaacacactgggtatc 5656 5050 277277 NM_000573.3_ex18R NM_000573.3_ex18R tgcagacatgggaaagatcctgcagacatgggaaagatcc 5858 5050 277277 NM_000573.3_ex19F NM_000573.3_ex19F tcagattactctacctggctcctcagattactctacctggctcc 6060 5050 200200 NM_000573.3_ex19R NM_000573.3_ex19R gaaagtactatcgctgtgctgggaaagtactatcgctgtgctgg 6060 5050 200200 NM_000573.3_ex20F NM_000573.3_ex20F gctgtcaggaagttgatgaggtgctgtcaggaagttgatgaggt 6060 5050 185185 NM_000573.3_ex20R NM_000573.3_ex20R taaacggtggggtgaatgggtaaacggtggggtgaatggg 6060 5555 185185 NM_000573.3_ex21_1F NM_000573.3_ex21_1F gcaagactctgtcccaaggtgcaagactctgtcccaaggt 6060 5555 296296 NM_000573.3_ex21_1R NM_000573.3_ex21_1R cacatttggaggcgtgcattcacatttggaggcgtgcatt 6060 6060 296296 NM_000573.3_ex21_2F NM_000573.3_ex21_2F cggcccctcagtgcattatacggcccctcagtgcattata 6161 5555 255255 NM_000573.3_ex21_2R NM_000573.3_ex21_2R acagcaacgcatgtcacttgacagcaacgcatcgtcacttg 6060 5050 255255 NM_000573.3_ex22F NM_000573.3_ex22F gctgtactttgtttctctctccccgctgtactttgtttctctctcccc 6161 5050 262262 NM_000573.3_ex22R NM_000573.3_ex22R ggcatgtggagaataaagacgcggcatgtggagaataaagacgc 6060 5050 262262 NM_000573.3_ex23F NM_000573.3_ex23F gcgtctttattctccacatgccgcgtctttattctccacatgcc 6060 5050 182182 NM_000573.3_ex23R NM_000573.3_ex23R gcaggtcaggcaagctcatagcaggtcaggcaagctcata 6060 5555 182182 NM_000573.3_ex24F NM_000573.3_ex24F gtgtcctcttggctgaaacaggtgtcctcttggctgaaacag 6060 5353 180180 NM_000573.3_ex24R NM_000573.3_ex24R tgaaggggagagattggccttgaaggggagagattggcct 6060 5555 180180 NM_000573.3_ex25F NM_000573.3_ex25F acctctggtgaaactcctgaacctctggtgaaactcctga 5959 5050 330330 NM_000573.3_ex25R NM_000573.3_ex25R atggaggggctgggttagatatggaggggctgggtagat 6060 5656 330330 NM_000573.3_ex26F NM_000573.3_ex26F gaggaaacacactgggtatcgaggaaacacactgggtatc 5656 5050 277277 NM_000573.3_ex26R NM_000573.3_ex26R tgcagacatgggaaagatcctgcagacatgggaaagatcc 5656 5555 277277 NM_000573.3_ex27F NM_000573.3_ex27F ctctacctggctccaaaacactctacctggctccaaaaca 6060 5050 183183 NM_000573.3_ex27R NM_000573.3_ex27R atcgctgtgctggaactcttatcgctgtgctggaactctt 6161 5050 183183 NM_000573.3_ex28FNM_000573.3_ex28F tgctgtcaggaagttgatgaggtgctgtcaggaagttgatgagg 6060 5050 185185 NM_000573.3_ex28RNM_000573.3_ex28R tcaatggtggggtgaatgggtcaatggtggggtgaatggg 6060 5555 185185 NM_000573.3_ex29_1FNM_000573.3_ex29_1F gcaagactctgtcccaaggtgcaagactctgtcccaaggt 5959 5555 268268 NM_000573.3_ex29_1RNM_000573.3_ex29_1R tataatgcactgaggggcggtataatgcactgaggggcgg 6060 5555 268268 NM_000573.3_ex29_2FNM_000573.3_ex29_2F ccgcccctcagtgcattataccgcccctcagtgcattata 6060 5555 264264 NM_000573.3_ex29_2RNM_000573.3_ex29_2R cctgatccaacagcaacacacctgatccaacagcaacaca 6060 5050 264264 NM_000573.3_ex30NM_000573.3_ex30 ggaagcataggaaattcccccaggaagcataggaaattccccca 6060 5050 294294 NM_000573.3_ex30NM_000573.3_ex30 agtaagacctccatgtgtgggagtaagacctccatgtgtggg 5959 5252 294294 NM_000573.3_ex31NM_000573.3_ex31 cacacatggaggtcttactccacacatggaggtcttactc 6060 5050 198198 NM_000573.3_ex31NM_000573.3_ex31 gcagtgctgagtccctgatcgcagtgctgagtccctgatc 5959 6060 198198 NM_000573.3_ex32NM_000573.3_ex32 atggtgcattcatccagccaatggtgcattcatccagcca 6060 5050 234234 NM_000573.3_ex32NM_000573.3_ex32 tcaaaagcgggcacaaacagtcaaaagcgggcacaaacag 6060 5050 234234 NM_000573.3_ex33NM_000573.3_ex33 ggcaacacagtcacagtatgggcaacacagtcacagtatg 5757 5050 370370 NM_000573.3_ex33NM_000573.3_ex33 gggtccacatattctgaacccagggtccacatattctgaaccca 6060 5050 370370 NM_000573.3_ex34NM_000573.3_ex34 gaggaggtagggtggaagtctgaggaggtagggtggaagtct 5959 7272 300300 NM_000573.3_ex34NM_000573.3_ex34 agcccggtcccacctatgagcccggtcccacctatg 6060 6666 300300 NM_000573.3_ex35NM_000573.3_ex35 cccaaattctgcttcttcccccccaaattctgcttcttcccc 6060 5252 183183 NM_000573.3_ex35NM_000573.3_ex35 tcagaagttggctctgctgttcagaagttggctctgctgt 6060 5555 183183 NM_000573.3_ex36F NM_000573.3_ex36F ctgccatggtgtaatctgtcctctgccatggtgtaatctgtcct 6060 5050 255255 NM_000573.3_ex36R NM_000573.3_ex36R gggcaagtcaggatcacacagggcaagtcaggatcacaca 6060 5555 255255 NM_000573.3_ex37_1F NM_000573.3_ex37_1F ctcttccttctctcagtcctcttccttctctcagtc 5050 5050 316316 NM_000573.3_ex37_1R NM_000573.3_ex37_1R tgatgatctcagtgagggtgatgatctcagtgaggg 5252 5050 316316 NM_000573.3_ex37_2F NM_000573.3_ex37_2F gagtaccaggaaacaggagtgagtaccaggaaacaggagt 5656 5050 181181 NM_000573.3_ex37_2R NM_000573.3_ex37_2R cctcacacccagcaaagtctcctcacacccagcaaagtct 5959 5555 181181 NM_000573.3_ex38F NM_000573.3_ex38F caagtgctctggaactgtcctcaagtgctctgggaactgtcct 6060 5252 262262 NM_000573.3_ex38R NM_000573.3_ex38R agtcctccatgtgaaggggaagtcctccatgtgaagggga 6060 5555 262262 NM_000573.3_ex39F NM_000573.3_ex39F tccccttcacatggaggacttccccttcacatggaggact 6060 5555 186186 NM_000573.3_ex39R NM_000573.3_ex39R tgagtccttggtctcaacgctgagtccttggtctcaacgc 6060 5555 186186 NM_000573.3_ex40F NM_000573.3_ex40F gggagagatgggaattgctcagggagagatgggaattgctca 6060 5252 222222 NM_000573.3_ex40R NM_000573.3_ex40R gacaacaggtgatgccatgcgacaacaggtgatgccatgc 6060 5555 222222 NM_000573.3_ex41F NM_000573.3_ex41F ttaagcgcacagtcacaggtttaagcgcacagtcacaggt 5959 5050 337337 NM_000573.3_ex41R NM_000573.3_ex41R ggatatgtggaagcaggtacggatatgtggaagcaggtac 5656 5050 337337 NM_000573.3_ex42F NM_000573.3_ex42F gtgtgggaacttgttcttagccgtgtgggaacttgttcttagcc 6161 5050 253253 NM_000573.3_ex42R NM_000573.3_ex42R gcctcatgcattccatacaaccgcctcatgcattccatacaacc 6060 5050 253253 NM_000573.3_ex43F NM_000573.3_ex43F tgcttcctcttagccaagggtgcttcctcttagccaaggg 6060 5555 326326 NM_000573.3_ex43R NM_000573.3_ex43R cccacattccttgcacttgccccacattccttgcacttgc 6161 5555 326326 NM_000573.3_ex44F NM_000573.3_ex44F tgttgcatgccagagtgatgtgttgcatgccagagtgatg 5959 5050 109109 NM_000573.3_ex44R NM_000573.3_ex44R gatgccagaattcctcagcagatgccagaattcctcagca 5959 5050 109109 NM_000573.3_ex45F NM_000573.3_ex45F ccttgttttactgcctaggcccttgttttactgcctaggc 5959 5050 154154 NM_000573.3_ex45R NM_000573.3_ex45R tgacttccaagagggggtaagtgacttccaagagggggtaag 5959 5252 154154 NM_000573.3_ex46F NM_000573.3_ex46F tcctttcagacgtcttgcaatcctttcagacgtcttgcaa 5757 4545 348348 NM_000573.3_ex46R NM_000573.3_ex46R ggtatcaatgacctacctagtgcaggtatcaatgacctacctagtgca 5959 4646 348348 NM_000573.3_ex47F NM_000573.3_ex47F ctgggtagttcagttgtctaccctgggtagttcagttgtctacc 5858 5050 102102 NM_000573.3_ex47R NM_000573.3_ex47R cgagatgttcttcagctgcgagatgttcttcagctg 5353 5050 102102

본 발명에서 디자인된 프라이머 (BIN1)The primer designed in the present invention ( BIN1 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_004305.3_ex1_1F NM_004305.3_ex1_1F ctccctcctcgcggacctctccctcctcgcggacct 6060 7272 364364 NM_004305.3_ex1_1R NM_004305.3_ex1_1R acccctttactgcccatctcacccctttactgcccatctc 6060 5555 364364 NM_004305.3_ex1_2F NM_004305.3_ex1_2F aagatctccccgcgcgagaagatctccccgcgcgag 6060 6666 212212 NM_004305.3_ex1_2R NM_004305.3_ex1_2R gaggatagggggacaggtgggaggatagggggacaggtgg 6060 6565 212212 NM_004305.3_ex2F NM_004305.3_ex2F tctccccttctctcttggcttctccccttctctcttggct 6060 5555 172172 NM_004305.3_ex2R NM_004305.3_ex2R ccatttttcacctggcagccccatttttcacctggcagcc 6060 5555 172172 NM_004305.3_ex3F NM_004305.3_ex3F tccctgacctggtccttgtctccctgacctggtccttgtc 6060 6060 138138 NM_004305.3_ex3R NM_004305.3_ex3R ctgcacccaccagctctacctgcacccaccagctctac 6060 6363 138138 NM_004305.3_ex4F NM_004305.3_ex4F ggaggcccacatacttccttggaggcccacatacttcctt 6060 5555 188188 NM_004305.3_ex4R NM_004305.3_ex4R ggacaggagctgagaccagaggacaggagctgagaccaga 6060 6060 188188 NM_004305.3_ex5F NM_004305.3_ex5F gtgctcttgcctgtctcagagtgctcttgcctgtctcaga 6060 5555 170170 NM_004305.3_ex5R NM_004305.3_ex5R tctctccagttccctccaggtctctccagttccctccagg 6060 6060 170170 NM_004305.3_ex6F NM_004305.3_ex6F gcttagtgccctcctctgtcgcttagtgccctcctctgtc 6060 6060 183183 NM_004305.3_ex6R NM_004305.3_ex6R ctctcagccccctgcagactctcagccccctgcaga 6161 6666 183183 NM_004305.3_ex7F NM_004305.3_ex7F ccaacagaggggaatgaccccaacagaggggaatgacc 5757 5858 132132 NM_004305.3_ex7R NM_004305.3_ex7R gctgggcctcacctgttcgctgggcctcacctgttc 6060 6666 132132 NM_004305.3_ex8F NM_004305.3_ex8F ccatccttccgcccttctgccatccttccgcccttctg 6060 6363 132132 NM_004305.3_ex8R NM_004305.3_ex8R ggtgtggcccctcagaggggtgtggcccctcagagg 6161 7272 132132 NM_004305.3_ex9F NM_004305.3_ex9F cactgtctctcctgcagctccactgtctctcctgcagctc 6060 6060 176176 NM_004305.3_ex9R NM_004305.3_ex9R ccaacagggtcacaggaaggccaacagggtcacaggaagg 6060 6060 176176 NM_004305.3_ex10F NM_004305.3_ex10F gaatgaaggcctccacctccgaatgaaggcctccacctcc 6060 6060 141141 NM_004305.3_ex10R NM_004305.3_ex10R atgcacagggccagccagatgcacagggccagccag 6262 6767 141141 NM_004305.3_ex11F NM_004305.3_ex11F gctccctttcttgtcctcccgctccctttcttgtcctccc 6060 6060 200200 NM_004305.3_ex11R NM_004305.3_ex11R gggacctgctaccaagacatgggacctgctaccaagacat 6161 5555 200200 NM_004305.3_ex12F NM_004305.3_ex12F gtcctgtgtctgaccccaaggtcctgtgtctgaccccaag 6161 6060 162162 NM_004305.3_ex12R NM_004305.3_ex12R aggaaaaggcagggctttgtaggaaaaggcagggctttgt 6060 5050 162162 NM_004305.3_ex13F NM_004305.3_ex13F ctgctcagctgacccgtacctgctcagctgacccgtac 6060 6363 171171 NM_004305.3_ex13R NM_004305.3_ex13R actgcagcagtcagaggctactgcagcagtcagaggct 6060 5858 171171 NM_004305.3_ex14F NM_004305.3_ex14F gggacggaaggtctgacttggggacggaaggtctgacttg 6161 6060 191191 NM_004305.3_ex14R NM_004305.3_ex14R caggatgcctgtggtccccaggatgcctgtggtccc 6060 6666 191191 NM_004305.3_ex15F NM_004305.3_ex15F ctctgcccctcaggatgaagctctgcccctcaggatgaag 5959 6060 371371 NM_004305.3_ex15R NM_004305.3_ex15R gggcgccagaaactcaactagggcgccagaaactcaacta 6060 5555 371371

본 발명에서 디자인된 프라이머 (TREM2)The primer ( TREM2 ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001271821.1_ex1F NM_001271821.1_ex1F ccccagtcctgactattgctccccagtcctgactattgct 6060 5555 229229 NM_001271821.1_ex1R NM_001271821.1_ex1R gagggagagaaggcatcacagagggagagaaggcatcaca 6060 5555 229229 NM_001271821.1_ex2F NM_001271821.1_ex2F tgaatgtctcctccccagagtgaatgtctcctccccagag 6060 5555 384384 NM_001271821.1_ex2R NM_001271821.1_ex2R ccactgcccactcacctgccactgcccactcacctg 5959 6666 384384 NM_001271821.1_ex3F NM_001271821.1_ex3F aggaggaaggggctggagaggaggaaggggctggag 6161 6666 185185 NM_001271821.1_ex3R NM_001271821.1_ex3R ctctgcagggtggaagtctgctctgcagggtggaagtctg 6161 6060 185185 NM_001271821.1_ex4F NM_001271821.1_ex4F cccatctgccttcttgtctccccatctgccttcttgtctc 6161 5555 247247 NM_001271821.1_ex4R NM_001271821.1_ex4R cttgatggctgtgctctcccttgatggctgtgctctcc 6060 5757 247247

본 발명에서 디자인된 프라이머 (CLU)The primer ( CLU ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001831.3_ex1F NM_001831.3_ex1F agcacagctattcgtggtgaagcacagctattcgtggtga 5959 5050 356356 NM_001831.3_ex1R NM_001831.3_ex1R gtgactgcgagctgtgtcatgtgactgcgagctgtgtcat 6060 5555 356356 NM_001831.3_ex2F NM_001831.3_ex2F gtgtccatggcaagtctggtgtgtccatggcaagtctggt 6161 5555 396396 NM_001831.3_ex2R NM_001831.3_ex2R ggcctgatagagaggcactgggcctgatagagaggcactg 6060 6060 396396 NM_001831.3_ex3F NM_001831.3_ex3F tgacagcccctgaactgaactgacagcccctgaactgaac 6161 5555 399399 NM_001831.3_ex3R NM_001831.3_ex3R taattgcagcctcagcatcataattgcagcctcagcatca 6161 4545 399399 NM_001831.3_ex4F NM_001831.3_ex4F ggagcaagggtaggcacttggagcaagggtaggcactt 5959 5858 396396 NM_001831.3_ex4R NM_001831.3_ex4R gcatgcggaatgaagcatagcatgcggaatgaagcata 6161 4747 396396 NM_001831.3_ex5_1F NM_001831.3_ex5_1F gtggccttggtgagcttctgtggccttggtgagcttct 6262 5555 258258 NM_001831.3_ex5_1R NM_001831.3_ex5_1R gaagggcaggtagtggtagggaagggcaggtagtggtagg 6464 5555 285285 NM_001831.3_ex5_2F NM_001831.3_ex5_2F tccaggacaggttcttcacctccaggacaggttcttcacc 6060 5555 308308 NM_001831.3_ex5_2R NM_001831.3_ex5_2R cagcatctaacgagttgctcacagcatctaacgagttgctca 6060 4545 308308 NM_001831.3_ex6F NM_001831.3_ex6F agagtcacctgagcctggaaagagtcacctgagcctggaa 6060 5555 376376 NM_001831.3_ex6R NM_001831.3_ex6R cataaaggcagcaccagtgacataaaggcagcaccagtga 6060 5050 376376 NM_001831.3_ex7F NM_001831.3_ex7F catgtgctaacttccattcacatgtgctaacttccattca 5555 4040 400400 NM_001831.3_ex7R NM_001831.3_ex7R tcagtcaaaagcacacatgctcagtcaaaagacacacatgc 5858 4545 400400 NM_001831.3_ex8F NM_001831.3_ex8F tttccttggagaagcaggagtttccttggagaagcaggag 6060 5050 392392 NM_001831.3_ex8R NM_001831.3_ex8R agtcgttcccaccaggctatagtcgttcccaccaggctat 6161 5555 392392 NM_001831.3_ex9F NM_001831.3_ex9F ccaagaacaaagccaggaagccaagaacaaagccaggaag 6060 5050 197197 NM_001831.3_ex9R NM_001831.3_ex9R tacttggtgacgtgcagagctacttggtgacgtgcagagc 6161 5555 197197

본 발명에서 디자인된 프라이머 (CTNNA3)The primers designed in the present invention ( CTNNA3 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) XM_005269717.1_ex1F XM_005269717.1_ex1F gtgaggtcagtgactagcgggtgaggtcagtgactagcgg 6060 6060 309309 XM_005269717.1_ex1R XM_005269717.1_ex1R gcagaaatgagaattcgctggcagaaatgagaattcgctg 5656 4545 309309 XM_005269717.1_ex2F XM_005269717.1_ex2F tggagcctttcttgaagcgttggagcctttcttgaagcgt 6060 5050 138138 XM_005269717.1_ex2R XM_005269717.1_ex2R gccctacaatttagccctgtgccctacaatttagccctgt 5959 5050 138138 XM_005269717.1_ex3F XM_005269717.1_ex3F agcatccttttgtgtttgtgcaagcatccttttgtgtttgtgca 6060 4141 134134 XM_005269717.1_ex3R XM_005269717.1_ex3R aatacctggattatgagaggctccaatacctggattatgagaggctcc 6161 4646 134134 XM_005269717.1_ex4F XM_005269717.1_ex4F tcccaggactgtgttctccttcccaggactgtgttctcct 6060 5555 291291 XM_005269717.1_ex4R XM_005269717.1_ex4R atgcagtttgctcctgaccaatgcagtttgctcctgacca 6161 5050 291291 XM_005269717.1_ex5F XM_005269717.1_ex5F ggggttgtatttttcaggtgaagcggggttgtatttttcaggtgaagc 6060 4646 227227 XM_005269717.1_ex5R XM_005269717.1_ex5R agtgaagacaatgccaaggtagtgaagacaatgccaaggt 6060 4545 227227 XM_005269717.1_ex6F XM_005269717.1_ex6F tcgactcttcgtgttagcaagttcgactcttcgtgttagcaagt 6060 4646 228228 XM_005269717.1_ex6R XM_005269717.1_ex6R tccaccaaggagagctctgatccaccaaggagagctctga 6060 5555 228228 XM_005269717.1_ex7F XM_005269717.1_ex7F cccattgtaagataccactccccattgtaagataccactc 5353 4545 329329 XM_005269717.1_ex7R XM_005269717.1_ex7R cacactttatctttctcccgaccacactttatctctctctcccgac 5757 4646 329329 XM_005269717.1_ex8F XM_005269717.1_ex8F gccatggagctctaaccatacagccatggagctctaaccataca 6060 5050 263263 XM_005269717.1_ex8R XM_005269717.1_ex8R aggcaaaccagtcacctacgaggcaaaccagtcacctacg 5959 5555 263263 XM_005269717.1_ex9F XM_005269717.1_ex9F ttcttctttgcaggctggttcttctttgcaggctgg 6060 5050 135135 XM_005269717.1_ex9R XM_005269717.1_ex9R agcccctatgtttctgactccagcccctatgtttctgactcc 6060 5252 135135 XM_005269717.1_ex10F XM_005269717.1_ex10F catttcttctcagctccgcacatttcttctcagctccgca 6060 5050 216216 XM_005269717.1_ex10R XM_005269717.1_ex10R ggagcctcattctcctggacggagcctcattctcctggac 6060 6060 216216 XM_005269717.1_ex11F XM_005269717.1_ex11F agtgttgctgcatttccttgcagtgttgctgcatttccttgc 6060 4848 165165 XM_005269717.1_ex11R XM_005269717.1_ex11R agttgtcatacctgtggacacaagttgtcatacctgtggacaca 6060 4646 165165 XM_005269717.1_ex12F XM_005269717.1_ex12F attgcatagtggtgaagtgtggattgcatagtggtgaagtgtgg 5959 4646 260260 XM_005269717.1_ex12R XM_005269717.1_ex12R acataccagatacagcaaggacataccagatacagcaagg 5555 4545 260260 XM_005269717.1_ex13F XM_005269717.1_ex13F acacagacacacgcaaaaacacacagacacacacgcaaaaac 5757 4545 273273 XM_005269717.1_ex13R XM_005269717.1_ex13R tgtgcagctgttattggcaactgtgcagctgttattggcaac 6060 4747 273273 XM_005269717.1_ex14F XM_005269717.1_ex14F caaagaggacaatcttctcccaaagaggacaatcttctcc 5353 4545 249249 XM_005269717.1_ex14R XM_005269717.1_ex14R ggcattccagatggtgaagaacggcattccagatggtgaagaac 6060 5050 249249 XM_005269717.1_ex15F XM_005269717.1_ex15F taaggtactgccgcgttgtttaaggtactgccgcgttgtt 6060 5050 225225 XM_005269717.1_ex15R XM_005269717.1_ex15R gcacagccttcagtgacacagcacagccttcagtgacaca 6060 5555 225225 XM_005269717.1_ex16F XM_005269717.1_ex16F cacatgttttaggctaagatgactccacatgttttaggctaagatgactc 5858 4040 272272 XM_005269717.1_ex16R XM_005269717.1_ex16R gagaatcttgaggtttcactgagaatcttgaggtttcact 5353 4040 272272 XM_005269717.1_ex17F XM_005269717.1_ex17F tagccgttctttgggatgcgtagccgttctttgggatgcg 6060 5555 266266 XM_005269717.1_ex17R XM_005269717.1_ex17R gtccacttgtaagtaactcacctggtccacttgtaagtaactcacctg 6060 4646 266266 XM_005269717.1_ex18F XM_005269717.1_ex18F atttagtgcccagatccatcatttagtgcccagatccatc 5555 4545 210210 XM_005269717.1_ex18R XM_005269717.1_ex18R acaagggtgtagttactctgacaagggtgtagttactctg 5555 4545 210210 XM_005269717.1_ex19F XM_005269717.1_ex19F ttccctacagttggacagtgtcttccctacagttttggacagtgtc 6060 5050 355355 XM_005269717.1_ex19R XM_005269717.1_ex19R aagcagtgtggttaggcaggaagcagtgtggttaggcagg 6060 5555 355355

본 발명에서 디자인된 프라이머 (DNMBP)The primer designed in the present invention ( DNMBP ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_015221.2_ex1F NM_015221.2_ex1F cgctgactcacacgggatccgctgactcacacgggatc 6262 6363 130130 NM_015221.2_ex1R NM_015221.2_ex1R cggcctctgacctgctttccggcctctgacctgctttc 6262 6363 130130 NM_015221.2_ex2F NM_015221.2_ex2F caggttataaaacatggaggctggcaggttataaaacatggaggctgg 6060 4646 205205 NM_015221.2_ex2R NM_015221.2_ex2R atggaaagaagtcagggcctgatggaaagaagtcagggcctg 6060 5252 205205 NM_015221.2_ex3F NM_015221.2_ex3F tgtccttgtacacagacgggtgtccttgtacacagacggg 6060 5555 256256 NM_015221.2_ex3R NM_015221.2_ex3R ttgtcgaaacgggcagactcttgtcgaaacgggcagactc 6060 5555 256256 NM_015221.2_ex4_1F NM_015221.2_ex4_1F aggtcaccatctctgctcctaggtcaccatctctgctcct 6060 5555 392392 NM_015221.2_ex4_1R NM_015221.2_ex4_1R tcatccacagtcctcaggggtcatccacagtcctcagggg 6060 6060 392392 NM_015221.2_ex4_2F NM_015221.2_ex4_2F tttgtagagctgttggggcctttgtagagctgttggggcc 6060 5555 380380 NM_015221.2_ex4_2R NM_015221.2_ex4_2R gaagtttccgggatcctggcgaagtttccgggatcctggc 5959 6060 380380 NM_015221.2_ex4_3F NM_015221.2_ex4_3F gccaggatcccggaaacttcgccaggatcccggaaacttc 5858 5555 398398 NM_015221.2_ex4_3R NM_015221.2_ex4_3R tctaggggaagaaggtcgggtctaggggaagaaggtcggg 5757 6060 398398 NM_015221.2_ex4_4F NM_015221.2_ex4_4F cacccgcactcagaacagtacacccgcactcagaacagta 6060 5555 387387 NM_015221.2_ex4_4R NM_015221.2_ex4_4R ccctgccaagctcttctcaaccctgccaagctcttctcaa 6060 5555 387387 NM_015221.2_ex4_5F NM_015221.2_ex4_5F ttgagaagagcttggcagggttgagaagagcttggcaggg 6060 5555 396396 NM_015221.2_ex4_5R NM_015221.2_ex4_5R atggggaggtctggtccagatgggggggtctggtccag 6060 6363 396396 NM_015221.2_ex4_6F NM_015221.2_ex4_6F ggccctggtcatatgggaagggccctggtcatatgggaag 6060 6060 300300 NM_015221.2_ex4_6R NM_015221.2_ex4_6R ctgggtaggctgtttctgggctgggtaggctgtttctggg 6060 6060 300300 NM_015221.2_ex5F NM_015221.2_ex5F tacacccagagctgctaacctacacccagagctgctaacc 6060 5555 300300 NM_015221.2_ex5R NM_015221.2_ex5R atcctaatgcttctggcctggatcctaatgcttctggcctgg 6060 5252 300300 NM_015221.2_ex6F NM_015221.2_ex6F ccattaagctcatttccgtgcaccattaagctcatttccgtgca 6060 4646 181181 NM_015221.2_ex6R NM_015221.2_ex6R agctgcttctgaaacaacacagagctgcttctgataaacaacacag 6060 4646 181181 NM_015221.2_ex7F NM_015221.2_ex7F gtgtgtattccaaaggacctgtggtgtgtattccaaaggacctgtg 5959 4747 180180 NM_015221.2_ex7R NM_015221.2_ex7R gtggtcaaaactcctacttcaggtggtcaaaactcctacttcag 5858 4747 180180 NM_015221.2_ex8F NM_015221.2_ex8F tcttttcatgcccactgccttcttttcatgcccactgcct 6060 5050 7575 NM_015221.2_ex8R NM_015221.2_ex8R gagcgcatacatcaagcagcgagcgcatacatcaagcagc 6060 5555 7575 NM_015221.2_ex9F NM_015221.2_ex9F ccttctcttacaggggatgcaccttctcttacaggggatgca 6060 5252 250250 NM_015221.2_ex9R NM_015221.2_ex9R gggcatacctccttttcagcagggcatacctccttttcagca 6060 5252 250250 NM_015221.2_ex10F NM_015221.2_ex10F gcccatgctgaggaaagtgcgcccatgctgaggaaagtgc 6060 6060 200200 NM_015221.2_ex10R NM_015221.2_ex10R cgctaagccttccaggatggcgctaagccttccaggatgg 6060 6060 200200 NM_015221.2_ex11F NM_015221.2_ex11F tgtccagatttgctaacagctgtccagatttgctaacagc 6060 4545 199199 NM_015221.2_ex11R NM_015221.2_ex11R aggggacagaattacatcgtaggggacagaattacatcgt 6060 4545 199199 NM_015221.2_ex12F NM_015221.2_ex12F gtgtctgtcctaactggctccgtgtctgtcctaactggctcc 6060 5555 183183 NM_015221.2_ex12R NM_015221.2_ex12R ggggccaacttttgaagaaaggggccaacttttgaagaaa 5757 5555 183183 NM_015221.2_ex13F NM_015221.2_ex13F gcaatgtgcctttctcgtccgcaatgtgcctttctcgtcc 5959 5555 391391 NM_015221.2_ex13R NM_015221.2_ex13R tgaccatcccactgaacaggtgaccatcccactgaacagg 6161 5555 391391 NM_015221.2_ex14F NM_015221.2_ex14F ctctgctcttcccatggaccctctgctcttcccatggacc 6060 6060 219219 NM_015221.2_ex14R NM_015221.2_ex14R cagttccctactcaccaggccagttccctactcaccaggc 6060 6060 219219 NM_015221.2_ex15F NM_015221.2_ex15F acgtcttacctttcagccaagtacgtcttacctttcagccaagt 6060 4646 248248 NM_015221.2_ex15R NM_015221.2_ex15R cagttacagtcctctgctgctcagttacagtcctctgctgct 5555 5252 248248 NM_015221.2_ex16_1F NM_015221.2_ex16_1F tcctttgtagtcaccaaaggcttcctttgtagtcaccaaaggct 6060 4646 397397 NM_015221.2_ex16_1R NM_015221.2_ex16_1R tggcagtgggttgctttacatggcagtgggttgctttaca 6060 5050 397397 NM_015221.2_ex16_2F NM_015221.2_ex16_2F ggggactctgcagatgtagcggggactctgcagatgtagc 6060 6060 274274 NM_015221.2_ex16_2R NM_015221.2_ex16_2R cgctggtacccacaacacatcgctggtacccacaacacat 6060 5555 274274 NM_015221.2_ex17F NM_015221.2_ex17F tctctccctcacacaggtcttctctccctcacacaggtct 6060 5555 369369 NM_015221.2_ex17R NM_015221.2_ex17R acaacccaatcgaggagaacaacaacccaatcgaggagaaca 6060 4848 369369

본 발명에서 디자인된 프라이머 (SORL1)The primer designed in the present invention ( SORL1 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_003105.5_ex1F NM_003105.5_ex1F cccgttcctattcaccctggcccgttcctattcaccctgg 5959 6060 395395 NM_003105.5_ex1R NM_003105.5_ex1R aggaagtgcagggagaggaaaggaagtgcagggagaggaa 6060 5555 395395 NM_003105.5_ex2F NM_003105.5_ex2F cgtgggtcctaattcctacacgtgggtcctaattcctaca 4646 5050 194194 NM_003105.5_ex2R NM_003105.5_ex2R gttgatggcaccaaggtgtggttgatggcaccaaggtgtg 6161 5555 194194 NM_003105.5_ex3F NM_003105.5_ex3F ctctgtattccaggtgtacgtgctctgtattccaggtgtacgtg 6060 5050 173173 NM_003105.5_ex3R NM_003105.5_ex3R gaagtcgggacaggagggatgaagtcgggacaggagggat 6060 6060 173173 NM_003105.5_ex4F NM_003105.5_ex4F gggcctgctctcaacttaccgggcctgctctcaacttacc 6060 6060 201201 NM_003105.5_ex4R NM_003105.5_ex4R ttacctgcttgttggggtggttacctgcttgttggggtgg 6060 5555 201201 NM_003105.5_ex5F NM_003105.5_ex5F agcgggtgtttgatggtgatagcgggtgtttgatggtgat 6060 5050 235235 NM_003105.5_ex5R NM_003105.5_ex5R tttcaggggagggcagtttgtttcaggggagggcagtttg 6161 5555 235235 NM_003105.5_ex6F NM_003105.5_ex6F tgcaaaacttccatgcctcttgcaaaacttccatgcctct 6060 4545 315315 NM_003105.5_ex6R NM_003105.5_ex6R cacagaatgccaaacttcaccacagaatgccaaacttcac 6060 4545 315315 NM_003105.5_ex7F NM_003105.5_ex7F tttctcctcttccttggcagctttctcctcttccttggcagc 6060 5252 180180 NM_003105.5_ex7R NM_003105.5_ex7R ctgacctctgcataaagacactgacctctgcataaagaca 5555 4545 180180 NM_003105.5_ex8F NM_003105.5_ex8F cccacagggcacatttgtttcccacagggcacatttgttt 6060 5050 254254 NM_003105.5_ex8R NM_003105.5_ex8R aggcaggagaaggactcacaaggcaggagaaggactcaca 6060 5555 254254 NM_003105.5_ex9F NM_003105.5_ex9F gtgaatgtgcttaatgccacgtgaatgtgcttaatgccac 5757 4545 374374 NM_003105.5_ex9R NM_003105.5_ex9R aaactaccacagagcagggcaaactaccacagagagcagggc 6060 5555 374374 NM_003105.5_ex10F NM_003105.5_ex10F tgctgacactgcctgaaacttgctgacactgcctgaaact 6060 5050 181181 NM_003105.5_ex10R NM_003105.5_ex10R accccttttgagaacaggcaaccccttttgagaacaggca 6060 5050 181181 NM_003105.5_ex11F NM_003105.5_ex11F cttgcattttaggctcagtgggcttgcattttaggctcagtggg 6060 5050 120120 NM_003105.5_ex11R NM_003105.5_ex11R ggtggaggggacgggattggtggaggggacgggatt 6060 6767 120120 NM_003105.5_ex12F NM_003105.5_ex12F cacagcagtggtgtcacccacagcagtggtgtcacc 6060 6161 150150 NM_003105.5_ex12R NM_003105.5_ex12R aaaggcctcatcagagacacaaaggcctcatcagagacac 6060 5050 150150 NM_003105.5_ex13F NM_003105.5_ex13F gcatttgggcagatacagtaccgcatttgggcagatacagtacc 6060 5050 218218 NM_003105.5_ex13R NM_003105.5_ex13R aaaaggtccaaggaggcagcaaaaggtccaaggaggcagc 6060 5555 218218 NM_003105.5_ex14F NM_003105.5_ex14F tgcctctaatgcttcgtgcttgcctctaatgcttcgtgct 6060 5050 263263 NM_003105.5_ex14R NM_003105.5_ex14R aacacaactcagtccccagcaacacaactcagtccccagc 6060 5555 263263 NM_003105.5_ex15F NM_003105.5_ex15F aaccgtggccttaacaaagcaaccgtggccttaacaaagc 5555 5050 185185 NM_003105.5_ex15R NM_003105.5_ex15R gcaacctctgtgatacatacccgcaacctctgtgatacataccc 6060 5050 185185 NM_003105.5_ex16F NM_003105.5_ex16F ctgacctcttgctcttggggctgacctcttgctcttgggg 6060 6060 191191 NM_003105.5_ex16R NM_003105.5_ex16R cggacttgggtgagatcgtgcggacttgggtgagatcgtg 5959 6060 191191 NM_003105.5_ex17F NM_003105.5_ex17F aacctcccacgtgtcttgtgaacctcccacgtgtcttgtg 6060 5555 238238 NM_003105.5_ex17R NM_003105.5_ex17R cacagctcccacagtcagaccacagctcccacagtcagac 6161 6060 238238 NM_003105.5_ex18F NM_003105.5_ex18F cagggggtcgtttgaacagtcagggggtcgtttgaacagat 6060 5555 229229 NM_003105.5_ex18R NM_003105.5_ex18R cccgcctgctcccttaattacccgcctgctcccttaatta 6060 5555 229229 NM_003105.5_ex19F NM_003105.5_ex19F ctcagcctcttttccccctgctcagcctcttttccccctg 6060 6060 165165 NM_003105.5_ex19R NM_003105.5_ex19R agcattggacgcaagactgaagcattggacgcaagactga 6060 6060 165165 NM_003105.5_ex20F NM_003105.5_ex20F ccccattttcgctagggtgaccccattttcgctagggtga 6161 5555 314314 NM_003105.5_ex20R NM_003105.5_ex20R tatgctcctcacccgctctatatgctcctcacccgctcta 6363 5555 314314 NM_003105.5_ex21F NM_003105.5_ex21F gctggactaatgggcaaagggctggactaatgggcaaagg 6161 5555 228228 NM_003105.5_ex21R NM_003105.5_ex21R cgcagcccctttcttgagatcgcagcccctttcttgagat 6060 5555 228228 NM_003105.5_ex22F NM_003105.5_ex22F tgctgctgtttgtcttcccttgctgctgtttgtcttccct 6060 5050 234234 NM_003105.5_ex22R NM_003105.5_ex22R aggaggatgacaggcaaaaggaggatgacaggcaaa 6060 5050 234234 NM_003105.5_ex23F NM_003105.5_ex23F ggtttcatttcctcccctgcggtttcatttcctcccctgc 6060 5050 180180 NM_003105.5_ex23R NM_003105.5_ex23R gtgcttaacgtccaatccaggtgcttaacgtccaatccag 6060 5555 180180 NM_003105.5_ex24F NM_003105.5_ex24F ccagtaggatgtttacatttgtgggccagtaggatgtttacatttgtggg 6161 4444 232232 NM_003105.5_ex24R NM_003105.5_ex24R ctccagagcagggtttcaggctccagagcagggtttcagg 6060 6060 232232 NM_003105.5_ex25F NM_003105.5_ex25F gcttttgtcctcacctctctgtgcttttgtcctcacctctctgt 6060 5050 200200 NM_003105.5_ex25R NM_003105.5_ex25R aacggatgagtgctgtcaactaacggatgagtgctgtcaact 6060 4848 200200 NM_003105.5_ex26F NM_003105.5_ex26F gtgtgcgactgtgtctctctgtgtgcgactgtgtctctct 6060 5555 229229 NM_003105.5_ex26R NM_003105.5_ex26R tctgtggcctctcttcctgatctgtggcctctcttcctga 6060 5555 229229 NM_003105.5_ex27F NM_003105.5_ex27F cctcctcgtcattcttctgtgtcctcctcgtcattcttctgtgt 6161 5050 190190 NM_003105.5_ex27R NM_003105.5_ex27R cactaggcctgagtgcttcccactaggcctgagtgcttcc 6060 6060 190190 NM_003105.5_ex28F NM_003105.5_ex28F cagtgctcatggcctcttcccagtgctcatggcctcttcc 6060 6060 190190 NM_003105.5_ex28R NM_003105.5_ex28R ctgcctgccccaactcacctgcctgccccaactcac 6060 6666 190190 NM_003105.5_ex29F NM_003105.5_ex29F ggaagttcctggacttcatggaggaagttcctggacttcatgga 6060 5050 195195 NM_003105.5_ex29R NM_003105.5_ex29R aggaggcagactggacatctaggaggcagactggacatct 6060 5555 195195 NM_003105.5_ex30F NM_003105.5_ex30F atgcagggaaagcaactgatgcagggaaagcaactg 6060 5050 192192 NM_003105.5_ex30R NM_003105.5_ex30R ccccaggggcctcttaccccccaggggcctcttacc 6161 7272 192192 NM_003105.5_ex31F NM_003105.5_ex31F ttttgggtttccgtgcttggttttgggtttccgtgcttgg 6161 5050 222222 NM_003105.5_ex31R NM_003105.5_ex31R ggtaccacaggagaggacctggtaccacaggagaggacct 6060 6060 222222 NM_003105.5_ex32F NM_003105.5_ex32F gttattggccagctccctcagttattggccagctccctca 6060 5555 224224 NM_003105.5_ex32R NM_003105.5_ex32R gctctctgactactcacggcgctctctgactactcacggc 6060 6060 224224 NM_003105.5_ex33F NM_003105.5_ex33F ccctccccgtggacttaagaccctccccgtggacttaaga 6060 6060 185185 NM_003105.5_ex33R NM_003105.5_ex33R tggaccggcactcaccactggaccggcactcaccac 6161 6666 185185 NM_003105.5_ex34F NM_003105.5_ex34F cgcccagccaagatgtaactcgcccagccaagatgtaact 6060 5555 240240 NM_003105.5_ex34R NM_003105.5_ex34R acagaacatcctggggcaatacagaacatcctggggcaat 6060 5050 240240 NM_003105.5_ex35F NM_003105.5_ex35F acggagtcagacatctcagcacggagtcagacatctcagc 6060 5555 250250 NM_003105.5_ex35R NM_003105.5_ex35R gaaacacttacatccctctggggaaacacttacatccctctggg 6060 5050 250250 NM_003105.5_ex36F NM_003105.5_ex36F ctctggttggctgctatgcactctggttggctgctatgca 6060 5555 214214 NM_003105.5_ex36R NM_003105.5_ex36R ctagcacccccaacacacatctagcacccccaacacacat 6060 5555 214214 NM_003105.5_ex37F NM_003105.5_ex37F atgccctggacctttggttcatgccctggacctttggttc 6060 5555 183183 NM_003105.5_ex37R NM_003105.5_ex37R ggctggaatggatgacgacaggctggaatggatgacgaca 6060 5555 183183 NM_003105.5_ex38F NM_003105.5_ex38F ctcacccctttagctcattcagctcacccctttagctcattcag 6060 5050 186186 NM_003105.5_ex38R NM_003105.5_ex38R ctgcaaatgctgggatcactgcaaatgctgggatca 6161 5050 186186 NM_003105.5_ex39F NM_003105.5_ex39F agtcctgccttcctcactttagtcctgccttcctcacttt 6060 5050 187187 NM_003105.5_ex39R NM_003105.5_ex39R ataaagccccatccagctgcataaagccccatccagctgc 6060 5555 187187 NM_003105.5_ex40F NM_003105.5_ex40F cttcttggttctcggcaggtcttcttggttctcggcaggt 6060 5555 173173 NM_003105.5_ex40R NM_003105.5_ex40R agcattggtccagccttaccagcattggtccagccttacc 6060 5555 173173 NM_003105.5_ex41F NM_003105.5_ex41F cacagttggcaatctgacagccacagttggcaatctgacagc 6060 5252 244244 NM_003105.5_ex41R NM_003105.5_ex41R agcattaggggacagtccacagcattaggggacagtccac 6060 5555 244244 NM_003105.5_ex42F NM_003105.5_ex42F catgagctgatgtcctcttccacatgagctgatgtcctcttcca 6060 5050 176176 NM_003105.5_ex42R NM_003105.5_ex42R cggtatgggaaacttacccggtatgggaaacttacc 5252 5050 176176 NM_003105.5_ex43F NM_003105.5_ex43F ttcctacgtgtgtgcttgggttcctacgtgtgtgcttggg 6161 5555 212212 NM_003105.5_ex43R NM_003105.5_ex43R ctggaagcccaacccactcctggaagcccaacccactc 6060 6363 212212 NM_003105.5_ex44F NM_003105.5_ex44F ggtcctagttgtatgcagttgcggtcctagttgtatgcagttgc 6060 5050 217217 NM_003105.5_ex44R NM_003105.5_ex44R gtgtgagaagacctctaacctctcgtgtgagaagacctctaacctctc 6060 5050 217217 NM_003105.5_ex45F NM_003105.5_ex45F tccactaaccgcatcccatctccactaacccccatcccatc 6262 5555 227227 NM_003105.5_ex45R NM_003105.5_ex45R ccagcatgctgtcaacaagcccagcatgctgtcaacaagc 6161 5555 227227 NM_003105.5_ex46F NM_003105.5_ex46F cgacttcctgagcaatctcttgcgacttcctgagcaatctcttg 6161 5050 257257 NM_003105.5_ex46R NM_003105.5_ex46R gacagaaacgggcagcaatcgacagaaacgggcagcaatc 5858 5555 257257 NM_003105.5_ex47F NM_003105.5_ex47F ggtgggcttattggtgggaaggtgggcttattggtgggaa 6060 5555 276276 NM_003105.5_ex47R NM_003105.5_ex47R gaagaaccgactctccctgcgaagaaccgactctccctgc 6060 6060 276276 NM_003105.5_ex48F NM_003105.5_ex48F ttggaactcaccaaggcctgttggaactcaccaaggcctg 6060 5555 382382 NM_003105.5_ex48R NM_003105.5_ex48R gacgtaaaagcatgcccagcgacgtaaaagcatgcccagc 6060 5555 382382

본 발명에서 디자인된 프라이머 (BACE1)The primer designed in the present invention ( BACE1 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_012104.4_ex1_1F NM_012104.4_ex1_1F cacaagtctttccgcctccccacaagtctttccgcctccc 6161 6060 372372 NM_012104.4_ex1_1R NM_012104.4_ex1_1R tctcaggagagggagcttggtctcaggagagggagcttgg 6060 6060 372372 NM_012104.4_ex1_2F NM_012104.4_ex1_2F ccaagctccctctcctgagaccaagctccctctcctgaga 6060 6060 397397 NM_012104.4_ex1_2R NM_012104.4_ex1_2R gctaagggctggcctgacgctaagggctggcctgac 5959 6060 397397 NM_012104.4_ex2F NM_012104.4_ex2F ctctcccctttctctgacagcctctcccctttctctgacagc 6060 5757 180180 NM_012104.4_ex2R NM_012104.4_ex2R ccctcccctgacccttcttaccctcccctgacccttctta 6060 6060 180180 NM_012104.4_ex3F NM_012104.4_ex3F gccttctttccacaggtccagccttctttccacaggtcca 6060 5555 240240 NM_012104.4_ex3R NM_012104.4_ex3R cctctcaccctggcaatctccctctcaccctggcaatctc 6060 6060 240240 NM_012104.4_ex4F NM_012104.4_ex4F ccaacctcttctccctgcagccaacctcttctccctgcag 6060 6060 129129 NM_012104.4_ex4R NM_012104.4_ex4R tctctccctcaatgccaggatctctccctcaatgccagga 6060 5555 129129 NM_012104.4_ex5F NM_012104.4_ex5F gtgccaggacacgggtacgtgccaggacacgggtac 6060 6666 192192 NM_012104.4_ex5R NM_012104.4_ex5R tctcccttggttttcttacctcctctcccttggttttcttacctcc 6060 4848 192192 NM_012104.4_ex6F NM_012104.4_ex6F taaccccctactgcccagagtaaccccctactgcccagag 6060 6060 185185 NM_012104.4_ex6R NM_012104.4_ex6R tagtccactcacggaggaggtagtccactcacggaggagg 6060 6060 185185 NM_012104.4_ex7F NM_012104.4_ex7F ccccttcttgccaacacagaccccttcttgccaacacaga 6060 5555 202202 NM_012104.4_ex7R NM_012104.4_ex7R agagagatccccctgactcagagagagatccccctgactcag 6060 5757 202202 NM_012104.4_ex8F NM_012104.4_ex8F catttgccctctccccagtgcatttgccctctccccagtg 6060 6060 400400 NM_012104.4_ex8R NM_012104.4_ex8R tcaaggcagaggcatttggttcaaggcagaggcatttggt 6060 6060 400400

본 발명에서 디자인된 프라이머 (PICALM)The primer designed in the present invention ( PICALM ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001206947.1_ex1F NM_001206947.1_ex1F taatcaccacagcagtcagctaatcaccacagcagtcagc 6060 5050 298298 NM_001206947.1_ex1R NM_001206947.1_ex1R aggcctctctctaccatggaaggcctctctctaccatgga 6060 5555 298298 NM_001206947.1_ex2F NM_001206947.1_ex2F tcttttgcctgtttgtatgcag tcttttgcctgtttgtatgcag 6060 4141 321321 NM_001206947.1_ex2R NM_001206947.1_ex2R cctgggagctgtttctgaag cctgggagctgtttctgaag 6060 5555 321321 NM_001206947.1_ex3F NM_001206947.1_ex3F tcgaattagagttggtgagatggctcgaattagagttggtgagatggc 5959 4646 200200 NM_001206947.1_ex3R NM_001206947.1_ex3R actctggagtaatcatcatgtgggactctggagtaatcatcatgtggg 6161 4646 200200 NM_001206947.1_ex4F NM_001206947.1_ex4F gccattggatgcaatgagttgtgccattggatgcaatgagttgt 5858 4646 322322 NM_001206947.1_ex4R NM_001206947.1_ex4R tgaggctcatcttttaaaactggctgaggctcatcttttaaaactggc 6161 4242 322322 NM_001206947.1_ex5F NM_001206947.1_ex5F tttcataacagggctgatggagtttcataacagggctgatggag 5858 4646 192192 NM_001206947.1_ex5R NM_001206947.1_ex5R gagtctgtgaaaacttgagggagtctgtgaaaacttgagg 5353 4545 192192 NM_001206947.1_ex6F NM_001206947.1_ex6F ttcactaacatgcctaatgcttcactaacatgcctaatgc 5454 4040 245245 NM_001206947.1_ex6R NM_001206947.1_ex6R aggctacagcagtatttacccaaggctacagcagtatttaccca 5959 4646 245245 NM_001206947.1_ex7F NM_001206947.1_ex7F tgctcctttagagacctatttgg tgctcctttagagacctatttggg 5959 4343 356356 NM_001206947.1_ex7R NM_001206947.1_ex7R ttgccacagaattcaatacagc ttgccacagacaattcaatacagc 6060 4141 356356 NM_001206947.1_ex8F NM_001206947.1_ex8F ctggtactagccgtgatgtcactggtactagccgtgatgtca 5959 5252 169169 NM_001206947.1_ex8R NM_001206947.1_ex8R cacaacagatagtggattggcacaacagatagtggattgg 5353 4545 169169 NM_001206947.1_ex9F NM_001206947.1_ex9F tacaattgcaggcccctagctacaattgcaggcccctagc 5959 5555 162162 NM_001206947.1_ex9R NM_001206947.1_ex9R agctggtttcatctactgcctagctggtttcatctactgcct 5959 4747 162162 NM_001206947.1_ex10F NM_001206947.1_ex10F gccagaccatttcatgacctggccagaccatttcatgacctg 6161 5252 274274 NM_001206947.1_ex10R NM_001206947.1_ex10R ctgtgcagaggccccatttactgtgcagaggccccattta 6060 5555 274274 NM_001206947.1_ex11F NM_001206947.1_ex11F tctggaatccttatggtagttccctctggaatccttatggtagttccc 6060 4646 191191 NM_001206947.1_ex11R NM_001206947.1_ex11R ccttaacttctactcctacctgccttaacttctactcctacctg 5555 4646 191191 NM_001206947.1_ex12F NM_001206947.1_ex12F atctgtggtgggtggagaag atctgtggtgggtggagaag 6060 5555 336336 NM_001206947.1_ex12R NM_001206947.1_ex12R ccttcaagggataaaattgc ccttcaagggataaaattgc 5656 4040 336336 NM_001206947.1_ex13F NM_001206947.1_ex13F gtgtggggaatttagtgc gtgtggggaatttagtgc 5454 5050 345345 NM_001206947.1_ex13R NM_001206947.1_ex13R gggggatgggacaatttct gggggatgggacaatttct 6161 5353 345345 NM_001206947.1_ex14F NM_001206947.1_ex14F ggagaaaaggcaaagacctc ggagaaaaggcaaagacctc 5858 5050 339339 NM_001206947.1_ex14R NM_001206947.1_ex14R agtggttccatttccgatgc agtggttccatttccgatgc 6262 5050 339339 NM_001206947.1_ex15F NM_001206947.1_ex15F agtggcctctcagaaccaga agtggcctctcagaaccaga 6060 5555 384384 NM_001206947.1_ex15R NM_001206947.1_ex15R aacagagcgagactccgtgt aacagagcgagactccgtgt 6060 5555 384384 NM_001206947.1_ex16F NM_001206947.1_ex16F ctcccaaagtgctgggatta ctcccaaagtgctgggatta 6060 5050 397397 NM_001206947.1_ex16R NM_001206947.1_ex16R taggcaaccagcttcctttg taggcaaccagcttcctttg 6060 5050 397397 NM_001206947.1_ex17F NM_001206947.1_ex17F ctcacagctgtcttagca ctcacagctgtcttagca 5050 5050 284284 NM_001206947.1_ex17R NM_001206947.1_ex17R gggctaggagtatgaggagca gggctaggagtatgaggagca 6161 5757 284284 NM_001206947.1_ex18F NM_001206947.1_ex18F ggacctgtcatccctgttgtggacctgtcatccctgttgt 6060 5555 222222 NM_001206947.1_ex18R NM_001206947.1_ex18R accacagttacatgtagtgtgtaccacagttacatgtagtgtgt 5757 4141 222222 NM_001206947.1_ex19F NM_001206947.1_ex19F ggtaaagaccacaaagcattggtaaagaccacaaagcatt 5454 4040 370370 NM_001206947.1_ex19R NM_001206947.1_ex19R acaggagttgaaagaattgaagggacaggagttgaaagaattgaaggg 5959 4242 370370

본 발명에서 디자인된 프라이머 (LRP6)The primer designed in the present invention ( LRP6 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_002336.2_ex1F NM_002336.2_ex1F ctcgcctcccccacttctctcgcctcccccacttct 6060 6666 152152 NM_002336.2_ex1R NM_002336.2_ex1R accccaccaactttccagtgaccccaccaactttccagtg 6161 5555 152152 NM_002336.2_ex2_1F NM_002336.2_ex2_1F tttttgttctagcggccccttttttgttctagcggcccct 5959 5050 250250 NM_002336.2_ex2_1R NM_002336.2_ex2_1R tcgggggacaataatccagatcggggggacaataatccaga 6060 5050 250250 NM_002336.2_ex2_2F NM_002336.2_ex2_2F ctgagagtgtgcagaatgctgagagtgtgcagaatg 5353 5050 262262 NM_002336.2_ex2_2R NM_002336.2_ex2_2R gtcagtggagaaaaaccggtcagtggagaaaaaccg 5353 5050 262262 NM_002336.2_ex2F NM_002336.2_ex2F tctagcggcccctttgttgtctagcggcccctttgttg 6060 5757 400400 NM_002336.2_ex2R NM_002336.2_ex2R cccacttgaaggatctaaggcacccacttgaaggatctaaggca 6060 5050 400400 NM_002336.2_ex3F NM_002336.2_ex3F tgatatctgctctgtcatggcttgatatctgctctgtcatggct 5959 4646 300300 NM_002336.2_ex3R NM_002336.2_ex3R tgtatcaaggcttcatcgagtgtatcaaggcttcatcgag 5555 4545 300300 NM_002336.2_ex4F NM_002336.2_ex4F tgttaataggcaggcagtggttgttaataggcaggcagtggt 6060 4848 322322 NM_002336.2_ex4R NM_002336.2_ex4R attcccgccaactatctttgattcccgccaactatctttg 5656 4545 322322 NM_002336.2_ex5F NM_002336.2_ex5F tgacagccacaaatccatgttgacagccacaaatccatgt 5858 4545 250250 NM_002336.2_ex5R NM_002336.2_ex5R aagtgactggtctcccaaagcaagtgactggtctcccaaagc 6060 5252 250250 NM_002336.2_ex6_1F NM_002336.2_ex6_1F cactttgttgttctaggtgccacactttgttgttctaggtgcca 5959 4545 256256 NM_002336.2_ex6_1R NM_002336.2_ex6_1R caggatgggcaatttgagcagcaggatgggcaatttgagcag 5959 5252 256256 NM_002336.2_ex6_2F NM_002336.2_ex6_2F tggatctggcagtcagtttgttggatctggcagtcagtttgt 5959 4848 220220 NM_002336.2_ex6_2R NM_002336.2_ex6_2R cagtagagcttcttacccaaccacagtagagcttcttacccaacca 5959 4848 220220 NM_002336.2_ex7F NM_002336.2_ex7F ctaggtacatgtattggactgactggctaggtacatgtattggactgactgg 6060 4646 235235 NM_002336.2_ex7R NM_002336.2_ex7R actgtcgactcaaaacccatactgtcgactcaaaacccat 5757 4545 235235 NM_002336.2_ex8F NM_002336.2_ex8F gcataattcatccccttctcgcataattcatccccttctc 5454 4646 296296 NM_002336.2_ex8R NM_002336.2_ex8R cctggttcccatttctaagaaagccctggttcccatttctaagaaagc 6060 4646 296296 NM_002336.2_ex9F NM_002336.2_ex9F gtgtccttctgtgcccctttgtgtccttctgtgccccttt 6060 5555 375375 NM_002336.2_ex9R NM_002336.2_ex9R gttctcccttttagtccctagctgttctcccttttagtccctagct 5959 4848 375375 NM_002336.2_ex10F NM_002336.2_ex10F ctggatagggtttagacttatgccctggatagggtttagacttatgcc 6060 4646 342342 NM_002336.2_ex10R NM_002336.2_ex10R tgccatgttccccgaaatgttgccatgttccccgaaatgt 5959 5050 342342 NM_002336.2_ex11F NM_002336.2_ex11F gactctttcccccagataatgactctttcccccagataat 5454 4545 305305 NM_002336.2_ex11R NM_002336.2_ex11R cagccactgatatttgcatggacagccactgatatttgcatgga 5959 4646 305305 NM_002336.2_ex12F NM_002336.2_ex12F actctgcttctcccctgtctactctgcttctcccctgtct 6060 5555 390390 NM_002336.2_ex12R NM_002336.2_ex12R gctttggagggaaatgcagcgctttggagggaaatgcagc 6060 5555 390390 NM_002336.2_ex13F NM_002336.2_ex13F tggatgatagaggatgtagggttggatgatagaggatgtagggt 5858 4646 318318 NM_002336.2_ex13R NM_002336.2_ex13R tggtgagtccagttattagtcaggtggtgagtccagttattagtcagg 5959 4646 318318 NM_002336.2_ex14F NM_002336.2_ex14F ttgcctcagggttatctgccttgcctcagggttatctgcc 6060 5555 307307 NM_002336.2_ex14R NM_002336.2_ex14R agccacagtatctgaacgccagccacagtatctgaacgcc 5959 5555 307307 NM_002336.2_ex15F NM_002336.2_ex15F ttcctcctttccctctaggtttcctcctttccctctaggt 5959 5050 312312 NM_002336.2_ex15R NM_002336.2_ex15R actgccaagaaatgtgccaaactgccaagaaatgtgccaa 6161 4545 312312 NM_002336.2_ex16F NM_002336.2_ex16F aacttgacccacatgagtcaaacttgacccacatgagtca 5656 4545 290290 NM_002336.2_ex16R NM_002336.2_ex16R cctccaattagctttatccccctccaattagctttatccc 5353 4545 290290 NM_002336.2_ex17F NM_002336.2_ex17F acttctctccccctccactcacttctctccccctccactc 5959 6060 222222 NM_002336.2_ex17R NM_002336.2_ex17R tgcatttagggttgcacaagtgcatttagggttgcacaag 6060 4545 222222 NM_002336.2_ex18F NM_002336.2_ex18F tgtcactccccttctccttgtgtcactccccttctccttg 5959 5555 307307 NM_002336.2_ex18R NM_002336.2_ex18R aaaggattgcatgctgaggcaaaggattgcatgctgaggc 5959 5050 307307 NM_002336.2_ex19F NM_002336.2_ex19F gccagagtttgactttacatgagccagagtttgactttacatga 6060 4141 190190 NM_002336.2_ex19R NM_002336.2_ex19R agatctcagtcctacttacaacaatccagatctcagtcctacttacaacaatcc 6060 4141 190190 NM_002336.2_ex20F NM_002336.2_ex20F actgcattcttcattgtagatccgactgcattcttcattgtagatccg 5959 4141 300300 NM_002336.2_ex20R NM_002336.2_ex20R agtcttgcaggaccaaagactagtcttgcaggaccaaagact 5959 4747 300300 NM_002336.2_ex21F NM_002336.2_ex21F attttaggaatgtctcgaggattttaggaatgtctcgagg 5252 4040 180180 NM_002336.2_ex21R NM_002336.2_ex21R atgtatgtcgcattcaaaggatgtatgtcgcattcaaagg 5454 4040 180180 NM_002336.2_ex22F NM_002336.2_ex22F tgaggaagccatagtcccaatgaggaagccatagtcccaa 5959 5050 302302 NM_002336.2_ex22R NM_002336.2_ex22R gcaccttattttagagaaggatgtggcaccttattttagagaagagatgtg 6161 4040 302302 NM_002336.2_ex23F NM_002336.2_ex23F ctgcttctctttattttctcccctgcttctctttattttctccc 5555 4141 355355 NM_002336.2_ex23R NM_002336.2_ex23R gttggaggcagtcagaggaggttggaggcagtcagaggag 6060 6060 355355

본 발명에서 디자인된 프라이머 (PSEN1)The primer designed in the present invention ( PSEN1 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_007318.2_ex1F NM_007318.2_ex1F gaaatgacgacaacggtgaggaaatgacgacaacggtgag 6060 5050 166166 NM_007318.2_ex1R NM_007318.2_ex1R actccccatcacgcacatacactccccatcacgcacatac 6060 5050 166166 NM_007318.2_ex2F NM_007318.2_ex2F tggatgacctggtgaaatcctggatgacctggtgaaatcc 6161 6060 214214 NM_007318.2_ex2R NM_007318.2_ex2R agcctcttgaggttctgaagcctcttgaggttctga 5353 5050 214214 NM_007318.2_ex3F NM_007318.2_ex3F ttggcctggaggagaacacttggcctggaggagaacac 6161 5858 300300 NM_007318.2_ex3R NM_007318.2_ex3R tccagtctggcaaaggcagttccagtctggcaaaggcagt 6363 5555 300300 NM_007318.2_ex4F NM_007318.2_ex4F ccgttaccttgattctgctgccgttaccttgattctgctg 6060 5050 354354 NM_007318.2_ex4R NM_007318.2_ex4R gccacactggctttgagaatgccacactggctttgagaat 6060 5555 354354 NM_007318.2_ex5F NM_007318.2_ex5F cactgacctagggcttttgtgcactgacctagggcttttgtg 6060 5252 220220 NM_007318.2_ex5R NM_007318.2_ex5R gaagaacagggtggaaagcagaagaacagggtggaaagca 6060 5050 220220 NM_007318.2_ex6F NM_007318.2_ex6F tttaagggttgtgggacctgtttaagggttgtgggacctg 6060 5050 176176 NM_007318.2_ex6R NM_007318.2_ex6R gctacacagcacaaaggtagttgctacacagcacaaaggtagtt 5656 4545 176176 NM_007318.2_ex7F NM_007318.2_ex7F tgtttgggagccatcacatgtttgggagccatcaca 6060 5050 348348 NM_007318.2_ex7R NM_007318.2_ex7R gggcattcctgtgacaaacagggcattcctgtgacaaaca 5959 5050 348348 NM_007318.2_ex8F NM_007318.2_ex8F attcctccctaccacccattattcctccctaccaccatt 5959 5050 239239 NM_007318.2_ex8R NM_007318.2_ex8R catgtgcttcagttccgatacatgtgcttcagttccgata 5757 4545 239239 NM_007318.2_ex9F NM_007318.2_ex9F ggagaaatgatggcttgttgggagaaatgatggcttgttg 5858 4545 219219 NM_007318.2_ex9R NM_007318.2_ex9R gcttataacagtgaccctgagcttataacagtgaccctga 5353 4545 219219 M_007318.2_ex10F M_007318.2_ex10F gagctgtaacttccactttctcgagctgtaacttccactttctc 5555 4646 250250 M_007318.2_ex10R M_007318.2_ex10R gctacctaaaggaatccatgacgctacctaaaggaatccatgac 5656 4646 250250 M_007318.2_ex11F M_007318.2_ex11F cattgtggggttgagtagggcattgtggggttgagtaggg 6060 5555 309309 M_007318.2_ex11R M_007318.2_ex11R ccacctggggttaaaacagaccacctggggttaaaacaga 6060 5050 309309 M_007318.2_ex12F M_007318.2_ex12F gtgtgtctttcccatcttctccgtgtgtctttcccatcttctcc 6060 5050 241241 M_007318.2_ex12R M_007318.2_ex12R acctttgtcctccccagattacctttgtcctccccagatt 6060 5050 241241

본 발명에서 디자인된 프라이머 (ADAM10)The primer designed in the present invention ( ADAM10 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001110.2_ex1F NM_001110.2_ex1F agccccttcagcttctcccagccccttcagcttctccc 6161 6363 152152 NM_001110.2_ex1R NM_001110.2_ex1R gcagtcgtgcctcacctcgcagtcgtgcctcacctc 6060 6060 152152 NM_001110.2_ex2F NM_001110.2_ex2F gaaggggtcttcaagatgatgaaggggtcttcaagatgat 5555 4545 238238 NM_001110.2_ex2R NM_001110.2_ex2R ggaacttcagacacagtcagcggaacttcagacacagtcagc 5858 5353 238238 NM_001110.2_ex3F NM_001110.2_ex3F gttgttcccccttcccatccgttgttcccccttcccatcc 6060 6060 173173 NM_001110.2_ex3R NM_001110.2_ex3R gggttctgttaaggtccaacgggttctgttaaggtccaac 5656 5050 173173 NM_001110.2_ex4F NM_001110.2_ex4F aggtgaagaaggaagttttagccaaggtgaagaaggaagttttagcca 6060 4242 280280 NM_001110.2_ex4R NM_001110.2_ex4R tgttctagcctgattagtaactcagtgttctagcctgattagtaactcag 5858 4040 280280 NM_001110.2_ex5F NM_001110.2_ex5F tgccttttccataggtgctttgccttttccataggtgctt 5757 4545 275275 NM_001110.2_ex5R NM_001110.2_ex5R ccatttcctaaatgcaagctagtgtccatttcctaaatgcaagctagtgt 6060 4040 275275 NM_001110.2_ex6F NM_001110.2_ex6F tggcagcagaaatacctatggttggcagcagaaatacctatggt 5959 4646 313313 NM_001110.2_ex6R NM_001110.2_ex6R tgggaactactaaaatagcgcatgggaactactaaaatagcgca 5757 4141 313313 NM_001110.2_ex7F NM_001110.2_ex7F aatctcccttcccagcgcagaatctcccttcccagcgcag 6262 6060 328328 NM_001110.2_ex7R NM_001110.2_ex7R acatagtctggactgtttcactacatagtctggactgtttcact 5858 4141 328328 NM_001110.2_ex8F NM_001110.2_ex8F cattcacactaaagctctgccattcacactaaagctctgc 5555 4545 296296 NM_001110.2_ex8R NM_001110.2_ex8R ctcccctttgtttcaagtagctcccctttgtttcaagtag 5454 4545 296296 NM_001110.2_ex9F NM_001110.2_ex9F acctttttgggggtaaggggacctttttgggggtaagggg 6060 5555 236236 NM_001110.2_ex9R NM_001110.2_ex9R gacaatacttactggggatccagacaatacttactggggatcca 6060 4646 236236 NM_001110.2_ex10F NM_001110.2_ex10F ggagagtccacaagcttccaggagagtccacaagcttcca 6060 5555 395395 NM_001110.2_ex10R NM_001110.2_ex10R atgcaggtggtgggtatgtcatgcaggtggtgggtatgtc 6060 5555 395395 NM_001110.2_ex11F NM_001110.2_ex11F attttcctcagaatctggccattttcctcagaatctggcc 5656 4545 182182 NM_001110.2_ex11R NM_001110.2_ex11R cactgaaattagcaaggtacctgccactgaaattagcaaggtacctgc 6060 4646 182182 NM_001110.2_ex12F NM_001110.2_ex12F ttcctctagtccaagtcaaggtcttcctctagtccaagtcaaggtc 5858 4747 200200 NM_001110.2_ex12R NM_001110.2_ex12R tgcttaccccattaatgcacactgcttaccccattaatgcacac 5858 4545 200200 NM_001110.2_ex13F NM_001110.2_ex13F ggaagctcatacttgcctgtc ggaagctcatacttgcctgtc 5959 5252 293293 NM_001110.2_ex13R NM_001110.2_ex13R tctggccaaactgtaggtca tctggccaaactgtaggtca 5959 5050 293293 NM_001110.2_ex14F NM_001110.2_ex14F gcatttcttttccagtggacccgcatttcttttccagtggaccc 6060 5050 310310 NM_001110.2_ex14R NM_001110.2_ex14R ttgatgacttctggccaagtttgatgacttctggccaagt 5757 4747 310310 NM_001110.2_ex15F NM_001110.2_ex15F tttctaggctcattggtgggtttctaggctcattggtggg 5555 5050 252252 NM_001110.2_ex15R NM_001110.2_ex15R cccattcttacggagaaagtactgcccattcttacggagaaagtactg 6060 4646 252252 NM_001110.2_ex16F NM_001110.2_ex16F ggcccatattattggacagcacggcccatattattggacagacac 6060 5050 246246 NM_001110.2_ex16R NM_001110.2_ex16R gcactaggaagaaccaaggcagcactaggaagaaccaaggca 6060 5252 246246

본 발명에서 디자인된 프라이머 (ABCA7)The primer designed in the present invention ( ABCA7 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_019112.3_ex1F NM_019112.3_ex1F ttctgtgatcccgtctcctc ttctgtgatcccgtctcctc 6060 5555 354354 NM_019112.3_ex1R NM_019112.3_ex1R attcagccgtcgtcaacatt attcagccgtcgtcaacatt 6161 4545 354354 NM_019112.3_ex2F NM_019112.3_ex2F gcgctcccattggtttact gcgctcccattggtttact 6060 5353 400400 NM_019112.3_ex2R NM_019112.3_ex2R aagagaggccacagcaattc aagagaggccacagcaattc 5959 5050 400400 NM_019112.3_ex3F NM_019112.3_ex3F gtaacgccccagtgtgagac gtaacgccccagtgtgagac 6161 6060 376376 NM_019112.3_ex3R NM_019112.3_ex3R cctgtggactctgcctgact cctgtggactctgcctgact 6060 6060 376376 NM_019112.3_ex4F NM_019112.3_ex4F ccaatacatggcatgggagt ccaatacatggcatgggagt 6161 5050 359359 NM_019112.3_ex4R NM_019112.3_ex4R gaccctggggacagagaga gaccctggggacagagaga 6060 6363 359359 NM_019112.3_ex5F NM_019112.3_ex5F gcctgagcaacttcaacgac gcctgagcaacttcaacgac 6161 5555 397397 NM_019112.3_ex5R NM_019112.3_ex5R gtggagactgcttggttggt gtggagactgcttggttggt 6060 5555 397397 NM_019112.3_ex6F NM_019112.3_ex6F agctctgagcctcaacttgc agctctgagcctcaacttgc 6060 5555 380380 NM_019112.3_ex6R NM_019112.3_ex6R cagacgagtcttcctcactgg cagacgagtcttcctcactgg 6060 5757 380380 NM_019112.3_ex7F NM_019112.3_ex7F gacccagtgaggaagactcg gacccagtgaggaagactcg 6060 6060 395395 NM_019112.3_ex7R NM_019112.3_ex7R cctctccctctcgctgtcta cctctccctctcgctgtcta 6060 6060 395395 NM_019112.3_ex8F NM_019112.3_ex8F gatcattgccagctccgtctgatcattgccagctccgtct 6060 5555 261261 NM_019112.3_ex8R NM_019112.3_ex8R ggtcagtcactcactcaggcggtcagtcactcactcaggc 6060 6060 261261 NM_019112.3_ex9F NM_019112.3_ex9F cagacagcagcctgagtgag cagacagcagcctgagtgag 6060 6060 370370 NM_019112.3_ex9R NM_019112.3_ex9R cctccatcggctaactccta cctccatcggctaactccta 5959 5555 370370 NM_019112.3_ex10F NM_019112.3_ex10F cttgtgcggaggatcagag cttgtgcggaggatcagag 6060 5858 360360 NM_019112.3_ex10R NM_019112.3_ex10R cagagcgagactccatctca cagagcgagactccatctca 5959 5555 360360 NM_019112.3_ex11F NM_019112.3_ex11F ctcctgacctcaggtgatcc ctcctgacctcaggtgatcc 6060 6060 393393 NM_019112.3_ex11R NM_019112.3_ex11R aaatcccaggctcttactaggg aaatcccaggctcttactaggg 6060 5050 393393 NM_019112.3_ex12F NM_019112.3_ex12F gaggtccagggggaggag gaggtccagggggaggag 6262 7272 398398 NM_019112.3_ex12R NM_019112.3_ex12R tctccaataggctgaatgctg tctccaataggctgaatgctg 6060 4848 398398 NM_019112.3_ex13F NM_019112.3_ex13F gattgcagctcttcactcca gattgcagctcttcactcca 5959 5050 392392 NM_019112.3_ex13R NM_019112.3_ex13R caggaaggttcccaacagag caggaaggttcccaacagag 6060 5555 392392 NM_019112.3_ex14F NM_019112.3_ex14F gtctccagcctccaccccgtctccagcctccacccc 6161 7272 295295 NM_019112.3_ex14R NM_019112.3_ex14R acccattctgcagccgggacccattctgcagccggg 6262 6666 295295 NM_019112.3_ex15F NM_019112.3_ex15F gctggagggtgacagacag gctggagggtgacagacagac 5959 6363 397397 NM_019112.3_ex15R NM_019112.3_ex15R agcaggctctgcggaaaa agcaggctctgcggaaaa 6262 5656 397397 NM_019112.3_ex16F NM_019112.3_ex16F actgaccgcccgcttttcactgaccgcccgcttttc 6060 6161 278278 NM_019112.3_ex16R NM_019112.3_ex16R cctcccgcaaagcaggtgcctcccgcaaagcaggtg 6161 6767 278278 NM_019112.3_ex17F NM_019112.3_ex17F agcttgcagcgagtcaaaat agcttgcagcgagtcaaaat 6060 4545 390390 NM_019112.3_ex17R NM_019112.3_ex17R agtgtcttcagggcaggtgt agtgtcttcagggcaggtgt 6060 5555 390390 NM_019112.3_ex18F NM_019112.3_ex18F catgacctccatggctgagtcatgacctccatggctgagt 6060 5555 227227 NM_019112.3_ex18R NM_019112.3_ex18R gagtggttgggggctcacgagtggttgggggctcac 6060 6767 227227 NM_019112.3_ex19F NM_019112.3_ex19F gggcaacagagtgaaactcc gggcaacagagtggaaactcc 6060 5555 391391 NM_019112.3_ex19R NM_019112.3_ex19R gtgcacagagcagagtgacc gtgcacagagcagagtgacc 6060 6060 391391 NM_019112.3_ex20F NM_019112.3_ex20F gctgtttgacatgtgcgtct gctgtttgacatgtgcgtct 6060 5050 351351 NM_019112.3_ex20R NM_019112.3_ex20R ctacccacgtggacctcagt ctacccacgtggacctcagt 6060 6060 351351 NM_019112.3_ex21F NM_019112.3_ex21F gaagccgggtactgaggtc gaagccgggtactgaggtc 6060 6363 331331 NM_019112.3_ex21R NM_019112.3_ex21R ggggtccacatgtagcaaac ggggtccacatgtagcaaac 6060 5555 331331 NM_019112.3_ex22F NM_019112.3_ex22F cttcatggggcagacaactc cttcatggggcagacaactc 6161 5555 388388 NM_019112.3_ex22R NM_019112.3_ex22R actgccctccatgtcagtgt actgccctccatgtcagtgt 6161 5555 388388 NM_019112.3_ex23F NM_019112.3_ex23F tgaccaccaatgagaaggtg tgaccaccaatgagaaggtg 6060 5050 349349 NM_019112.3_ex23R NM_019112.3_ex23R ccccttccacctcttactcc ccccttccacctcttactcc 6060 6060 349349 NM_019112.3_ex24F NM_019112.3_ex24F acagtcccctcacaggtcac acagtcccctcacaggtcac 6060 6060 395395 NM_019112.3_ex24R NM_019112.3_ex24R ccttgctgctcataaacacg ccttgctgctcataaacacg 5959 5050 395395 NM_019112.3_ex25F NM_019112.3_ex25F agctctggtggctcagatgt agctctggtggctcagatgt 6060 5555 319319 NM_019112.3_ex25R NM_019112.3_ex25R aagttgagggtcacggattg aagttgagggtcacggattg 6060 5050 319319 NM_019112.3_ex26F NM_019112.3_ex26F ccaaggcatagcctttaccc ccaaggcatagcctttaccc 6161 5555 387387 NM_019112.3_ex26R NM_019112.3_ex26R agaaagcgcttgagaagcag agaaagcgcttgagaagcag 6060 5050 387387 NM_019112.3_ex27F NM_019112.3_ex27F gacgtaaccctacggctcaa gacgtaaccctacggctcaa 6060 5555 376376 NM_019112.3_ex27R NM_019112.3_ex27R ggtttggattaggccactga ggtttggattaggccactga 6060 5050 376376 NM_019112.3_ex28F NM_019112.3_ex28F agccatgggtggttgtagag agccatgggtggttgtagag 6060 5555 304304 NM_019112.3_ex28R NM_019112.3_ex28R tcactgtgtgtgaggggaga tcactgtgtgtgaggggaga 6060 5555 304304 NM_019112.3_ex29F NM_019112.3_ex29F gtacggtgctcaggtgtcct gtacggtgctcaggtgtcct 6060 6060 392392 NM_019112.3_ex29R NM_019112.3_ex29R agggtcaaggtgaaggtctg agggtcaaggtgaaggtctg 5959 5555 392392 NM_019112.3_ex30F NM_019112.3_ex30F ttgagtgtgcacagcccattttgagtgtgcacagcccatt 6060 5050 330330 NM_019112.3_ex30R NM_019112.3_ex30R ggacccatgctatagccaggggacccatgctatagccagg 6060 6060 330330 NM_019112.3_ex31F NM_019112.3_ex31F ttgactctgtgctcccctct ttgactctgtgctcccctct 6060 5555 259259 NM_019112.3_ex31R NM_019112.3_ex31R agcgagaagcctccgtatct agcgagaagcctccgtatct 6161 5555 259259 NM_019112.3_ex32F NM_019112.3_ex32F ggtgaggaggggtctagctt ggtgaggaggggtctctctt 6060 6060 388388 NM_019112.3_ex32R NM_019112.3_ex32R ggtgggggtcaaggtcatag ggtgggggtcaaggtcatag 6262 6060 388388 NM_019112.3_ex33F NM_019112.3_ex33F agtctcaaggtgggaactgg agtctcaaggtgggaactgg 5959 5555 365365 NM_019112.3_ex33R NM_019112.3_ex33R tgtgtcagggttcaaatcca tgtgtcagggttcaaatcca 6060 4545 365365 NM_019112.3_ex34F NM_019112.3_ex34F tgactgccccatagaccttt tgactgccccatagaccttt 6060 5050 383383 NM_019112.3_ex34R NM_019112.3_ex34R actttacccaggccatcttg actttacccaggccatcttg 5959 5050 383383 NM_019112.3_ex35F NM_019112.3_ex35F caaaaagcaaggaggtcagg caaaaagcaaggaggtcagg 6060 5050 362362 NM_019112.3_ex35R NM_019112.3_ex35R cttggcacaccactgaattg cttggcacaccactgaattg 6060 5050 362362 NM_019112.3_ex36F NM_019112.3_ex36F gcagagaagatgggaatgga gcagagaagatgggaatgga 6060 5050 380380 NM_019112.3_ex36R NM_019112.3_ex36R aagcagaagtgggggaagat aagcagaagtgggggaagat 6060 5050 380380 NM_019112.3_ex37F NM_019112.3_ex37F atgtggtgctcacctgcata atgtggtgctcacctgcata 6060 5050 387387 NM_019112.3_ex37R NM_019112.3_ex37R ggggctgtttttctccactc ggggctgtttttctctccc 6161 5555 387387 NM_019112.3_ex38F NM_019112.3_ex38F gactccagctgagtggccta gactccagctgagtggccta 6161 6060 354354 NM_019112.3_ex38R NM_019112.3_ex38R aggagtggcagagacctcac aggagtggcagagacctcac 5959 6060 354354 NM_019112.3_ex39F NM_019112.3_ex39F acctcttggccatggtgata acctcttggccatggtgata 6060 5050 360360 NM_019112.3_ex39R NM_019112.3_ex39R tacctgggagagtgcaggtc tacctgggagagtgcaggtc 6060 6060 360360 NM_019112.3_ex40F NM_019112.3_ex40F tgttggtgctgaggaacttg tgttggtgctgaggaacttg 6060 5050 287287 NM_019112.3_ex40R NM_019112.3_ex40R gtgcccaataaaaggtggtg gtgcccaataaaaggtggtg 6060 5050 287287 NM_019112.3_ex41F NM_019112.3_ex41F aaggcaggagaattgcttga aaggcaggagaattgcttga 6060 4545 380380 NM_019112.3_ex41R NM_019112.3_ex41R ccagtccattcactggaggt ccagtccattcactggaggt 6060 5555 380380 NM_019112.3_ex42F NM_019112.3_ex42F agacccctgcacctctacct agacccctgcacctctacct 6060 6060 384384 NM_019112.3_ex42R NM_019112.3_ex42R gattgggccaggctttaga gattgggccaggctttaga 6060 5353 384384 NM_019112.3_ex43F NM_019112.3_ex43F ctgctccacactcaatgctg ctgctccacactcaatgctg 6161 5555 370370 NM_019112.3_ex43R NM_019112.3_ex43R caaaaggctgttccaaagga caaaaggctgttccaaagga 6060 4545 370370 NM_019112.3_ex44F NM_019112.3_ex44F ctacagcggagggaacaaac ctacagcggagggaacaaac 6060 5555 339339 NM_019112.3_ex44R NM_019112.3_ex44R cctgtggccttgtgcttt cctgtggccttgtgcttt 6060 5656 339339 NM_019112.3_ex45F NM_019112.3_ex45F agaacggtctggggaagagt agaacggtctggggaagagt 6060 5555 367367 NM_019112.3_ex45R NM_019112.3_ex45R cccctgcaggacaatctaaa cccctgcaggacaatctaaa 6060 5050 367367 NM_019112.3_ex46F NM_019112.3_ex46F gaaaggcccgatccggtaggaaaggcccgatccggtag 6060 6363 290290 NM_019112.3_ex46R NM_019112.3_ex46R cgtgatcacctcctccagccgtgatcacctcctccagc 6060 6363 290290 NM_019112.3_ex47F NM_019112.3_ex47F tccctcttgtcccctctggtccctcttgtcccctctgg 6060 6363 365365 NM_019112.3_ex47R NM_019112.3_ex47R cctggctcaaggacacacatcctggctcagagacacacat 6060 5555 365365

본 발명에서 디자인된 프라이머 (CD33)The primer ( CD33 ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001772.3_ex1F NM_001772.3_ex1F ttctgctcacacaggaagccttctgctcacacaggaagcc 6060 5555 138138 NM_001772.3_ex1R NM_001772.3_ex1R gtggggaaacgagggtcaggtggggaaacgagggtcag 6060 6363 138138 NM_001772.3_ex2_1F NM_001772.3_ex2_1F gaccctcgtttccccacaggaccctcgtttccccacag 6060 6363 246246 NM_001772.3_ex2_1R NM_001772.3_ex2_1R gccctgagtctcctcctgtagccctgagtctcctcctgta 6060 6060 246246 NM_001772.3_ex2_2F NM_001772.3_ex2_2F ggccacaaacaagctagatcggccacaaacaagctagatc 5656 5050 245245 NM_001772.3_ex2_2R NM_001772.3_ex2_2R acccatgaacttcccttgcgacccatgaacttcccttgcg 6060 5555 245245 NM_001772.3_ex3F NM_001772.3_ex3F ggaccctccctcctgattctggaccctccctcctgattct 6060 5555 376376 NM_001772.3_ex3R NM_001772.3_ex3R atcctgtctcccctacacccatcctgtctcccctacaccc 6060 5555 376376 NM_001772.3_ex4F NM_001772.3_ex4F acccccaactgaaggaaatccacccccaactgaaggaaatcc 6060 5252 124124 NM_001772.3_ex4R NM_001772.3_ex4R atgtcagtaacagccccaggatgtcagtaacagccccagg 6161 5555 124124 NM_001772.3_ex5F NM_001772.3_ex5F acccctctctacatgctggaacccctctctacatgctgga 5959 5555 223223 NM_001772.3_ex5R NM_001772.3_ex5R ctcttcacctctggcccatgctcttcacctctggcccatg 6060 6060 223223 NM_001772.3_ex6F NM_001772.3_ex6F cccacagcctgagaaaaccacccacagcctgagaaaacca 6060 5555 190190 NM_001772.3_ex6R NM_001772.3_ex6R ccacattgggaggaggtgtcccacattgggaggaggtgtc 6060 6060 190190 NM_001772.3_ex7F NM_001772.3_ex7F ctcactgccctgctctaaccctcactgccctgctctaacc 6060 6060 271271 NM_001772.3_ex7R NM_001772.3_ex7R gtccccgacctgtagaggatgtccccgacctgtagaggat 6060 6060 271271

본 발명에서 디자인된 프라이머 (APP)The primer ( APP ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001136131.2_ex1F NM_001136131.2_ex1F gggctccgtcagtttcctgggctccgtcagtttcct 6060 6161 311311 NM_001136131.2_ex1R NM_001136131.2_ex1R cccggcttctctgcattacccggcttctctgcatta 6060 5555 311311 NM_001136131.2_ex2F NM_001136131.2_ex2F ctctgccttggagctatggactctgccttggagctatgga 6161 5555 240240 NM_001136131.2_ex2R NM_001136131.2_ex2R tagccaccggacaggacttatagccaccggacaggactta 6161 5555 240240 NM_001136131.2_ex3F NM_001136131.2_ex3F cacttctggtcccaagcatt cacttctggtcccaagcatt 6060 5050 375375 NM_001136131.2_ex3R NM_001136131.2_ex3R gagtggcaatgtgctgaaga gagtggcaatgtgctgaaga 6060 5050 375375 NM_001136131.2_ex4F NM_001136131.2_ex4F tagggtcttgattgggttgc tagggtcttgattgggttgc 6060 5050 339339 NM_001136131.2_ex4R NM_001136131.2_ex4R gctgttgcctcaaaataccc gctgttgcctcaaaataccc 6060 5050 339339 NM_001136131.2_ex5F NM_001136131.2_ex5F cactttgtagacatgcagtgagcactttgtagacatgcagtgag 5656 4646 221221 NM_001136131.2_ex5R NM_001136131.2_ex5R cacaaaggccaccttacctccacaaaggccaccttacctc 6060 5656 221221 NM_001136131.2_ex6F NM_001136131.2_ex6F ggacgacttttcttttccttccggacgacttttcttttccttcc 5858 4646 363363 NM_001136131.2_ex6R NM_001136131.2_ex6R cagtggtgctagggtggatacagtggtgctagggtggata 5858 5555 363363 NM_001136131.2_ex7F NM_001136131.2_ex7F aatgtggttccccacatctcaatgtggttccccacatctc 5959 5050 257257 NM_001136131.2_ex7R NM_001136131.2_ex7R agcagagtcagtggcgagagagcagagtcagtggcgagag 6060 6060 257257 NM_001136131.2_ex8F NM_001136131.2_ex8F gtggactcgtgcatttcagcgtggactcgtgcatttcagc 6161 5555 192192 NM_001136131.2_ex8R NM_001136131.2_ex8R gtgaaccaagcagcatcctcgtgaaccaagcagcatcctc 6060 5555 192192 NM_001136131.2_ex9F NM_001136131.2_ex9F tctcaaacctccttctcttctctcaaacctccttctcttc 5353 4545 205205 NM_001136131.2_ex9R NM_001136131.2_ex9R cccaatatcgtagggctgaacccaatatcgtagggctgaa 5959 5050 205205 NM_001136131.2_ex10F NM_001136131.2_ex10F tcctagtgggaggtcaaatcctagtgggaggtcaaa 5454 5050 331331 NM_001136131.2_ex10R NM_001136131.2_ex10R ggtaggaaatgggttcaggtggtaggaaatgggttcaggt 5858 5050 331331 NM_001136131.2_ex11F NM_001136131.2_ex11F tcagtccccatggacatatcagtccccatggacata 5555 5050 306306 NM_001136131.2_ex11R NM_001136131.2_ex11R gtgctcaaggcatttctcctgtgctcaaggcatttctcct 5959 5050 306306 NM_001136131.2_ex12F NM_001136131.2_ex12F tacgttcacatgaccggatg tacgttcacatgaccggatg 6060 5050 355355 NM_001136131.2_ex12R NM_001136131.2_ex12R cttgccatagggaaaacacc cttgccatagggaaaacacc 5959 5050 355355 NM_001136131.2_ex13F NM_001136131.2_ex13F aaccattcctacccccagacaaccattcctacccccagac 6060 5555 205205 NM_001136131.2_ex13R NM_001136131.2_ex13R ctgggggaaaatacatgtccctgggggaaaatacatgtcc 6060 5050 205205 NM_001136131.2_ex14F NM_001136131.2_ex14F tgctgctgctgctgttgttgctgctgctgctgttgt 6060 5555 359359 NM_001136131.2_ex14R NM_001136131.2_ex14R ctctctctcttgcacacacgctctctctctttgcacacacg 5959 5555 359359 NM_001136131.2_ex15F NM_001136131.2_ex15F ttctgtgtcccttgcttcctttctgtgtcccttgcttcct 6060 5050 105105 NM_001136131.2_ex15R NM_001136131.2_ex15R cacaagtcaagcggttctgacacaagtcaagcggttctga 6060 5050 105105 NM_001136131.2_ex16F NM_001136131.2_ex16F gggtaggctttgtcttacagtggggtaggctttgtcttacagtg 5858 5050 228228 NM_001136131.2_ex16R NM_001136131.2_ex16R ggcaagacaaacagtagtggggcaagacaaacagtagtgg 5656 5555 228228 NM_001136131.2_ex17F NM_001136131.2_ex17F caaccagttgggcagagaatcaaccagttgggcagagaat 6060 5050 334334 NM_001136131.2_ex17R NM_001136131.2_ex17R ccacttggaaacatgcagtcccacttggaaacatgcagtc 6060 5050 334334 NM_001136131.2_ex18F NM_001136131.2_ex18F agctctcctcttgtttttcaggagctctcctcttgtttttcagg 5959 4545 220220 NM_001136131.2_ex18R NM_001136131.2_ex18R gggtttgtttcttcccacatgggtttgtttcttcccacat 5858 4545 220220

본 발명에서 디자인된 프라이머 (PINK1)The primer ( PINK1 ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_032409.2_ex1_1F NM_032409.2_ex1_1F gctgctgctgcgcttcacgctgctgctgcgcttcac 6262 6767 350350 NM_032409.2_ex1_1R NM_032409.2_ex1_1R ccccgctcacctggatctccccgctcacctggatct 6060 6767 350350 NM_032409.2_ex1_2F NM_032409.2_ex1_2F cagcggcagttcgtggtgcagcggcagttcgtggtg 6161 6666 187187 NM_032409.2_ex1_2R NM_032409.2_ex1_2R ttagctccgtcctccgctttagctccgtcctccgct 6060 6161 187187 NM_032409.2_ex2F NM_032409.2_ex2F tcccttttcttgggccttcctcccttttcttgggccttcc 6161 5555 367367 NM_032409.2_ex2R NM_032409.2_ex2R tgaaaggcctggtgcttacctgaaaggcctggtgcttacc 6060 5555 367367 NM_032409.2_ex3F NM_032409.2_ex3F cctgtgtaaccctgggttcccctgtgtaaccctgggttcc 6060 6060 164164 NM_032409.2_ex3R NM_032409.2_ex3R gtcagtctggcaggcagaggtcagtctggcaggcagag 6161 6363 164164 NM_032409.2_ex4F NM_032409.2_ex4F tgtatctgatgctggcctcatgtatctgatgctggcctca 5858 5050 270270 NM_032409.2_ex4R NM_032409.2_ex4R gatgtatcagctccaggcccgatgtatcagctccaggccc 6060 6060 270270 NM_032409.2_ex5F NM_032409.2_ex5F agtcgtcgatgtgtggtagcagtcgtcgatgtgtggtagc 6060 5555 230230 NM_032409.2_ex5R NM_032409.2_ex5R atggtgcagcaggttcctacatggtgcagcaggttcctac 6060 5555 230230 NM_032409.2_ex6F NM_032409.2_ex6F tggtcactttgcttgctccttggtcactttgcttgctcct 5050 5555 209209 NM_032409.2_ex6R NM_032409.2_ex6R cagtggacatgtgggggaagcagtggacatgtgggggaag 6060 5050 209209 NM_032409.2_ex7F NM_032409.2_ex7F gtgatgtctcacccactgctgtgatgtctcacccactgct 6060 5555 309309 NM_032409.2_ex7R NM_032409.2_ex7R gtttctacccacaccgtcccgtttctacccacaccgtccc 5959 6060 309309 NM_032409.2_ex8F NM_032409.2_ex8F gcttcccttcctgttgcagagcttcccttcctgttgcaga 6060 5555 384384 NM_032409.2_ex8R NM_032409.2_ex8R tctctgcgctgtcttgtctctctctgcgctgtcttgtctc 6060 5555 384384

본 발명에서 디자인된 프라이머 (PARK7)The primer designed in the present invention ( PARK7 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_007262.4_ex1F NM_007262.4_ex1F gggctgtccagctagaaact gggctgtccagctagaaact 5959 5555 316316 NM_007262.4_ex1R NM_007262.4_ex1R gtccagcacagggacacc gtccagcacagggacacc 6060 6767 316316 NM_007262.4_ex2F NM_007262.4_ex2F ctctgcttgaaaatgctcct ctctgcttgaaaatgctcct 5757 4545 375375 NM_007262.4_ex2R NM_007262.4_ex2R gcgttaaatgtgagcagtgg gcgttaaatgtgagcagtgg 5959 5050 375375 NM_007262.4_ex3F NM_007262.4_ex3F gagctggaggctgcagtaag gagctggaggctgcagtaag 6060 6060 376376 NM_007262.4_ex3R NM_007262.4_ex3R ggggaagacattcaagcaaa ggggaagacattcaagcaaa 6060 4545 376376 NM_007262.4_ex4F NM_007262.4_ex4F acaccattccgtcatgtgg acaccattccgtcatgtgg 6060 5353 348348 NM_007262.4_ex4R NM_007262.4_ex4R cctcctcccgaaatatttgaa cctcctcccgaaatatttgaa 6060 4343 348348 NM_007262.4_ex5F NM_007262.4_ex5F atgagaaatgccttgcttgg atgagaaatgccttgcttgg 6060 4545 386386 NM_007262.4_ex5R NM_007262.4_ex5R agatgccctgcatgctttat agatgccctgcatgctttat 6060 4545 386386 NM_007262.4_ex6F NM_007262.4_ex6F tctacctaggcctccccaat tctacctaggcctccccaat 6060 5555 311311 NM_007262.4_ex6R NM_007262.4_ex6R tgcagtaagccaagatcacg tgcagtaagccaagatcacg 6060 5050 311311 NM_007262.4_ex7F NM_007262.4_ex7F tgcaggtcattacacctactctgtgcaggtcattacacctactctg 6060 4848 381381 NM_007262.4_ex7R NM_007262.4_ex7R gccctgtttattctgcaaacgccctgtttattctgcaaac 5757 4545 381381

본 발명에서 디자인된 프라이머 (PARK9 ( atp13a2 ))The primer designed in the present invention ( PARK9 ( atp13a2 ) ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) XM_005245809.1_ex1F XM_005245809.1_ex1F ggtgtgtgcggaggagca ggtgtgtgcggaggagca 6262 6464 333333 XM_005245809.1_ex1R XM_005245809.1_ex1R gacccggactccgcactcgacccggactccgcactc 6262 6565 333333 XM_005245809.1_ex2F XM_005245809.1_ex2F ctcccaaagtgctgggatta ctcccaaagtgctgggatta 6060 5050 372372 XM_005245809.1_ex2R XM_005245809.1_ex2R tccatggactgccacagtag tccatggactgccacagtag 6060 5555 372372 XM_005245809.1_ex3F XM_005245809.1_ex3F aaagctgcagggggtgaat aaagctgcagggggtgaat 6262 5353 388388 XM_005245809.1_ex3R XM_005245809.1_ex3R gtcccatggaaagtcagtgg gtcccatggaaagtcagtgg 6060 5555 388388 XM_005245809.1_ex4F XM_005245809.1_ex4F ctcagctttcccatctgagc ctcagctttcccatctgagc 6060 5555 325325 XM_005245809.1_ex4R XM_005245809.1_ex4R gccagagtcagcctttatgg gccagagtcagcctttatgg 6060 5555 325325 XM_005245809.1_ex5F XM_005245809.1_ex5F tagggagggaagatggctct tagggagggaagatggctct 6060 5555 332332 XM_005245809.1_ex5R XM_005245809.1_ex5R tggatgtttgggacaacaga tggatgtttgggacaacaga 6060 4545 332332 XM_005245809.1_ex6F XM_005245809.1_ex6F tctgttgtcccaaacatcca tctgttgtcccaaacatcca 6060 4545 398398 XM_005245809.1_ex6R XM_005245809.1_ex6R gtaacctgcccaaggtttca gtaacctgcccaaggtttca 6060 5050 398398 XM_005245809.1_ex7F XM_005245809.1_ex7F ggaacccagtgagaggaaca ggaacccagtgagaggaaca 6060 5555 359359 XM_005245809.1_ex7R XM_005245809.1_ex7R agagaaggcaggtgactgga agagaaggcaggtgactgga 6060 5555 359359 XM_005245809.1_ex8F XM_005245809.1_ex8F tccagtcacctgccttctct tccagtcacctgccttctct 6060 5555 316316 XM_005245809.1_ex8R XM_005245809.1_ex8R ccactatggagaaggggaca ccactatggagaaggggaca 6060 5555 316316 XM_005245809.1_ex9F XM_005245809.1_ex9F gatgggattgaccaggagaa gatgggattgaccaggagaa 6060 5050 380380 XM_005245809.1_ex9R XM_005245809.1_ex9R agagtctggctttgctgtgg agagtctggctttgctgtgg 6161 5555 380380 XM_005245809.1_ex10F XM_005245809.1_ex10F cctcatttcctccatctcca cctcatttcctccatctcca 6060 5050 330330 XM_005245809.1_ex10R XM_005245809.1_ex10R cactggagtccacccactct cactggagtccacccctct 6060 6060 330330 XM_005245809.1_ex11F XM_005245809.1_ex11F gggaggtgaggagctaggg gggaggtgaggagctaggg 6161 6868 381381 XM_005245809.1_ex11R XM_005245809.1_ex11R cagcctggacaacagagtga cagcctggacaacagagtga 6060 5555 381381 XM_005245809.1_EX12F XM_005245809.1_EX12F aactcctggtttgctggtggaactcctggtttgctggtgg 6060 5555 253253 XM_005245809.1_EX12R XM_005245809.1_EX12R gatctctctcaagcccagcc gatctctctcaagcccagcc 5959 5050 253253 XM_005245809.1_ex13F XM_005245809.1_ex13F ctccacactgctgatggcta ctccacactgctgatggcta 6060 5555 377377 XM_005245809.1_ex13R XM_005245809.1_ex13R cggtttcggtagaggatgaa cggtttcggtagaggatgaa 6060 5050 377377 XM_005245809.1_ex14F XM_005245809.1_ex14F cctctctgtcctgggtgagt cctctctgtcctgggtgagt 5959 6060 266266 XM_005245809.1_ex14R XM_005245809.1_ex14R gagcccggattacaatctca gagcccggattacaatctca 6060 5050 266266 XM_005245809.1_ex15F XM_005245809.1_ex15F cctctaccgaaaccgggta cctctaccgaaaccgggta 6060 5858 390390 XM_005245809.1_ex15R XM_005245809.1_ex15R gtgggtgctgctgagagaat gtgggtgctgctgagagaat 6060 5555 390390 XM_005245809.1_ex16F XM_005245809.1_ex16F agttcctggggttcccatag agttcctggggttcccatag 6060 5555 398398 XM_005245809.1_ex16R XM_005245809.1_ex16R aagatggagagggaagacagg aagatggagagggaagacagg 6060 5252 398398 XM_005245809.1_ex17F XM_005245809.1_ex17F gctgggagatttggagtgac gctgggagatttggagtgac 6060 5555 390390 XM_005245809.1_ex17R XM_005245809.1_ex17R ctcctgcagggttggagag ctcctgcagggttggagag 6161 6363 390390 XM_005245809.1_ex18F XM_005245809.1_ex18F cagtgatgagacccccactt cagtgatgagacccccactt 6060 5555 390390 XM_005245809.1_ex18R XM_005245809.1_ex18R gaggcaggtgtcacaaggag gaggcaggtgtcacaaggag 6161 6060 390390 XM_005245809.1_ex19F XM_005245809.1_ex19F ctctgcaaccccgagacag ctctgcaaccccgagacag 6262 6363 388388 XM_005245809.1_ex19R XM_005245809.1_ex19R acctggatcagaggtcatgc acctggatcagaggtcatgc 6060 5555 388388 XM_005245809.1_ex20F XM_005245809.1_ex20F cccacccactctgaggacta cccacccactctgaggacta 6060 6060 353353 XM_005245809.1_ex20R XM_005245809.1_ex20R aagatgccccaaaaaggaat aagatgccccaaaaaggaat 6060 4040 353353 XM_005245809.1_ex21F XM_005245809.1_ex21F cagcctgttttcccatctgt cagcctgttttcccatctgt 6060 5050 396396 XM_005245809.1_ex21R XM_005245809.1_ex21R gtgtagcttgcagcctggtc gtgtagcttgcagcctggtc 6161 6060 396396 XM_005245809.1_ex22F XM_005245809.1_ex22F ccagctgtacctcacccagt ccagctgtacctcacccagt 6060 6060 395395 XM_005245809.1_ex22R XM_005245809.1_ex22R ccagctctgtcttctgctca ccagctctgtcttctgctca 5959 5555 395395 XM_005245809.1_ex23F XM_005245809.1_ex23F cccctgctctgtctccttc cccctgctctgtctccttc 6060 6363 321321 XM_005245809.1_ex23R XM_005245809.1_ex23R catgaaagacctgggagagc catgaaagacctgggagagc 6060 5555 321321 XM_005245809.1_ex24F XM_005245809.1_ex24F ggcccagctgtcatcatatt ggcccagctgtcatcatatt 6060 5050 363363 XM_005245809.1_ex24R XM_005245809.1_ex24R gacgctgaacgaagtgtcaa gacgctgaacgaagtgtcaa 6060 5050 363363 XM_005245809.1_ex25F XM_005245809.1_ex25F gcagaagcctcagtggtctc gcagaagcctcagtggtctc 6060 6060 358358 XM_005245809.1_ex25R XM_005245809.1_ex25R gcccacgtcatctattctgg gcccacgtcatctattctgg 6060 5555 358358 XM_005245809.1_ex26FXM_005245809.1_ex26F tatcagactaggggctgccatatcagactaggggctgcca 5959 5555 307307 XM_005245809.1_ex26RXM_005245809.1_ex26R agtcagctccctactcaccaagtcagctccctactcacca 5959 5555 307307 XM_005245809.1_ex27FXM_005245809.1_ex27F agctagggggctacttcctg agctagggggctacttcctg 6060 6060 364364 XM_005245809.1_ex27RXM_005245809.1_ex27R ggcacctctctcccatctg ggcacctctctccccctg 6161 6363 364364 XM_005245809.1_ex28FXM_005245809.1_ex28F gactacaagtcccggcagcgactacaagtcccggcagc 6060 6363 362362 XM_005245809.1_ex28RXM_005245809.1_ex28R ctccaaggggtgacgacaacctccaaggggtgacgacaac 6060 6060 362362

본 발명에서 디자인된 프라이머 (SNCA)The primers designed in the present invention ( SNCA ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001146055.1_ex1F NM_001146055.1_ex1F cctcacgccttgccttcaacctcacgccttgccttcaa 5959 5858 100100 NM_001146055.1_ex1R NM_001146055.1_ex1R ggagtgggaggcaaacccggagtgggaggcaaaccc 6060 6767 100100 NM_001146055.1_ex2F NM_001146055.1_ex2F tccccgaaagttctcattcatccccgaaagttctcattca 5757 4545 235235 NM_001146055.1_ex2R NM_001146055.1_ex2R ccatcactcatgaacaagcaccccatcactcatgaacaagcacc 6060 5050 235235 NM_001146055.1_ex3F NM_001146055.1_ex3F aggctagcttgagacttatgaggctagcttgagacttatg 5252 4545 150150 NM_001146055.1_ex3R NM_001146055.1_ex3R atactgggccacactaatcacatactgggccacactaatcac 5757 4848 150150 NM_001146055.1_ex4F NM_001146055.1_ex4F agtcactgttattctaccacccagtcactgttattctaccaccc 5757 4646 210210 NM_001146055.1_ex4R NM_001146055.1_ex4R tacacagccataccttgccctacacagccataccttgccc 6060 5555 210210 NM_001146055.1_ex5F NM_001146055.1_ex5F ttcaagatccgtggccaacattcaagatccgtggccaaca 6060 5050 221221 NM_001146055.1_ex5R NM_001146055.1_ex5R tcagcttggactcctacctcatcagcttggactcctacctca 6060 5252 221221 NM_001146055.1_ex6F NM_001146055.1_ex6F cagtgtgtgctgtctttttgcagtgtgtgctgtctttttg 5656 4545 101101 NM_001146055.1_ex6R NM_001146055.1_ex6R agatctcaagaaactgggagcaagatctcaagaaactgggagca 5959 4545 101101

본 발명에서 디자인된 프라이머 (LRRK2)The primer ( LRRK2 ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_198578.3_ex1F NM_198578.3_ex1F ttcctcataaacaggcgggcttcctcataaacaggcgggc 6060 5555 311311 NM_198578.3_ex1R NM_198578.3_ex1R ggagtacgtgaacaccagcaggagtacgtgaacaccagca 6060 5555 311311 NM_198578.3_ex2F NM_198578.3_ex2F tccccacccacttgttttcctccccacccacttgttttcc 6060 5555 172172 NM_198578.3_ex2R NM_198578.3_ex2R gccagtaaaacgtctccttccgccagtaaaacgtctccttcc 5858 5252 172172 NM_198578.3_ex3F NM_198578.3_ex3F cttgttttcaggtgggttggtccttgttttcaggtgggttggtc 6060 5050 201201 NM_198578.3_ex3R NM_198578.3_ex3R acacagtgtatcaagggaaggtacacagtgtatcaagggaaggt 5555 4545 201201 NM_198578.3_ex4F NM_198578.3_ex4F acacatgagcttcactacagggacacatgagcttcactacaggg 6060 5050 340340 NM_198578.3_ex4R NM_198578.3_ex4R gctaccctaatcctgatcttcagctaccctaatcctgatcttca 5656 4646 340340 NM_198578.3_ex5F NM_198578.3_ex5F aaccatgggtctacaaaccaaaccatgggtctacaaacca 5555 4545 325325 NM_198578.3_ex5R NM_198578.3_ex5R ctgtgttctacttttcccagctgtgttctacttttcccag 5454 4545 325325 NM_198578.3_ex6F NM_198578.3_ex6F ttaagtctcagaggagcaactgacttaagtctcagaggagcaactgac 6060 4949 255255 NM_198578.3_ex6R NM_198578.3_ex6R gggttgagcatccacaagttgggttgagcatccacaagtt 5858 5050 255255 NM_198578.3_ex7F NM_198578.3_ex7F gaaatgcagtcattatgctgccgaaatgcagtcattatgctgcc 5959 4646 251251 NM_198578.3_ex7R NM_198578.3_ex7R tcacctaatgtaagcctatggagctcacctaatgtaagcctatggagc 6060 4646 251251 NM_198578.3_ex8F NM_198578.3_ex8F cttccatggatgagaattcagccttccatggatgagaattcagc 5858 4646 180180 NM_198578.3_ex8R NM_198578.3_ex8R tagtgaagttacttactgaggagggctagtgaagttacttactgaggagggc 6161 4646 180180 NM_198578.3_ex9F NM_198578.3_ex9F agcacacctcattctgttggtagcacacctcattctgttggt 6060 4848 264264 NM_198578.3_ex9R NM_198578.3_ex9R gagagtcctacctgcacgtggagagtcctacctgcacgtg 5959 6060 264264 NM_198578.3_ex10F NM_198578.3_ex10F cgtggcatagaaagaacaagcacgtggcatagaaagaacaagca 6060 4646 205205 NM_198578.3_ex10R NM_198578.3_ex10R actaactggccatcttcatctccactaactggccatcttcatctcc 6060 4747 205205 NM_198578.3_ex11F NM_198578.3_ex11F ctcttgtaagtggaggtggcactcttgtaagtggaggtggca 6060 5252 259259 NM_198578.3_ex11R NM_198578.3_ex11R tggcccactgcttaccattttggcccactgcttaccattt 6060 5050 259259 NM_198578.3_ex12F NM_198578.3_ex12F gctttcctgtaaatttggacgctttcctgtaaatttggac 5353 4040 283283 NM_198578.3_ex12R NM_198578.3_ex12R ttctacctggcccaatatgattctacctggcccaatatga 5656 4545 283283 NM_198578.3_ex13F NM_198578.3_ex13F atattggttctgccctcctgatattggttctgccctcctg 5757 5050 234234 NM_198578.3_ex13R NM_198578.3_ex13R ctatgtaacttaccaggcacctatgtaacttaccaggcac 5353 4545 234234 NM_198578.3_ex14F NM_198578.3_ex14F gcatttaggcatgccagaagagcatttaggcatgccagaaga 6060 4848 200200 NM_198578.3_ex14R NM_198578.3_ex14R actgaaaaagcgcccctagtactgaaaaagcgcccctagt 6060 5050 200200 NM_198578.3_ex15F NM_198578.3_ex15F agttcattggaaatcctgggagttcattggaaatcctggg 6060 4545 210210 NM_198578.3_ex15R NM_198578.3_ex15R tccagtcaccagctaatgcctccagtcaccagctaatgcc 6060 5555 210210 NM_198578.3_ex16F NM_198578.3_ex16F ggcattagctggtgactggaggcattagctggtgactgga 6060 5555 271271 NM_198578.3_ex16R NM_198578.3_ex16R gtgaaattcgcacaagttcccagtgaaattcgcacaagttccca 6060 4646 271271 NM_198578.3_ex17F NM_198578.3_ex17F actttaaagcaccaacccaactttaaagcaccaaccca 5656 4242 280280 NM_198578.3_ex17R NM_198578.3_ex17R acactgtacctgttgatcctacactgtacctgttgatcct 5656 4545 280280 NM_198578.3_ex18F NM_198578.3_ex18F aggatcaacaggtacagtgtaggatcaacaggtacagtgt 6060 4545 325325 NM_198578.3_ex18R NM_198578.3_ex18R acaatggcagggctcttacaacaatggcagggctcttaca 5959 5050 325325 NM_198578.3_ex19_1F NM_198578.3_ex19_1F ttgccagtctcctaaaaggattgccagtctcctaaaagga 5656 4545 209209 NM_198578.3_ex19_1R NM_198578.3_ex19_1R gccagcctccttaagagcaagccagcctccttaagagcaa 6060 5555 209209 NM_198578.3_ex19_2F NM_198578.3_ex19_2F gcgttgacgataagcattggggcgttgacgataagcattggg 6060 5252 280280 NM_198578.3_ex19_2R NM_198578.3_ex19_2R ggtccctcaaactggcatgaggtccctcaaactggcatga 6060 5555 280280 NM_198578.3_ex20F NM_198578.3_ex20F tctccagaagcatagcaatacg tctccagaagcatagcaatacg 6060 4545 375375 NM_198578.3_ex20R NM_198578.3_ex20R ttaggtcaggtttttgtcttgg ttaggtcaggtttttgtcttgg 5858 4141 375375 NM_198578.3_ex21F NM_198578.3_ex21F caaagggaatggactgtgaaa caaagggaatggactgtgaaa 6060 4343 364364 NM_198578.3_ex21R NM_198578.3_ex21R catcagggaaatccctacca catcagggaaatccctacca 6060 5050 364364 NM_198578.3_ex22F NM_198578.3_ex22F tcatttgagcactgaactggag tcatttgagcactgaactggag 6060 4545 362362 NM_198578.3_ex22R NM_198578.3_ex22R agatgaaactggcaccaagaa agatgaaactggcaccaagaa 6060 4343 362362 NM_198578.3_ex23F NM_198578.3_ex23F gggtcatcaaaacttcaatcccgggtcatcaaaacttcaatccc 5858 4646 395395 NM_198578.3_ex23R NM_198578.3_ex23R tgctcctgaacatcacacagatgctcctgaacatcacacaga 6060 4848 395395 NM_198578.3_ex24F NM_198578.3_ex24F agttaccagaggtgtgtaaggcagttaccagaggtgtgtaaggc 5959 5050 390390 NM_198578.3_ex24R NM_198578.3_ex24R catcagcatatttaggcaaccccatcagcatatttaggcaaccc 6161 4646 390390 NM_198578.3_ex25F NM_198578.3_ex25F cctctttgatgctgttctttga cctctttgatgctgttctttga 5959 4141 337337 NM_198578.3_ex25R NM_198578.3_ex25R aaatccacaactaaagggtcca aaatccacaactaaagggtcca 6060 4141 337337 NM_198578.3_ex26F NM_198578.3_ex26F gtgacacactattggtagctgtgtgacacactattggtagctgt 5252 4646 237237 NM_198578.3_ex26R NM_198578.3_ex26R ggttctgttccagctaatgtgcggttctgttccagctaatgtgc 5252 5050 237237 NM_198578.3_ex27F NM_198578.3_ex27F acactttattctcaccctggggacactttattctcaccctgggg 5959 5050 304304 NM_198578.3_ex27R NM_198578.3_ex27R gtggcaataatcgtcttacctcgtggcaataatcgtcttacctc 5959 4646 304304 NM_198578.3_ex28F NM_198578.3_ex28F cttccttcccaccaacaggtcttccttcccaccaacaggt 5959 5555 300300 NM_198578.3_ex28R NM_198578.3_ex28R tgtccatcaaagtcacagagagtgtccatcaaagtcacagagag 5959 4646 300300 NM_198578.3_ex29F NM_198578.3_ex29F actaggtttcttcaacagcgactaggtttcttcaacagcg 5858 4545 290290 NM_198578.3_ex29R NM_198578.3_ex29R ccctgttccaaacaaatggtccctgttccaaacaaatggt 5757 4545 290290 NM_198578.3_ex30F NM_198578.3_ex30F ggctgtgccttataaccgaaggctgtgccttataaccgaa 6060 5050 240240 NM_198578.3_ex30R NM_198578.3_ex30R acacgcacacagacacatgaacacgcacacagacacatga 6060 5050 240240 NM_198578.3_ex31F NM_198578.3_ex31F gtgaatgtcacggaaagcaagtgaatgtcacggaaagcaa 5959 4545 325325 NM_198578.3_ex31R NM_198578.3_ex31R cagcctaccatgttaccttgaacagcctaccatgttaccttgaa 5959 4545 325325 NM_198578.3_ex32F NM_198578.3_ex32F actgttagcactgaatttgc actgttagcactgaatttgc 5353 4040 397397 NM_198578.3_ex32R NM_198578.3_ex32R gaaccgtatggatattctctca gaaccgtatggatattctctca 5656 4141 397397 NM_198578.3_ex33F NM_198578.3_ex33F gaccataggatgcacagcttcgaccataggatgcacagcttc 5959 5252 306306 NM_198578.3_ex33R NM_198578.3_ex33R gcgccatctgttctatgcttgcgccatctgttctatgctt 6060 6060 306306 NM_198578.3_ex34F NM_198578.3_ex34F ggtactgtgttgcacttgaaggtactgtgttgcacttgaa 5555 4545 333333 NM_198578.3_ex34R NM_198578.3_ex34R ggttttctttacctgcttggggttttctttacctgcttgg 5757 4545 333333 NM_198578.3_ex35F NM_198578.3_ex35F gctcaacaaggttgggtgttgctcaacaaggttgggtgtt 6161 5050 298298 NM_198578.3_ex35R NM_198578.3_ex35R tgccatctccctaatttctctgccatctccctaatttctc 6060 4545 298298 NM_198578.3_ex36F NM_198578.3_ex36F caatcacttgtgttgtgtgcagcaatcacttgtgttgtgtgcag 6060 4646 327327 NM_198578.3_ex36R NM_198578.3_ex36R aacctcatactgtcgcaaagcaacctcatactgtcgcaaagc 5959 4848 327327 NM_198578.3_ex37F NM_198578.3_ex37F aagctttgcgacagtatgaggaagctttgcgacagtatgagg 5959 4848 261261 NM_198578.3_ex37R NM_198578.3_ex37R caaaacataccttcctctgccaaaacataccttcctctgc 5959 4545 261261 NM_198578.3_ex38F NM_198578.3_ex38F tggttagaaagggagggatttggttagaaagggagggatt 5858 4545 275275 NM_198578.3_ex38R NM_198578.3_ex38R ttacctaggagaaactctggttacctaggagaaactctgg 5252 4545 275275 NM_198578.3_ex39F NM_198578.3_ex39F attcaatgaaacaagtaggtcagg attcaatgaaacaagtaggtcagg 6060 4040 380380 NM_198578.3_ex39R NM_198578.3_ex39R ccacaacgaaaagacaaactagg ccacaacgaaaagacaaactagg 6060 4343 380380 NM_198578.3_ex40F NM_198578.3_ex40F catgttcagcctgttgatgc catgttcagcctgttgatgc 6060 5050 385385 NM_198578.3_ex40R NM_198578.3_ex40R tgttactggggcacagtgtt tgttactggggcacagtgtt 5959 5050 385385 NM_198578.3_ex41F NM_198578.3_ex41F tgcattttctggcagatacctgcattttctggcagatacc 6060 4545 233233 NM_198578.3_ex41R NM_198578.3_ex41R gaggtcagtggttatccatcctgaggtcagtggttatccatcct 5959 5050 233233 NM_198578.3_ex42F NM_198578.3_ex42F gagccctgatgttggtcatagagccctgatgttggtcata 5858 5050 239239 NM_198578.3_ex42R NM_198578.3_ex42R tgtagagaaaacagaacttaccagtgtagagaaaacagaacttaccag 5555 3838 239239 NM_198578.3_ex43F NM_198578.3_ex43F ctttgcaatgtctggaccttttctttgcaatgtctggacctttt 5959 4141 200200 NM_198578.3_ex43R NM_198578.3_ex43R aatacctgggcagaagtaggcaatacctgggcagaagtaggc 6060 5252 200200 NM_198578.3_ex44F NM_198578.3_ex44F tggtgatctagttgggttccatggtgatctagttgggttcca 6060 4848 349349 NM_198578.3_ex44R NM_198578.3_ex44R gagcatttggatttacctcagagagcatttggatttacctcaga 6060 4141 349349 NM_198578.3_ex45F NM_198578.3_ex45F caggaagttgctgatagtagaacaggaagttgctgatagtagaa 5454 4949 236236 NM_198578.3_ex45R NM_198578.3_ex45R gatctgtaatttccccattggatctgtaatttccccattg 5454 4040 236236 NM_198578.3_ex46F NM_198578.3_ex46F gggaagagtctgggaaaagg gggaagagtctgggaaaagg 6060 5555 351351 NM_198578.3_ex46R NM_198578.3_ex46R atcccataagaggggtgtga atcccataagaggggtgtga 5959 5050 351351 NM_198578.3_ex47F NM_198578.3_ex47F ggcaaagcttaaaggagctgggcaaagcttaaaggagctg 5959 5050 372372 NM_198578.3_ex47R NM_198578.3_ex47R acccttctgctttctggaatacccttctgctttctggaat 5757 4545 372372 NM_198578.3_ex48F NM_198578.3_ex48F ctctgtaggttttcttatgcagcttctctgtaggttttcttatgcagctt 6060 4040 256256 NM_198578.3_ex48R NM_198578.3_ex48R ttcagaggcagaaaggaagaattcagaggcagaaaggaagaa 6060 4343 256256 NM_198578.3_ex49F NM_198578.3_ex49F tttatggttctagggaggtaatggtttatggttctagaggaggtaatgg 6060 4242 241241 NM_198578.3_ex49R NM_198578.3_ex49R ctaaaggaaagaaacttgcctagcctaaaggaaagaaacttgcctagc 6060 4242 241241 NM_198578.3_ex50_1F NM_198578.3_ex50_1F tctagagatacaatcttgcttgacctctagagatacaatcttgcttgacc 5959 4040 255255 NM_198578.3_ex50_1R NM_198578.3_ex50_1R aacattccttcatacacacgagaacattccttcatacacacgag 6060 4141 255255 NM_198578.3_ex50_2F NM_198578.3_ex50_2F agctcgtgtgtatgaaggaatgagctcgtgtgtatgaaggaatg 5656 4646 282282 NM_198578.3_ex50_2R NM_198578.3_ex50_2R tcgacaagcaatagtcctgtctttcgacaagcaatagtcctgtctt 6060 4444 282282 NM_198578.3_ex51_1F NM_198578.3_ex51_1F tctagagatacaatcttgcttgacctctagagatacaatcttgcttgacc 5959 4040 255255 NM_198578.3_ex51_1R NM_198578.3_ex51_1R aacattccttcatacacacgagaacattccttcatacacacgag 5858 4040 255255 NM_198578.3_ex51_2F NM_198578.3_ex51_2F tagctcgtgtgtatgaaggaatgtagctcgtgtgtatgaaggaatg 5959 4343 370370 NM_198578.3_ex51_2R NM_198578.3_ex51_2R gtgcatttcgatgcaatctgtgcatttcgatgcaatct 5757 4242 370370

본 발명에서 디자인된 프라이머 (TDP-43)The primer designed in the present invention ( TDP-43 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) XM_005263435.1_ex1F XM_005263435.1_ex1F ccgaaaccatctgctacgttccgaaaccatctgctacgtt 6060 5050 329329 XM_005263435.1_ex1R XM_005263435.1_ex1R gaagcccgacagggacacgaagcccgacagggacac 6161 6767 329329 XM_005263435.1_ex2F XM_005263435.1_ex2F tcagaactctgacatggtttggtcagaactctgacatggtttgg 6060 4646 389389 XM_005263435.1_ex2R XM_005263435.1_ex2R cacctgaacacacttcagcacacctgaacacacttcagca 5959 5050 389389 XM_005263435.1_ex3F XM_005263435.1_ex3F tttgggaatggagtgtgtgatttgggaatggagtgtgtga 6161 4545 223223 XM_005263435.1_ex3R XM_005263435.1_ex3R ccaaagcacagacgcaagtaccaaagcacagacgcaagta 6161 5555 223223 XM_005263435.1_ex4F XM_005263435.1_ex4F cagcaaagccaagatgagccagcaaagccaagatgagc 5959 5252 251251 XM_005263435.1_ex4R XM_005263435.1_ex4R ctcggcctccaaagtgctctcggcctccaaagtgct 6060 6161 251251 XM_005263435.1_ex5_1F XM_005263435.1_ex5_1F gattgcgcagtctctttgtggattgcgcagtctctttgtg 5959 5050 383383 XM_005263435.1_ex5_1R XM_005263435.1_ex5_1R cctggtttggctccctctcctggtttggctccctct 6060 6161 383383 XM_005263435.1_ex5_2F XM_005263435.1_ex5_2F ggccttcggttctggaaataggccttcggttctggaaata 6161 5252 397397 XM_005263435.1_ex5_2R XM_005263435.1_ex5_2R caggcaaacagcagttcacaggcaaacagcagttca 5757 5555 397397 XM_005263435.1_ex5_3F XM_005263435.1_ex5_3F ggtaaaccaacacactacaaggtaaaccaacacactacaa 5151 4040 389389 XM_005263435.1_ex5_3R XM_005263435.1_ex5_3R cttgaatgagaaagcatgtagacagcttgaatgagaaagcatgtagacag 5959 4040 389389 XM_005263435.1_ex5_4F XM_005263435.1_ex5_4F atcacaggccgcgtctttatcacaggccgcgtcttt 6161 5757 350350 XM_005263435.1_ex5_4R XM_005263435.1_ex5_4R tccaacagatgtggatgtccttccaacagatgtggatgtcct 6060 4848 350350 XM_005263435.1_ex5_5F XM_005263435.1_ex5_5F cccctacccctttgtcaactcccctacccctttgtcaact 6060 5555 392392 XM_005263435.1_ex5_5R XM_005263435.1_ex5_5R gttccatctcaaaagggtcagttccatctcaaaagggtca 5757 4545 392392 XM_005263435.1_ex5_6F XM_005263435.1_ex5_6F tgacccttttgagatggaactgacccttttgagatggaac 5757 4545 371371 XM_005263435.1_ex5_6R XM_005263435.1_ex5_6R atcaacattttgcccactccatcaacattttgcccactcc 5959 4545 371371 XM_005263435.1_ex5_7F XM_005263435.1_ex5_7F aagggaatatcagcaccttccaagggaatatcagcaccttcc 5959 4747 203203 XM_005263435.1_ex5_7R XM_005263435.1_ex5_7R gttaccacattcccccacctgttaccacattcccccacct 6060 5555 203203

본 발명에서 디자인된 프라이머 (SIGMAR1)The primer designed in the present invention ( SIGMAR1 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) XM_005251339.1_ex1F XM_005251339.1_ex1F ccgattggtcagggcgagccgattggtcagggcgag 5959 6868 264264 XM_005251339.1_ex1R XM_005251339.1_ex1R atctcttcgcgctggaagacatctcttcgcgctggaagac 5959 5555 264264 XM_005251339.1_ex2F XM_005251339.1_ex2F ggtgccagccctgactccggtgccagccctgactcc 6262 7272 286286 XM_005251339.1_ex2R XM_005251339.1_ex2R ctttacaaccccagcctcccctttacaaccccagcctccc 6060 6060 286286 XM_005251339.1_ex3F XM_005251339.1_ex3F tgtgcgattgtcactcagggtgtgcgattgtcactcaggg 5959 5555 152152 XM_005251339.1_ex3R XM_005251339.1_ex3R cgtgaagggacccacttctccgtgaagggacccacttctc 6060 6060 152152 XM_005251339.1_ex4_1F XM_005251339.1_ex4_1F aggggagacggtagtacacgaggggagacggtagtacacg 6060 6060 400400 XM_005251339.1_ex4_1R XM_005251339.1_ex4_1R ccatgggtctctgtgtttggaccatgggtctctgtgtttgga 6161 5353 400400 XM_005251339.1_ex4_2F XM_005251339.1_ex4_2F tgcagatcctgagttcctgctgcagatcctgagttcctgc 6060 5555 399399 XM_005251339.1_ex4_2R XM_005251339.1_ex4_2R aagggcatcatagctgcaggaagggcatcatagctgcagg 6060 5555 399399 XM_005251339.1_ex4_3F XM_005251339.1_ex4_3F cctgcagctatgatgcccttcctgcagctatgatgccctt 6060 5555 373373 XM_005251339.1_ex4_3R XM_005251339.1_ex4_3R aggggctgtgtgaaaactgtaggggctgtgtgaaaactgt 6060 5050 373373

본 발명에서 디자인된 프라이머 (FUS)The primer designed in the present invention ( FUS ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_004960.3_ex1F NM_004960.3_ex1F acttaagcttcgacgcaggaacttaagcttcgacgcagga 6060 5050 200200 NM_004960.3_ex1R NM_004960.3_ex1R cccggtcccactgaaaaccccggtcccactgaaaac 6161 6161 200200 NM_004960.3_ex2F NM_004960.3_ex2F ggcctacgtggtcctttttaggcctacgtggtccttttta 6060 5050 200200 NM_004960.3_ex2R NM_004960.3_ex2R cagaaaacatggcgtgacccagaaaacatggcgtgacc 6060 5252 200200 NM_004960.3_ex3F NM_004960.3_ex3F ctgatcacgctggttttcctctgatcacgctggttttcct 6060 5050 200200 NM_004960.3_ex3R NM_004960.3_ex3R cccgctgagaaagactcactcccgctgagaaagactcact 6060 5555 200200 NM_004960.3_ex4F NM_004960.3_ex4F ctctttcctggtggcttttgctctttcctggtggcttttg 6161 5555 233233 NM_004960.3_ex4R NM_004960.3_ex4R acccctcttttcaagccttcacccctcttttcaagccttc 6060 5555 233233 NM_004960.3_ex5F NM_004960.3_ex5F ggctatgctgggattgtgatggctatgctgggattgtgat 6060 5050 261261 NM_004960.3_ex5R NM_004960.3_ex5R gctgcagacaaagctgaagagctgcagacaaagctgaaga 6060 5050 261261 NM_004960.3_ex6F NM_004960.3_ex6F cctggcacttgtcaaaccttcctggcacttgtcaaacctt 6060 5050 344344 NM_004960.3_ex6R NM_004960.3_ex6R atgagacacctaccccatgcatgagacacctaccaccatgc 6060 5555 344344 NM_004960.3_ex7F NM_004960.3_ex7F ctacccatgtttggggaatgctacccatgtttggggaatg 6060 5050 179179 NM_004960.3_ex7R NM_004960.3_ex7R gacaaagcattgctgggagtgacaaagcattgctgggagt 6060 4545 179179 NM_004960.3_ex8F NM_004960.3_ex8F cggctcatcttttccttgcggctcatcttttccttg 5656 5050 151151 NM_004960.3_ex8R NM_004960.3_ex8R tccaggcagtcttgataccactccaggcagtcttgataccac 6060 5252 151151 NM_004960.3_ex9F NM_004960.3_ex9F ctgttcaacaagcagaacaggactgttcaacaagcagaakhga 6060 4646 170170 NM_004960.3_ex9R NM_004960.3_ex9R tccacaagcctacaacactgatccacaagcctacaacactga 5959 4747 170170 NM_004960.3_ex10F NM_004960.3_ex10F tggaaagggagtactgtagcctggaaagggagtactgtagcc 6060 5252 210210 NM_004960.3_ex10R NM_004960.3_ex10R tctgccagccttctcatacatctgccagccttctcataca 6060 5050 210210 NM_004960.3_ex11F NM_004960.3_ex11F agaaaggcacgcttctcttgagaaaggcacgcttctcttg 6060 5050 218218 NM_004960.3_ex11R NM_004960.3_ex11R cattacccctctgcaccactcattacccctctgcaccact 6060 5555 218218 NM_004960.3_ex12F NM_004960.3_ex12F caaacttggagagggagcagcaaacttggagagggagcag 6060 5555 214214 NM_004960.3_ex12R NM_004960.3_ex12R gcacgcatgcaagagaactagcacgcatgcaagagaacta 6060 5050 214214 NM_004960.3_ex13F NM_004960.3_ex13F aggtcttgcctattccccatcaggtcttgcctattccccatc 6060 5252 200200 NM_004960.3_ex13R NM_004960.3_ex13R ggattctttggtcccagctcggattctttggtcccagctc 6060 5555 200200 NM_004960.3_ex14F NM_004960.3_ex14F ctcggggaacataggggaatctcggggagaacataggggaat 6262 5555 252252 NM_004960.3_ex14R NM_004960.3_ex14R atggcctctgttcaactgctatggcctctgttcaactgct 6060 5050 252252 NM_004960.3_ex15F NM_004960.3_ex15F cttggagaggctggtaactcacttggagaggctggtaactca 6060 5252 159159 NM_004960.3_ex15R NM_004960.3_ex15R cgagggtaacactgggtacagcgagggtataacactgggtacag 6262 5757 `159`159

본 발명에서 디자인된 프라이머 (GRN)The primer ( GRN ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_002087.2_ex1F NM_002087.2_ex1F ggccaatggaaactgaggtaggccaatggaaactgaggta 6060 5050 133133 NM_002087.2_ex1R NM_002087.2_ex1R gagcaggcgagaggtctggagcaggcgagaggtctg 6060 6767 133133 NM_002087.2_ex2F NM_002087.2_ex2F ggcttaagcagttgccagacggcttaagcagttgccagac 6060 5555 242242 NM_002087.2_ex2R NM_002087.2_ex2R gatgaccctttgggaaaaccgatgaccctttgggaaaacc 6060 5050 242242 NM_002087.2_ex3F NM_002087.2_ex3F ccaggcacaagtctgtggttccaggcacaagtctgtggtt 6161 5555 208208 NM_002087.2_ex3R NM_002087.2_ex3R cagacctaagcccctccactcagacctaagcccctccact 6060 6060 208208 NM_002087.2_ex4F NM_002087.2_ex4F gccaatgcaggtttctctgtgccaatgcaggtttctctgt 6060 5050 172172 NM_002087.2_ex4R NM_002087.2_ex4R ggttccagactccacatgctggttccagactccacatgct 6060 5555 172172 NM_002087.2_ex5F NM_002087.2_ex5F ggagtcaccttccctgagtgggagtcaccttccctgagtg 6060 6060 200200 NM_002087.2_ex5R NM_002087.2_ex5R cctccacatacccccatctcctccacatacccccatct 6060 5757 200200 NM_002087.2_ex6F NM_002087.2_ex6F ggggtgaagacggagtcagggggtgaagacggagtcag 6060 6363 201201 NM_002087.2_ex6R NM_002087.2_ex6R ccctggcctgatgctctcccctggcctgatgctctc 6060 6767 201201 NM_002087.2_ex7F NM_002087.2_ex7F ctcacgtttgctcctcttccctcacgtttgctcctcttcc 6060 5555 150150 NM_002087.2_ex7R NM_002087.2_ex7R ctccagcccctcactcacctccagcccctcactcac 6060 6767 150150 NM_002087.2_ex8F NM_002087.2_ex8F gcctggaagtgacaaagaccgcctggaagtgacaaagacc 6060 5555 225225 NM_002087.2_ex8R NM_002087.2_ex8R caggcctaaaagggaggaaacaggcctaaaagggaggaaa 6060 5050 225225 NM_002087.2_ex9F NM_002087.2_ex9F cctctctgcttccctcacagcctctctgcttccctcacag 6060 6060 160160 NM_002087.2_ex9R NM_002087.2_ex9R gcctgccacactgtgctcgcctgccacactgtgctc 6161 6767 160160 NM_002087.2_ex10F NM_002087.2_ex10F cacctgcccttcttcatctgcacctgcccttcttcatctg 6060 5555 292292 NM_002087.2_ex10R NM_002087.2_ex10R tgctgtcccctcccatatactgctgtcccctcccatatac 6060 5555 292292 NM_002087.2_ex11F NM_002087.2_ex11F ggctacctacaacgccctttggctacctacaacgcccttt 6060 5555 315315 NM_002087.2_ex11R NM_002087.2_ex11R ctgggcttagctcccctatcctgggcttagctcccctatc 6060 6060 315315 NM_002087.2_ex12F NM_002087.2_ex12F cagtgaggggacaggaacatcagtgaggggacaggaacat 6060 5555 318318 NM_002087.2_ex12R NM_002087.2_ex12R catacccagccccaggatcatacccagccccaggat 6060 6161 318318 NM_002087.2_ex13F NM_002087.2_ex13F cacctcgtccaaccctctccacctcgtccaaccctctc 6161 6363 279279 NM_002087.2_ex13R NM_002087.2_ex13R ggtccagggagaatttggttggtccagggagaatttggtt 6060 5050 279279

본 발명에서 디자인된 프라이머 (MAPT)The primer ( MAPT ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001203251.1_ex1F NM_001203251.1_ex1F actagtggccggaggagaagactagtggccggaggagaag 6161 6060 306306 NM_001203251.1_ex1R NM_001203251.1_ex1R gacggcgaggcagatttcgacggcgaggcagatttc 6161 6161 306306 NM_001203251.1_ex2F NM_001203251.1_ex2F ccccaacactcctcagaactccccaacactcctcagaact 6060 5555 212212 NM_001203251.1_ex2R NM_001203251.1_ex2R gcatggctgtccactaacctgcatggctgtccactaacct 6060 5555 212212 NM_001203251.1_ex3F NM_001203251.1_ex3F cgttctgagggctcactgtacgttctgagggctcactgta 6060 5555 177177 NM_001203251.1_ex3R NM_001203251.1_ex3R ctcaaagcacggctaagcacctcaaagcacggctaagcac 6161 5555 177177 NM_001203251.1_ex4F NM_001203251.1_ex4F ggtgaggggctgggtatgggtgaggggctgggtatg 6161 6666 180180 NM_001203251.1_ex4R NM_001203251.1_ex4R gactgcctgggggtctctgactgcctgggggctctct 6060 6666 180180 NM_001203251.1_ex5F NM_001203251.1_ex5F ccccttcatttgctgacacccccttcatttgctgacac 6060 5252 126126 NM_001203251.1_ex5R NM_001203251.1_ex5R caagtcatggcaggcaattccaagtcatggcaggcaattc 5555 5050 126126 NM_001203251.1_ex6F_1 NM_001203251.1_ex6F_1 acagagcctgaaagtggtaaggacagagcctgaaagtggtaagg 6060 5050 400400 NM_001203251.1_ex6R_1 NM_001203251.1_ex6R_1 ggatgctggtggcttctctggatgctggtggcttctct 6060 5757 400400 NM_001203251.1_ex6F_2 NM_001203251.1_ex6F_2 cagagaagccaccagcatccagagaagccaccagcatc 6060 5757 400400 NM_001203251.1_ex6R_2 NM_001203251.1_ex6R_2 gcgaagaagctcaagacacagcgaagaagctcaagacaca 5959 5050 400400 NM_001203251.1_ex7F NM_001203251.1_ex7F caaacatggacctatcccagagcaaacatggacctatcccagag 6060 5050 200200 NM_001203251.1_ex7R NM_001203251.1_ex7R aacttgaccagctgcagagcaacttgaccagctgcagagc 6060 5555 200200 NM_001203251.1_ex8F NM_001203251.1_ex8F cagtttgtttccctcctccacagtttgtttccctcctcca 6060 5050 300300 NM_001203251.1_ex8R NM_001203251.1_ex8R gcagagcagcctggttcttgcagagcagcctggttctt 6060 5757 300300 NM_001203251.1_ex9F NM_001203251.1_ex9F ggtggcagtaacttttccggtggcagtaacttttcc 5353 5050 231231 NM_001203251.1_ex9R NM_001203251.1_ex9R tctgagagcttcagcttcctcttctgagagcttcagcttcctct 6060 5050 231231 NM_001203251.1_ex10F NM_001203251.1_ex10F ctcgagtcctggcttcactcctcgagtcctggcttcactc 6060 6060 363363 NM_001203251.1_ex10R NM_001203251.1_ex10R acagccctacccctccagacagccctaccccctccag 6060 6767 363363 NM_001203251.1_ex11F NM_001203251.1_ex11F cgcatgtcactcatcgaaagcgcatgtcactcatcgaaag 6060 5050 253253 NM_001203251.1_ex11R NM_001203251.1_ex11R cgcactcacaccacttcctacgcactcacaccacttccta 6060 5555 253253 NM_001203251.1_ex12F NM_001203251.1_ex12F ttcctctctctctgcctttccttcctctctctctctgcctttcc 6060 5252 161161 NM_001203251.1_ex12R NM_001203251.1_ex12R gtcccaaccctcaccttccgtcccaaccctcaccttcc 6060 5353 161161 NM_001203251.1_ex13F NM_001203251.1_ex13F ccacagaagatgatggcaagccacagaagatgatggcaag 6060 5050 202202 NM_001203251.1_ex13R NM_001203251.1_ex13R catatacccaagggcagcatcatatacccaagggcagcat 6060 5050 202202 NM_001203251.1_ex14F NM_001203251.1_ex14F ctcaccctccctcccttcctcaccctccctcccttc 6060 6666 300300 NM_001203251.1_ex14R NM_001203251.1_ex14R ccacactctctcattctctcctcccacactctctcattctctcctc 6060 5555 300300

본 발명에서 디자인된 프라이머 (ALS2)The primer designed in the present invention ( ALS2 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_020919.3_ex1F NM_020919.3_ex1F ggtagctaggcttggacgacggtagctaggcttggacgac 6060 6060 390390 NM_020919.3_ex1R NM_020919.3_ex1R ttagccaatagccaacccggttagccaatagccaacccgg 6161 5555 390390 NM_020919.3_ex2F NM_020919.3_ex2F gcacttgttagagggctgctgcacttgttagagggctgct 5959 5555 217217 NM_020919.3_ex2R NM_020919.3_ex2R tgctatgttttcctaggaggtgctatgttttcctaggagg 6060 4545 217217 NM_020919.3_ex3F NM_020919.3_ex3F gatgttttagctcaacagaggcaggatgttttagctcaacagaggcag 6060 4646 220220 NM_020919.3_ex3R NM_020919.3_ex3R ctcaggcatttgttagcattgcctcaggcatttgttagcattgc 6060 4646 220220 NM_020919.3_ex4_1F NM_020919.3_ex4_1F accttcagatggtgaggtctaccttcagatggtgaggtct 6060 5050 397397 NM_020919.3_ex4_1R NM_020919.3_ex4_1R tgggaaggcagtggtaatgagtgggaaggcagtggtaatgag 5959 5252 397397 NM_020919.3_ex4_2F NM_020919.3_ex4_2F cattaccactgccttcccagtcattaccactgccttcccagt 6060 5252 400400 NM_020919.3_ex4_2R NM_020919.3_ex4_2R gctgcttgtgatctgagcacgctgcttgtgatctgagcac 6060 5555 400400 NM_020919.3_ex4_3F NM_020919.3_ex4_3F gtgctcagatcacaagcagcgtgctcagatcacaagcagc 6060 5555 281281 NM_020919.3_ex4_3R NM_020919.3_ex4_3R gctaccaagccttactcagctaccaagccttactca 5454 5050 281281 NM_020919.3_ex5_1F NM_020919.3_ex5_1F gcgatggatattagcctttcgcgatggatattagcctttc 5454 4545 284284 NM_020919.3_ex5_1R NM_020919.3_ex5_1R ctgcctgagctccagtttcactgcctgagctccagtttca 6060 5555 284284 NM_020919.3_ex5_2F NM_020919.3_ex5_2F atgaagctggtgccttgtcaatgaagctggtgccttgtca 6060 5050 305305 NM_020919.3_ex5_2R NM_020919.3_ex5_2R atgcgatgtcaggagcatccatgcgatgtcaggagcatcc 6060 5555 305305 NM_020919.3_ex6F NM_020919.3_ex6F cttcaccccacgtctggttgcttcaccccacgtctggttg 6060 6060 221221 NM_020919.3_ex6R NM_020919.3_ex6R tcggtaaatgttggtagcgcttcggtaaatgttggtagcgct 6060 4848 221221 NM_020919.3_ex7F NM_020919.3_ex7F tgactttgtgtgcctgtgtgtgactttgtgtgcctgtgtg 5959 5050 180180 NM_020919.3_ex7R NM_020919.3_ex7R tgttggccttccatgaaaattgttggccttccatgaaaat 6060 4040 180180 NM_020919.3_ex8F NM_020919.3_ex8F cgcttagctacttttctgtgcgcttagctacttttctgtg 5555 4646 220220 NM_020919.3_ex8R NM_020919.3_ex8R taggttgtacgtatgaaattcccccgtaggttgtacgtatgaaattcccccg 6262 4646 220220 NM_020919.3_ex9F NM_020919.3_ex9F ctgtcgttgcagataagcagtgctgtcgttgcagataagcagtg 6060 5050 228228 NM_020919.3_ex9R NM_020919.3_ex9R gaatgtgggccttaggatccagaatgtgggccttaggatcca 6060 5252 228228 NM_020919.3_ex10F NM_020919.3_ex10F gccagcttcagtataccagccagcttcagtatacca 5454 5050 276276 NM_020919.3_ex10R NM_020919.3_ex10R taatggtgggagagagggggtaatggtgggagagaggggg 6060 5050 276276 NM_020919.3_ex11F NM_020919.3_ex11F ccttagttgagagcacatggcccttagttgagagcacatggc 6060 5353 333333 NM_020919.3_ex11R NM_020919.3_ex11R tgaacatgacacgggactggtgaacatgacacgggactgg 6060 5555 333333 NM_020919.3_ex12F NM_020919.3_ex12F ccaggtatgtgtttggaaactgccaggtatgtgtttggaaactg 6060 4646 182182 NM_020919.3_ex12R NM_020919.3_ex12R tggcggagagaatgataactggtggcggagagaatgataactgg 6060 5050 182182 NM_020919.3_ex13F NM_020919.3_ex13F tcctctgcctctagtgatttcctcctctgcctctagtgatttcc 6060 5050 203203 NM_020919.3_ex13R NM_020919.3_ex13R ccaaagaggtatacatgggagcccaaagaggtatacatgggagc 6060 5050 203203 NM_020919.3_ex14F NM_020919.3_ex14F aggcagactgaggctacagaaggcagactgaggctacaga 6060 5555 257257 NM_020919.3_ex14R NM_020919.3_ex14R tggttgctgtttgctagggttggttgctgtttgctagggt 6060 5050 257257 NM_020919.3_ex15F NM_020919.3_ex15F tccaggattccttgaggatccaggattccttgagga 6060 5050 154154 NM_020919.3_ex15R NM_020919.3_ex15R aggttaggaatccagcctacctaggttaggaatccagcctacct 5959 5050 154154 NM_020919.3_ex16F NM_020919.3_ex16F aagtgcctccgtgttctctgaagtgcctccgtgttctctg 6060 5555 135135 NM_020919.3_ex16R NM_020919.3_ex16R cttggacggggtggggtgcttggacggggtggggtg 6060 7272 135135 NM_020919.3_ex17F NM_020919.3_ex17F gcccaaaaccaagcaagcatgcccaaaaccaagcaagcat 6060 5050 245245 NM_020919.3_ex17R NM_020919.3_ex17R ccagggcgaagattgaaggaccagggcgaagattgaagga 5959 5555 245245 NM_020919.3_ex18F NM_020919.3_ex18F tgctcctagacaaagtggcttgctcctagacaaagtggct 6060 5050 250250 NM_020919.3_ex18R NM_020919.3_ex18R tcatcctcaccccaggcatatcatcctcaccccaggcata 6060 5555 250250 NM_020919.3_ex19F NM_020919.3_ex19F tggggtgaggatgatcatcatggggtgaggatgatcatca 6060 5050 207207 NM_020919.3_ex19R NM_020919.3_ex19R acgaccttaccgaacttgacgaccttaccgaacttg 6060 5050 207207 NM_020919.3_ex20F NM_020919.3_ex20F tcatggcaggtatggagatcatggcaggtatggaga 5454 5050 140140 NM_020919.3_ex20R NM_020919.3_ex20R aaacaccagtccaacagcctaaacaccagtccaacagcct 6060 5050 140140 NM_020919.3_ex21F NM_020919.3_ex21F ccattctttccaaccacagcccattctttccaaccacagc 5757 5050 212212 NM_020919.3_ex21R NM_020919.3_ex21R ctgtgggaatagaaggagctgtgggaatagaaggag 5151 5050 212212 NM_020919.3_ex22F NM_020919.3_ex22F ttatttctgtgcagggggttatttctgtgcaggggg 5454 5050 274274 NM_020919.3_ex22R NM_020919.3_ex22R cgcagtcatatccccaaagccgcagtcatatccccaaagc 6060 5555 274274 NM_020919.3_ex23F NM_020919.3_ex23F cttcttgtagggaaatggggcttcttgtagggaaatgggg 5555 5050 203203 NM_020919.3_ex23R NM_020919.3_ex23R aacgtgcacttgaaaggggtaacgtgcacttgaaaggggt 6060 5050 203203 NM_020919.3_ex24F NM_020919.3_ex24F ctctgactttacctagggctctgactttacctaggg 5050 5050 324324 NM_020919.3_ex24R NM_020919.3_ex24R gcactccagcctggtgacgcactccagcctggtgac 6060 5757 324324 NM_020919.3_ex25F NM_020919.3_ex25F gcaggaagctaggaaacctgggcaggaagctaggaaacctgg 6060 5757 252252 NM_020919.3_ex25R NM_020919.3_ex25R tgtggtgagccttgactacttgtggtgagccttgactact 5757 5050 252252 NM_020919.3_ex26F NM_020919.3_ex26F ggatgctccactttgactggaggatgctccactttgactgga 6060 5252 307307 NM_020919.3_ex26R NM_020919.3_ex26R gctgtgagtctatctgaatggctgtgagtctatctgaatg 5353 4545 307307 NM_020919.3_ex27F NM_020919.3_ex27F tcctactcaggcctgtgacatcctactcaggcctgtgaca 6060 5555 206206 NM_020919.3_ex27R NM_020919.3_ex27R ttccatagcccgcagactttttccatagcccgcagacttt 6060 5050 206206 NM_020919.3_ex28F NM_020919.3_ex28F ccccctagaggtataattgtccccctagaggtataattgt 5353 4545 171171 NM_020919.3_ex28R NM_020919.3_ex28R ccctggctctggtgattcagccctggctctggtgattcag 6060 6060 171171 NM_020919.3_ex29F NM_020919.3_ex29F gctccttttctcccactccagctccttttctcccactcca 6060 5555 241241 NM_020919.3_ex29R NM_020919.3_ex29R ccatttggttgcgcttgtccatttggttgcgcttgt 5959 5050 241241 NM_020919.3_ex30F NM_020919.3_ex30F tctctggggcaggattaggatctctggggcaggattagga 5959 5555 300300 NM_020919.3_ex30R NM_020919.3_ex30R tgaggaacaactggcttatccttgaggaacaactggcttatcct 6060 4646 300300 NM_020919.3_ex31F NM_020919.3_ex31F tcctccttgaccttcactctcttcctccttgaccttcactctct 5959 5050 197197 NM_020919.3_ex31R NM_020919.3_ex31R tggggatgcttaaggcttaggtggggatgcttaaggcttagg 6060 5252 197197 NM_020919.3_ex32F NM_020919.3_ex32F agtgtccgggttaaggcatgagtgtccgggttaaggcatg 6060 5555 275275 NM_020919.3_ex32R NM_020919.3_ex32R aaaacagttacctggcccgtaaaacagttacctggcccgt 6060 5050 275275 NM_020919.3_ex33F NM_020919.3_ex33F tctctggggcaggattaggatctctggggcaggattagga 6060 5555 300300 NM_020919.3_ex33R NM_020919.3_ex33R tgaggaacaactggcttatccttgaggaacaactggcttatcct 5959 4646 300300 NM_020919.3_ex34_1F NM_020919.3_ex34_1F gaacttttcttccaggcatggaacttttcttccaggcatg 6060 4545 373373 NM_020919.3_ex34_1R NM_020919.3_ex34_1R gctgacataccctttactgtaggagctgacataccctttactgtagga 5959 4646 373373 NM_020919.3_ex34_2F NM_020919.3_ex34_2F atcccttcctacagtaaagggtatcccttcctacagtaaagggt 6060 4646 370370 NM_020919.3_ex34_2R NM_020919.3_ex34_2R gaggcagaagactcctatttggagaggcagaagactcctatttgga 6060 4848 370370 NM_020919.3_ex34_3F NM_020919.3_ex34_3F aggagtcttctgcctcttaactaggagtcttctgcctcttaact 5858 4646 390390 NM_020919.3_ex34_3R NM_020919.3_ex34_3R ccaacaacttacaatagggcccaacaacttacaatagggc 5454 4545 390390

본 발명에서 디자인된 프라이머 (CSF1R)The primer ( CSF1R ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_005211.3_ex1F NM_005211.3_ex1F cagctgctagagcccagattcagctgctagagcccagatt 6060 5555 192192 NM_005211.3_ex1R NM_005211.3_ex1R ctattccctcccctgtccttctattccctcccctgtcctt 6060 5555 192192 NM_005211.3_ex2F NM_005211.3_ex2F aaactctgtggttgccttgcaaactctgtggttgccttgc 6060 5050 313313 NM_005211.3_ex2R NM_005211.3_ex2R tcacaggggtcttctccatctcacaggggtcttctccatc 6060 5555 313313 NM_005211.3_ex3F NM_005211.3_ex3F gcgcatcctagacctcacttgcgcatcctagacctcactt 6161 5555 331331 NM_005211.3_ex3R NM_005211.3_ex3R cttgggaggaggctcagaccttgggaggaggctcagac 6060 6363 331331 NM_005211.3_ex4F NM_005211.3_ex4F agggcagttgtaaccctgtgagggcagttgtaaccctgtg 5959 5555 371371 NM_005211.3_ex4R NM_005211.3_ex4R ctctgtccccactcttcaggctctgtccccactcttcagg 6060 6060 371371 NM_005211.3_ex5F NM_005211.3_ex5F ctgggtgttcaggggtctctctgggtgttcaggggctctct 6161 6060 190190 NM_005211.3_ex5R NM_005211.3_ex5R tgtgatctgcagggactgactgtgatctgcagggactgac 6060 5555 190190 NM_005211.3_ex6F NM_005211.3_ex6F ctcgcaatccctcaacaatcctcgcaatccctcaacaatc 6060 5050 200200 NM_005211.3_ex6R NM_005211.3_ex6R aggatccctaccgactgtccaggatccctaccgactgtcc 6060 6060 200200 NM_005211.3_ex7F NM_005211.3_ex7F cccactaatgccagatgcttcccactaatgccagatgctt 6060 5050 283283 NM_005211.3_ex7R NM_005211.3_ex7R gcataccccatctggttgtcgcataccccatctggttgtc 6060 5555 283283 NM_005211.3_ex8F NM_005211.3_ex8F catactaggctggggctcaccatactaggctggggctcac 6060 6060 222222 NM_005211.3_ex8R NM_005211.3_ex8R ccatccctccaggcagtcccatccctccaggcagtc 6060 6666 222222 NM_005211.3_ex9F NM_005211.3_ex9F ctgggagattgggaggtgctgggagattgggaggtg 6060 6161 199199 NM_005211.3_ex9R NM_005211.3_ex9R tgagtggagcccacttaccttgagtggagcccacttacct 6060 5555 199199 NM_005211.3_ex10F NM_005211.3_ex10F ctgaagctctgagccacattcctgaagctctgagccacattc 6060 5252 240240 NM_005211.3_ex10R NM_005211.3_ex10R gaaggctccctctcacctggaaggctccctctcacctg 6060 6363 240240 NM_005211.3_ex11F NM_005211.3_ex11F ctcactgctttgcttcatgcctcactgctttgcttcatgc 6060 5050 199199 NM_005211.3_ex11R NM_005211.3_ex11R accatccaaatctggctcacaccatccaaatctggctcac 6060 5050 199199 NM_005211.3_ex12F NM_005211.3_ex12F acgtgctcccttcctcttctacgtgctcccttcctcttct 6060 5555 194194 NM_005211.3_ex12R NM_005211.3_ex12R gccctgtgataggaagctgtgccctgtgataggaagctgt 6161 5555 194194 NM_005211.3_ex13F NM_005211.3_ex13F gggacttaagggacctgtgtggggacttaagggacctgtgtg 6060 5757 189189 NM_005211.3_ex13R NM_005211.3_ex13R cacccccagcatctaccaccacccccagcatctaccac 6060 6363 189189 NM_005211.3_ex14F NM_005211.3_ex14F cctgtctttgggactgtggtcctgtctttgggactgtggt 6060 5555 200200 NM_005211.3_ex14R NM_005211.3_ex14R ccctgagattccccagaggccctgagattccccagagg 6161 6363 200200 NM_005211.3_ex15F NM_005211.3_ex15F cacacccttggctgctctacacacccttggctgctcta 6060 5757 221221 NM_005211.3_ex15R NM_005211.3_ex15R cagacctggcctttttcttgcagacctggcctttttcttg 6060 5050 221221 NM_005211.3_ex16F NM_005211.3_ex16F tgagcagtgcagtgatgatgtgagcagtgcagtgatgatg 6060 5050 203203 NM_005211.3_ex16R NM_005211.3_ex16R cccttctccttttcccttgtcccttctccttttcccttgt 6060 5050 203203 NM_005211.3_ex17F NM_005211.3_ex17F gtgaggggtggggagtgtgtgaggggtggggagtgt 6060 6666 170170 NM_005211.3_ex17R NM_005211.3_ex17R agggccaggttcctactcacagggccaggttcctactcac 6060 6060 170170 NM_005211.3_ex18F NM_005211.3_ex18F ggtaggagaaggcccaagacggtaggagaaggcccaagac 6060 6060 183183 NM_005211.3_ex18R NM_005211.3_ex18R ccctcccagcacttacattgccctcccagcacttacattg 6060 5555 183183 NM_005211.3_ex19F NM_005211.3_ex19F gcccaaaataactggggactgcccaaaataactggggact 6060 5050 201201 NM_005211.3_ex19R NM_005211.3_ex19R agtggggcaaccagaggagagtggggcacaccagaggag 6262 6363 201201 NM_005211.3_ex20F NM_005211.3_ex20F gggaatggggagaagacaatgggaatggggagaagacaat 6060 5050 172172 NM_005211.3_ex20R NM_005211.3_ex20R gggatcccttcgcttacatagggatcccttcgcttacata 6060 5050 172172 NM_005211.3_ex21F NM_005211.3_ex21F tgggcatcctctgtcctatctgggcatcctctgtcctatc 6060 5555 185185 NM_005211.3_ex21R NM_005211.3_ex21R cagcccaacgtgctttacccagcccaacgtgctttacc 6161 5858 185185 NM_005211.3_ex22F NM_005211.3_ex22F gcctgatggatctggactgagcctgatggatctggactga 5959 5555 244244 NM_005211.3_ex22R NM_005211.3_ex22R agtttgtgggaggggagagtagtttgtgggaggggagagt 6060 5555 244244

본 발명에서 디자인된 프라이머 (NOTCH3)The primer designed in the present invention ( NOTCH3 ) Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_000435.2_ex1F NM_000435.2_ex1F cagggaaggagggaggagcagggaaggagggaggag 5959 6666 222222 NM_000435.2_ex1R NM_000435.2_ex1R cttgggggttcttgcactccttgggggttcttgcactc 6060 5757 222222 NM_000435.2_ex2F NM_000435.2_ex2F tccttcacccccacacagtccttcacccccacacag 6060 6161 116116 NM_000435.2_ex2R NM_000435.2_ex2R ctctgagccaggcactcacctctgagccaggcactcac 6060 6363 116116 NM_000435.2_ex3F NM_000435.2_ex3F cccaaccaagccatctctgcccaaccaagccatctctg 6060 5757 203203 NM_000435.2_ex3R NM_000435.2_ex3R cgactacctcccctccagaccgactacctcccctccagac 6060 6565 203203 NM_000435.2_ex4F NM_000435.2_ex4F tcctaaactcaccctgtcctgtcctaaactcaccctgtcctg 6060 5252 381381 NM_000435.2_ex4R NM_000435.2_ex4R ggctcactcaccaggaagacggctcactcaccaggaagac 5959 6060 381381 NM_000435.2_ex5F NM_000435.2_ex5F agccctactcaggagagtcagaagccctactcaggagagtcaga 6060 5555 288288 NM_000435.2_ex5R NM_000435.2_ex5R acacagatgcagcagtccagacacagatgcagcagtccag 6060 5555 288288 NM_000435.2_ex6F NM_000435.2_ex6F ctggactgctgcatctgtgtctggactgctgcatctgtgt 6161 5555 281281 NM_000435.2_ex6R NM_000435.2_ex6R cagagaaaacggccactcaccagagaaaacggccactcac 6060 5555 281281 NM_000435.2_ex7F NM_000435.2_ex7F ctgcctatgacttctgcttaccctgcctatgacttctgcttacc 5858 5050 239239 NM_000435.2_ex7R NM_000435.2_ex7R cctcctctcccctctttcccctcctctccccctctttcc 6060 6363 239239 NM_000435.2_ex8F NM_000435.2_ex8F acaccgatcgcactccatacaccgatcgcactccat 6060 5656 220220 NM_000435.2_ex8R NM_000435.2_ex8R accacccacctgccatacaccacccacctgccatac 6060 6161 220220 NM_000435.2_ex9F NM_000435.2_ex9F gtagcccccgctttcctagtagcccccgctttccta 6060 6161 185185 NM_000435.2_ex9R NM_000435.2_ex9R gtcttttcgggctccctctgtcttttcgggctccctct 5959 5757 185185 NM_000435.2_ex10F NM_000435.2_ex10F ctttctgggcctctgctcatctttctgggcctctgctcat 6060 5555 181181 NM_000435.2_ex10R NM_000435.2_ex10R tcttgtcggactgtcattggtcttgtcggactgtcattgg 6060 6060 181181 NM_000435.2_ex11F NM_000435.2_ex11F gagctgaaccaggattggtcgagctgaaccaggattggtc 6060 5555 358358 NM_000435.2_ex11R NM_000435.2_ex11R cctccaggtgtgctgtttctcctccaggtgtgctgtttct 6060 5555 358358 NM_000435.2_ex12F NM_000435.2_ex12F gccactccatgccatgttgccactccatgccatgtt 6060 5656 180180 NM_000435.2_ex12R NM_000435.2_ex12R cgatctaaggaccccctctccgatctaaggaccccctctc 6060 6060 180180 NM_000435.2_ex13F NM_000435.2_ex13F ccagggcccctttgtaacccagggcccctttgtaac 6060 6161 234234 NM_000435.2_ex13R NM_000435.2_ex13R agagggggcagtgtctgagagagggggcagtgtctgag 6060 6363 234234 NM_000435.2_ex14F NM_000435.2_ex14F acctccctggcctgactacacctccctggcctgactac 6161 6363 209209 NM_000435.2_ex14R NM_000435.2_ex14R tgcagagggaaggtgaggtatgcagagggaaggtgaggta 6060 5555 209209 NM_000435.2_ex15F NM_000435.2_ex15F ctctcttccacccccaacagctctcttccacccccaacag 6060 6060 170170 NM_000435.2_ex15R NM_000435.2_ex15R atggagaggaggagggaagaatggagaggaggagggaaga 6060 5555 170170 NM_000435.2_ex16F NM_000435.2_ex16F tgtaaccttgctccctaccctgtaaccttgctccctaccc 6060 5555 229229 NM_000435.2_ex16R NM_000435.2_ex16R atgactgtgttccccagagcatgactgtgttccccagagc 6060 5555 229229 NM_000435.2_ex17F NM_000435.2_ex17F ggcaaggtaggtgaccagacggcaaggtaggtgaccagac 6060 6060 300300 NM_000435.2_ex17R NM_000435.2_ex17R gagtccctgctctccaagcgagtccctgctctccaagc 6060 6363 300300 NM_000435.2_ex18F NM_000435.2_ex18F ctccagctcctgcttcaatgctccagctcctgcttcaatg 6060 5555 225225 NM_000435.2_ex18R NM_000435.2_ex18R ccagtaactccacccacctgccagtaactccacccacctg 6060 6060 225225 NM_000435.2_ex19F NM_000435.2_ex19F cccaccccacagtactgactcccaccccacagtactgact 6060 6060 201201 NM_000435.2_ex19R NM_000435.2_ex19R atgctcccactcaccgatctatgctcccactcaccgatct 6262 5555 201201 NM_000435.2_ex20F NM_000435.2_ex20F tcctgtgccactctcctctttcctgtgccactctcctctt 6060 5555 220220 NM_000435.2_ex20R NM_000435.2_ex20R gcccccttacctcacacatgcccccttacctcacacat 6060 5959 220220 NM_000435.2_ex21F NM_000435.2_ex21F agtgggtccctctcttacccagtgggtccctctcttaccc 6060 6060 170170 NM_000435.2_ex21R NM_000435.2_ex21R ctggcatacccagcgttcctggcatacccagcgttc 6060 6161 170170 NM_000435.2_ex22F NM_000435.2_ex22F ctcttgaccacccctcgttctcttgaccacccctcgtt 6060 5858 300300 NM_000435.2_ex22R NM_000435.2_ex22R gccaacgcttacctgagaaggccaacgcttacctgagaag 6161 5555 300300 NM_000435.2_ex23F NM_000435.2_ex23F ccccattgtggctgatctacccccattgtggctgatctac 6060 5555 195195 NM_000435.2_ex23R NM_000435.2_ex23R cccctactcctcctccaaagcccctactcctcctccaaag 6060 6060 195195 NM_000435.2_ex24_1F NM_000435.2_ex24_1F cttctcctccttccctccaccttctcctccttccctccac 6060 6060 200200 NM_000435.2_ex24_1R NM_000435.2_ex24_1R caggagggtcccgacaaccaggagggtcccgacaac 6161 6666 200200 NM_000435.2_ex24_2F NM_000435.2_ex24_2F gttgtcgggaccctcctggttgtcgggaccctcctg 6161 6666 371371 NM_000435.2_ex24_2R NM_000435.2_ex24_2R agcggctgttgttgaagagagcggctgttgttgaagag 5959 5353 371371 NM_000435.2_ex25F NM_000435.2_ex25F agcccggtgtacgagaagtaagcccggtgtacgagaagta 6060 5555 344344 NM_000435.2_ex25R NM_000435.2_ex25R gtcactcacccgatcacctcgtcactcacccgatcacctc 6060 6060 344344 NM_000435.2_ex26F NM_000435.2_ex26F gagacctgtgggtggagatg gagacctgtgggtggagatg 6161 6060 396396 NM_000435.2_ex26R NM_000435.2_ex26R ccctaagagcaggaagcaga ccctaagagcaggaagcaga 6060 5555 396396 NM_000435.2_ex27F NM_000435.2_ex27F ccctctgcttcctgctcttaccctctgcttcctgctctta 6161 5555 257257 NM_000435.2_ex27R NM_000435.2_ex27R gcagggttctcacttcatgcgcagggttctcacttcatgc 6060 5555 257257 NM_000435.2_ex28F NM_000435.2_ex28F acatcccctcttcccattgtacatcccctcttcccattgt 6060 5555 150150 NM_000435.2_ex28R NM_000435.2_ex28R gtcagaggagggggcaaaggtcagaggagggggcaaag 6060 6363 150150 NM_000435.2_ex29F NM_000435.2_ex29F cctgcccctccaggtagacctgcccctccaggtaga 6161 6666 195195 NM_000435.2_ex29R NM_000435.2_ex29R gaggggcactgtcactaaccgaggggcactgtcactaacc 6060 6060 195195 NM_000435.2_ex30F NM_000435.2_ex30F ttcctgctgacacactcctgttcctgctgacacactcctg 6060 5555 369369 NM_000435.2_ex30R NM_000435.2_ex30R ccagctctgaggtccaaagtccagctctgaggtccaaagt 5959 5555 369369 NM_000435.2_ex31F NM_000435.2_ex31F tgctgcatccactctctgtctgctgcatccactctctgtc 6060 5555 214214 NM_000435.2_ex31R NM_000435.2_ex31R tgacaccaacccagcttagatgacaccaacccagcttaga 6060 5050 214214 NM_000435.2_ex32F NM_000435.2_ex32F gacctctctccccttcatccgacctctctcccccttcatcc 6060 6060 160160 NM_000435.2_ex32R NM_000435.2_ex32R actgctgacacccagtggacactgctgacacccagtggac 6060 6060 160160 NM_000435.2_ex33_1F NM_000435.2_ex33_1F ctgacctctgtgggttctggctgacctctgtgggttctgg 6060 6060 311311 NM_000435.2_ex33_1R NM_000435.2_ex33_1R gcctcctgctcttcttggacgcctcctgctcttcttggac 6161 6060 311311 NM_000435.2_ex33_2F NM_000435.2_ex33_2F gggtccaagaagagcaggaggggtccaagaagagcaggag 5959 6060 327327 NM_000435.2_ex33_2R NM_000435.2_ex33_2R agccacagggttcagcagagccacagggttcagcag 6161 6060 327327

본 발명에서 디자인된 프라이머 (PRNP)The primer ( PRNP ) designed in the present invention Primer IDPrimer ID 서열order Tm (oC)Tm ( o C) GC (%)GC (%) 길이 (bp)Length (bp) NM_001271561.1_ex1FNM_001271561.1_ex1F cctgtcctccgagccagtcctgtcctccgagccagt 6161 6767 7575 NM_001271561.1_ex1RNM_001271561.1_ex1R gtttacctgcctcggtcgtggtttacctgcctcggtcgtg 6262 6060 7575 NM_001080121.1_ex2_1FNM_001080121.1_ex2_1F agcagtcattatggcgaaccagcagtcattatggcgaacc 6060 5050 300300 NM_001080121.1_ex2_1RNM_001080121.1_ex2_1R ctgtgggtgccacctcctctgtgggtgccacctcct 6262 6767 300300 NM_001080121.1_ex2_2FNM_001080121.1_ex2_2F gaggtggcacccacagtcgaggtggcacccacagtc 6161 6767 352352 NM_001080121.1_ex2_2RNM_001080121.1_ex2_2R acgcgctccatcatcttaacacgcgctccatcatcttaac 6060 5050 352352 NM_001080121.1_ex2_3FNM_001080121.1_ex2_3F ccgagaccgacgttaagatgccgagaccgacgttaagatg 6060 5555 221221 NM_001080121.1_ex2_3RNM_001080121.1_ex2_3R cctccctcaagctggaaaacctccctcaagctggaaaa 6060 5252 221221

이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (12)

진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 알츠하이머 진단을 위한 정보제공방법.
Wherein said gene mutation is selected from the group consisting of APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTHNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin- Beta-secretase 1), PICALM (phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7) CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), sigma non-opioid intracellular receptor 1, FUS (fused-in-Sarcoma), GRN (PGRN) , MAPT (microtubule associated Tau protein), ALS2 (amyotro phic lateral sclerosis, PTEN-induced putative kinase 1, PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2 ), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene), and combinations thereof, for the diagnosis of Alzheimer's disease Information delivery method.
제 1 항에 있어서, 상기 유전자는 APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3, PRNP 및 이의 조합으로 구성된 군에서 선택되는 것을 특징으로 하는 정보제공방법.
The gene of claim 1, wherein the gene is selected from the group consisting of APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, , PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3, PRNP, and combinations thereof.
제 1 항에 있어서, 상기 생물학적 시료는 혈액, 정액, 질 세포, 모발, 타액, 소변, 구강세포, 태반세포 또는 태아세포를 포함하는 양수 및 이의 혼합물로 구성된 군에서 선택되는 시료로부터 분리된 DNA 시료인 것을 특징으로 하는 정보제공방법.
The method according to claim 1, wherein the biological sample is a DNA sample separated from a sample selected from the group consisting of blood, semen, vaginal cells, hair, saliva, urine, oral cells, placental cells or fetal cells, The information providing method comprising the steps of:
제 1 항에 있어서, 상기 돌연변이 분석은 상기 유전자에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자를 증폭하고, 상기 증폭산물의 시퀀싱(sequencing) 데이터를 이용하여 유전자 돌연변이를 분석하는 것을 특징으로 하는 정보제공방법.
The method according to claim 1, wherein the mutation analysis is performed by amplifying a gene using each primer complementarily binding to the gene, and analyzing gene mutation using sequencing data of the amplification product Information delivery method.
제 4 항에 있어서, 상기 시퀀싱은 NGS (next generation sequencing) 방법인 것을 특징으로 하는 정보제공방법.
5. The method of claim 4, wherein the sequencing is a Next Generation Sequencing (NGS) method.
제 4 항에 있어서, 상기 유전자 증폭은 각 유전자에 대한 프라이머 세트를 1세트 이상 사용하는것을 특징으로 하는 정보제공방법.
5. The method according to claim 4, wherein the gene amplification uses at least one set of primers for each gene.
제 4 항에 있어서, 상기 유전자 증폭은 Emulsion PCR, Polony PCR, Bridge PCR 증폭인 것을 특징으로 하는 정보제공방법.
5. The method according to claim 4, wherein the gene amplification is Emulsion PCR, Polony PCR, or Bridge PCR amplification.
제 4 항에 있어서, 상기 유전자 증폭은 멀티플렉스 PCR(Polymerase Chain Reaction) 증폭인 것을 특징으로 하는 정보제공방법.
5. The method of claim 4, wherein the gene amplification is a Polymerase Chain Reaction (PCR) amplification.
APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 알츠하이머 진단 또는 예후 분석용 키트.
(Amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU Related proteins such as Cadherin-associated protein alpha 3, DNMBP, SORL1, BACE1, PICALM, LPR6, protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP- (FUS), GRN (PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1 ), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SN (CA), alpha-synuclein (CA), leucine-rich repeat kinase 2 (LRRK2), colony stimulating factor 1 receptor (CSF1R), neurogenic locus notch homolog protein 3 (NOCTH3), prion protein gene A kit for the diagnosis or prognosis of Alzheimer's disease that analyzes gene mutations using respective primers complementarily binding to the exon region of a gene.
진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 신경 퇴행성 질환(neurodegenerative disease) 진단을 위한 정보제공방법.
Wherein said gene mutation is selected from the group consisting of APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTHNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin- Beta-secretase 1), PICALM (phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7) CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), sigma non-opioid intracellular receptor 1, FUS (fused-in-Sarcoma), GRN (PGRN) , MAPT (microtubule associated Tau protein), ALS2 (amyotro phic lateral sclerosis, PTEN-induced putative kinase 1, PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2 ), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene), and combinations thereof. neurodegenerative disease).
제 10 항에 있어서, 상기 신경 퇴행성 질환은 알츠하이머병(Alzheimer's disease), 루게릭병(Amyotrophic Lateral Sclerosis), 전두측두엽성 치매(Frontotemporal dementia), 루이소체 치매(Dementia with Lewy Bodies), 크루츠펠트 야콥병 (Creutzfeldt Jakob Disease), 파킨슨병(Parkinson’s disease), 뇌졸중(stroke), 근위축성측색경화증(amyotrophic lateral sclerosis), 빈스완거병(Binswanger’s disease), 헌팅톤 무도병(Huntington’s chorea), 다발성 경화증(multiple sclerosis), 중증 근무력증(myasthenia gravis) 또는 피크병(Pick’s disease)인 것을 특징으로 하는 정보제공방법.
11. The method of claim 10, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer ' s disease, Amyotrophic Lateral Sclerosis, Frontotemporal dementia, Dementia with Lewy Bodies, Creutzfeldt Jakob Disease, Parkinson's disease, stroke, amyotrophic lateral sclerosis, Binswanger's disease, Huntington's chorea, multiple sclerosis, Myasthenia gravis, or Pick's disease.
APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 신경 퇴행성 질환(neurodegenerative disease) 진단 또는 예후 분석용 키트.
(Amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU Related proteins such as Cadherin-associated protein alpha 3, DNMBP, SORL1, BACE1, PICALM, LPR6, protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP- (FUS), GRN (PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1 ), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SN (CA), alpha-synuclein (CA), leucine-rich repeat kinase 2 (LRRK2), colony stimulating factor 1 receptor (CSF1R), neurogenic locus notch homolog protein 3 (NOCTH3), prion protein gene A kit for the diagnosis or prognosis of a neurodegenerative disease in which gene mutations are analyzed using primers complementarily binding to the exon region of a gene.
KR1020170065179A 2017-05-26 2017-05-26 Genetic diagnostic method using 30 genes associated with Alzheimer's disease KR102040364B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020170065179A KR102040364B1 (en) 2017-05-26 2017-05-26 Genetic diagnostic method using 30 genes associated with Alzheimer's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170065179A KR102040364B1 (en) 2017-05-26 2017-05-26 Genetic diagnostic method using 30 genes associated with Alzheimer's disease

Publications (2)

Publication Number Publication Date
KR20180130060A true KR20180130060A (en) 2018-12-06
KR102040364B1 KR102040364B1 (en) 2019-11-05

Family

ID=64671458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170065179A KR102040364B1 (en) 2017-05-26 2017-05-26 Genetic diagnostic method using 30 genes associated with Alzheimer's disease

Country Status (1)

Country Link
KR (1) KR102040364B1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646668A (en) * 2019-01-04 2019-04-19 厦门大学 A kind of polypeptide is used to prepare the purposes of prevention and treatment Alzheimer disease drugs
KR102078500B1 (en) 2019-03-12 2020-02-17 건국대학교 산학협력단 Composition for diagnosing Alzheimer's disease
KR20200109245A (en) 2019-03-12 2020-09-22 건국대학교 산학협력단 Composition for diagnosing Alzheimer's disease
WO2020251263A1 (en) * 2019-06-10 2020-12-17 연세대학교 산학협력단 Biomarker for diagnosis of cerebral nervous system diseases
KR20210085319A (en) * 2019-12-30 2021-07-08 경상국립대학교산학협력단 Composition for predicting clinical stage of Alzheimer's disease and kit using the same
KR102364890B1 (en) 2020-10-12 2022-02-18 경북대학교 산학협력단 Expression cassette and vector with genes related alzheimer's disease and transgenic human pluripotent stem cell line made from it and alzheimer's diseae organoid and neuron model differentiated from this cell line
KR20220102073A (en) * 2021-01-12 2022-07-19 전남대학교산학협력단 Assessment methods and diagnostic kit for predicting later remission in male patients with depressive disorders in response to early improvement of antidepressants using genetic biomarkers
WO2022251658A1 (en) * 2021-05-28 2022-12-01 La Jolla Institute For Immunology T cell transcriptomic profiles in parkinsons disease, and methods and uses thereof
WO2023275376A1 (en) * 2021-07-02 2023-01-05 Aarhus Universitet Methods of treating alzheimer's disease
EP3917620A4 (en) * 2019-02-01 2023-02-08 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230032737A (en) 2021-08-31 2023-03-07 가천대학교 산학협력단 PSEN1 mutant cell and use thereof
KR102647919B1 (en) 2021-08-31 2024-03-13 가천대학교 산학협력단 APP mutant cell and use thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Annual Review of Neuroscience, 34:185-204 (2011) *
Clinical Interventions in Aging, 11:1467-1488 (2016) *
Clinical Interventions in Aging, 12:367-375 (2017.02.13.) *
Clinical Interventions in Aging, 9:535-551 (2014)* *
Eva Bagyinszky, "Genetic analysis of Korean patients with different kinds of neurodegenerative dementia", 가천대학교 바이오나노학과, 박사학위논문 (2014) *
Journal of Clinical Laboratory Analysis, 30:1092-1099 (2016) *
Neurobiology of Aging, 32:1990-1993 (2011) *
Neurobiology of Aging, 56:212.e11-212.e17 (2017.04.26.) *
Neurobiology of Aging, 56:212.e11-e212.e17 (2017.04.26.) *
PLoS Medicine, 14(3):e1002270 (2017.03.28.) *
The Open Neurology Journal, 5:8-11 (2011) *
Vo Van Giau, "Genetic analysis of neurodegenerative diseases using next generation sequencing", 가천대학교 바이오나노학과, 박사학위논문 (2017.08.) *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646668A (en) * 2019-01-04 2019-04-19 厦门大学 A kind of polypeptide is used to prepare the purposes of prevention and treatment Alzheimer disease drugs
EP3917620A4 (en) * 2019-02-01 2023-02-08 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
KR102078500B1 (en) 2019-03-12 2020-02-17 건국대학교 산학협력단 Composition for diagnosing Alzheimer's disease
KR20200109245A (en) 2019-03-12 2020-09-22 건국대학교 산학협력단 Composition for diagnosing Alzheimer's disease
WO2020251263A1 (en) * 2019-06-10 2020-12-17 연세대학교 산학협력단 Biomarker for diagnosis of cerebral nervous system diseases
KR20210085319A (en) * 2019-12-30 2021-07-08 경상국립대학교산학협력단 Composition for predicting clinical stage of Alzheimer's disease and kit using the same
WO2021137366A1 (en) * 2019-12-30 2021-07-08 경상국립대학교 산학협력단 Composition for predicting stage of alzheimer's disease, and prediction kit using composition
KR102364890B1 (en) 2020-10-12 2022-02-18 경북대학교 산학협력단 Expression cassette and vector with genes related alzheimer's disease and transgenic human pluripotent stem cell line made from it and alzheimer's diseae organoid and neuron model differentiated from this cell line
KR20220106733A (en) * 2021-01-12 2022-07-29 전남대학교산학협력단 Assessment methods and diagnostic kit for predicting later remission in male patients with depressive disorders in response to early improvement of antidepressants using genetic biomarkers
KR20220106938A (en) * 2021-01-12 2022-08-01 전남대학교산학협력단 Assessment methods and diagnostic kit for predicting later remission in male patients with depressive disorders in response to early improvement of antidepressants using genetic biomarkers
KR20220106939A (en) * 2021-01-12 2022-08-01 전남대학교산학협력단 Assessment methods and diagnostic kit for predicting later remission in male patients with depressive disorders in response to early improvement of antidepressants using genetic biomarkers
KR20220102073A (en) * 2021-01-12 2022-07-19 전남대학교산학협력단 Assessment methods and diagnostic kit for predicting later remission in male patients with depressive disorders in response to early improvement of antidepressants using genetic biomarkers
WO2022251658A1 (en) * 2021-05-28 2022-12-01 La Jolla Institute For Immunology T cell transcriptomic profiles in parkinsons disease, and methods and uses thereof
WO2023275376A1 (en) * 2021-07-02 2023-01-05 Aarhus Universitet Methods of treating alzheimer's disease

Also Published As

Publication number Publication date
KR102040364B1 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
KR102040364B1 (en) Genetic diagnostic method using 30 genes associated with Alzheimer's disease
Bonnet et al. An innovative strategy for the molecular diagnosis of Usher syndrome identifies causal biallelic mutations in 93% of European patients
AU2016250529A1 (en) Method to increase sensitivity of next generation sequencing
JP6723924B2 (en) Primer set and method for amplifying exons of PKD1 gene and PKD2 gene
WO2018186930A1 (en) Method and kit for constructing nucleic acid library
CN115141884B (en) Novel ATP7B mutant gene and diagnostic reagent thereof
ES2546743A1 (en) Mitochondrial markers of neurodegenerative diseases (Machine-translation by Google Translate, not legally binding)
CN106350586A (en) Method for determining gene mutation site of hemophagocytic syndrome
Kaur et al. Investigations of Huntington’s disease and Huntington’s disease-like syndromes in Indian choreatic patients
Yu et al. Single nucleotide polymorphism rs1333049 on chromosome 9p21. 3 is associated with Alzheimer's disease in Han Chinese
CN108410990B (en) Application of IGFBP3 in preparation of product for diagnosing I-type neurofibroma combined with spinal malformation disease
JP5879665B2 (en) Editorial profiling of PDE8A mRNA precursor: Use of ADARs activity as a specific biomarker in human tissues to diagnose and predict and evaluate therapeutic efficacy and / or efficacy or potential drug side effects
Van Giau et al. Optimization of specific multiplex DNA primers to detect variable CLU genomic lesions in patients with Alzheimer’s disease
Carrasco-Miranda et al. Mutations in NPHS2 (podocin) in Mexican children with nephrotic syndrome who respond to standard steroid treatment
US20060057624A1 (en) Alternatively spliced pre-mRNA transcripts in neurodegenerative disease
KR20160009397A (en) Methods for detecting drug resistant Mycobacterium tuberculosis
CN115216536A (en) Novel NIPBL mutant gene and diagnostic reagent thereof
KR20210154527A (en) Markers for Predicting side effects of statin
KR20220012896A (en) Methods for detecting rare DNA sequences in fecal samples
CN114752666B (en) Tegrelor-related dyspnea genotype detection reagent or kit
JP2007166962A (en) Method for predicting or diagnosing alzheimer's disease
WO2002024905A1 (en) Method of judging gene mutation
CN115927354B (en) SH3TC2 gene pathogenic mutant and application thereof in preparation of fibula muscular atrophy 4C type diagnostic kit
KR102063240B1 (en) Novel SNP marker for pattern identification of lung cancer patients and uses thereof
CN116004799B (en) CRTAP pathogenic mutant and application thereof in preparation of gristle syndrome VII type diagnosis kit

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant